








Investigation of a Functional Relationship Between Toll-Like Receptor 4 and Transient 
Receptor Potential Cation Channel Subfamily V Member 1 in Relation to a Novel 
Neuroimmune Pain Model 
 
 
A thesis submitted in fulfilment for the degree of 




The Discipline of Physiology 
Adelaide Medical School 












































Table of Contents 
 
Abstract  ................................................................................................................................ i 
Thesis declaration  .............................................................................................................. iii 
Acknowledgements  ............................................................................................................ iv 
Abbreviations  ..................................................................................................................... vi 
Chapter 1. An introduction to pain and neuroimmune signalling  ................................. 1 
1.1 Definition of pain  ...................................................................................................... 1 
1.1.1    Acute pain ...................................................................................................... 1 
1.1.2 Pathological and chronic pain  ....................................................................... 2 
1.2 Pain mechanisms  ...................................................................................................... 3 
1.2.1    Peripheral and central nervous systems  ........................................................ 3 
1.2.2    Nociception - neural pathways  ..................................................................... 6 
1.2.3    Signal generation and transmission  .............................................................. 7 
1.2.4    Descending influence  .................................................................................. 10 
1.3 Pathological pain models  ........................................................................................ 12 
1.3.1 Neurogenic pain models  ............................................................................. 12 
1.3.2 Inflammatory pain models  .......................................................................... 12 
1.3.3 Neuropathic pain models  ............................................................................ 13 
1.3.4 Measurable outcomes  ................................................................................. 14 
1.4 Neuroimmune pain .................................................................................................. 15 
1.4.1 Neuroimmune background  ......................................................................... 15 
1.4.2 Immunologically active glia  ....................................................................... 16 
1.4.3 Neuroimmune interactions – peripheral sensitisation  ................................. 19 
1.4.4 Neuroimmune interactions – central sensitisation  ...................................... 22 
1.5 Conclusion .............................................................................................................. 25 
Chapter 2. Introducing toll-like receptor 4 and transient receptor potential cation 
channel subfamily V member 1 ........................................................................................ 27 
2.1 Toll-like receptor 4 (TLR4) ..................................................................................... 27 
2.1.1 Structure ....................................................................................................... 27 
2.1.2 Signal transduction ...................................................................................... 27 
2.1.3 TLR4 and pain ............................................................................................. 31 
2.2 Transient receptor potential cation channel subfamily V member 1 (TRPV1) ....... 33 
2.2.1    Structure ....................................................................................................... 34 
 
2.2.2    TRPV1 in pain literature .............................................................................. 34 
2.2.3    Activation and agonists ................................................................................ 36 
2.2.4    Regulation .................................................................................................... 38 
2.2.4.1     Kinases ............................................................................................... 38 
2.2.4.2     Lipids ................................................................................................. 40 
2.2.4.3     Prostaglandins .................................................................................... 40 
2.2.4.4     Nerve growth factor (NGF) and bradykinin .....................................  41 
2.2.4.5     Serotonin and dopamine .................................................................... 41 
2.2.4.6     Opioids ............................................................................................... 41 
2.2.4.7     Cytokines ........................................................................................... 42 
2.2.4.8     Other .................................................................................................. 42 
2.3 TLR4/TRPV1 interaction ........................................................................................ 43 
2.3.1    Nociception - TLR4/TRPV1 in vitro ........................................................... 44 
2.3.2    Pain - TLR4/TRPV1 in vivo ........................................................................ 45 
2.3.3    Outside pain literature .................................................................................. 46 
2.4 Conclusion ............................................................................................................... 46 
Thesis aims and hypotheses  ............................................................................................. 49 
Chapter 3. Activation and antagonism of toll-like receptor 4 signalling potentiates 
TRPV1 mediated calcium accumulation in HEK293FT cells .......................................  51 
3.1 Abstract .................................................................................................................... 51 
3.2 Introduction .............................................................................................................. 51 
3.3 Methods ................................................................................................................... 53 
3.3.1 Materials ...................................................................................................... 53 
3.3.2    Cell culture ................................................................................................... 54 
3.3.3    TRPV1 transient transfection ....................................................................... 54 
3.3.4 Fluo-4AM calcium assay ............................................................................. 54 
3.3.4.1     Plate reader ........................................................................................ 55 
3.3.4.2     Live cell ............................................................................................. 55 
3.3.5 Antagonist assays ......................................................................................... 55 
3.3.6 Endotoxin-capsaicin study ........................................................................... 55 
3.3.7 Assessment of TLR4 function ..................................................................... 56 
3.3.8 Analysis ....................................................................................................... 56 
3.4 Results ...................................................................................................................... 56 
3.4.1 TLR4 alters TRPV1 dependent capsaicin responses in HEK293FT cells ... 56 
 
3.4.2 Live cell calcium analysis reveals a population of fast responding 
TLR4/TRPV1 expressing HEK293FT cells ................................................ 59 
3.4.3 TLR4 antagonists potentiate capsaicin-induced calcium accumulation in 
TLR4/TRPV1 expressing HEK293FT cells ................................................ 60 
3.4.4 Endotoxin potentiates capsaicin-induced calcium accumulation following 
18 min but not 4 h pre-treatment ................................................................. 62 
3.5 Discussion ................................................................................................................ 64 
3.6 Supplementary figures ............................................................................................. 69 
Chapter 4. Review: The use of capsaicin as a pro-nociceptive stimulus in animal pain 
models utilising behavioural assessment ......................................................................... 70 
4.1 Abstract .................................................................................................................... 70 
4.2 Introduction .............................................................................................................. 71 
4.3 Methods ................................................................................................................... 74 
4.3.1 Research strategy ......................................................................................... 74 
4.3.2 Systematic review publication selection criteria ......................................... 74 
4.3.3 Systematic review publication data extraction ............................................ 74 
4.4 Results ...................................................................................................................... 76 
4.4.1 Systematic review search outcomes ............................................................ 76 
4.4.2 Paper characteristics .................................................................................... 78 
4.4.3 Behaviour assessed ...................................................................................... 80 
4.4.3.1     Spontaneous pain ............................................................................... 80 
4.4.3.2     Elicited pain ....................................................................................... 81 
4.4.3.3     Reporting consistency ........................................................................ 84 
4.4.4 Capsaicin administration ............................................................................. 85 
4.4.4.1     Administration route and location ..................................................... 85 
4.4.4.2     Dose and sensitivity ........................................................................... 88 
4.4.5 Sex differences ............................................................................................. 93 
4.4.6 Capsaicin purpose ........................................................................................ 93 
4.5 Discussion ................................................................................................................ 93 
4.5.1 Species assessed ........................................................................................... 94 
4.5.2 Pain type assessed ........................................................................................ 94 
4.5.3 Dose and capsaicin administration .............................................................. 97 
4.5.4 Sex bias ........................................................................................................ 98 
4.5.5 Limitations ................................................................................................... 99 
 
4.6 Conclusion ............................................................................................................... 99 
Chapter 5. A peripherally administrated primed LPS response potentiates capsaicin-
induced mechanical hypersensitivity in BALB/c mice ................................................. 100 
5.1 Abstract .................................................................................................................. 100 
5.2 Introduction ............................................................................................................ 101 
5.3 Methods ................................................................................................................ .104 
5.3.1 Animals ...................................................................................................... 104 
5.3.2 Materials .................................................................................................... 104 
5.3.3 Intraplantar (i.pl.) drug administration ...................................................... 105 
5.3.4 Behavioural testing .................................................................................... 106 
5.3.5 Systemic endotoxin-capsaicin model ......................................................... 107 
5.3.6 Local administration endotoxin-capsaicin model ...................................... 107 
5.3.7    Analysis ..................................................................................................... 107 
5.4 Results .................................................................................................................... 108 
5.4.1 The human endotoxin-capsaicin model does not directly translate to 
BALB/c mice ............................................................................................. 108 
5.4.2 Local LPS administration does not consistently produce potentiated 
capsaicin-induced hypersensitivity at multiple time points ....................... 110 
5.4.3 A primed LPS response produces extended capsaicin-induced 
hypersensitivity, an effect reversed by (+)-naltrexone .............................. 112 
5.5 Discussion .............................................................................................................. 114 
5.6 Supplementary figures ........................................................................................... 118 
Chapter 6. Naltrexone non-stereoselectively reverses intraplantar injection-induced 
analgesia and extends capsaicin-induced mechanical hypersensitivity ...................... 120 
6.1 Abstract .................................................................................................................. 120 
6.2 Introduction ............................................................................................................ 121 
6.3 Methods .................................................................................................................. 124 
6.3.1 Animals ...................................................................................................... 124 
6.3.2 Materials .................................................................................................... 124 
6.3.3 Intraplantar (i.pl.) drug administration ...................................................... 125 
6.3.4 Behavioural testing .................................................................................... 126 
6.3.5 Naltrexone studies ..................................................................................... 127 
6.3.5.1     Intermediate saline ........................................................................... 127 
6.3.5.2     Naltrexone pre-capsaicin ................................................................. 127 
 
6.3.5.3     Naltrexone post-capsaicin ................................................................ 128 
6.3.6 Tissue collection ........................................................................................ 128 
6.3.7 Immunohistochemistry .............................................................................. 128 
6.3.8 Analysis ..................................................................................................... 129 
6.4 Results .................................................................................................................... 129 
6.4.1 I.pl. saline attenuates i.pl. capsaicin-induced mechanical hypersensitivity 
when administered 15 min prior, an effect reversed by (-)-naltrexone ..... 129 
6.4.2 Neither (+)- or (-)-naltrexone affect capsaicin-induced mechanical 
hypersensitivity when administered pre-capsaicin .................................... 132 
6.4.3 Both (+)- and (-)-naltrexone administered post-capsaicin extend 
hypersensitivity .......................................................................................... 133 
6.4.4 Administration of (-)-naltrexone at later time points does not restore 
mechanical hypersensitivity following capsaicin ...................................... 135 
6.4.5 Spinal cord c-Fos is unaltered by (-)-naltrexone applied 30 min following 
capsaicin administration ............................................................................ 136 
6.5 Discussion .............................................................................................................. 138 
6.6 Supplementary figures ........................................................................................... 143 
Chapter 7. Discussion ...................................................................................................... 145 





















































Chronic pain represents a significant global disease burden, affecting 1 in 5 adults 
worldwide and costing billions of dollars annually. Due to poor efficacy and undesirable 
side effects including tolerance, nausea, constipation, diarrhoea, dizziness and addiction; 
current therapeutic options are less than ideal. In order to improve upon current therapeutic 
options, an improved mechanistic understanding underlying the generation and 
maintenance of chronic pain conditions is required. Communication between the immune 
system and the nervous system is an emerging area of interest in pain research. Known as 
neuroimmune signalling, this interaction is involved in altering key elements of the 
nociceptive signalling pathway and therefore represents an interesting target for future 
novel therapeutics. Recently, an interaction between innate immune receptor toll-like 
receptor 4 (TLR4), and neuronal ion channel transient receptor potential cation channel 
subfamily V member 1 (TRPV1) has been suggested as a clinically relevant neuroimmune 
interaction. A clinical model provides evidence that TLR4 agonist lipopolysaccharide 
(LPS), potentiates responses mediated by TRPV1 agonist capsaicin. We aim to further 
clarify the nature of this interaction in an in vitro overexpression system. And secondly, we 
aim to replicate the clinical findings in a preclinical model that allows investigation of 
peripheral and central mechanisms. Our in vitro investigations reveal that TLR4 alters 
TRPV1 mediated calcium influx dynamic and accumulation in HEK293FT cells. The 
dynamic was not altered by antagonising or activating TLR4 signalling, although both 
potentiated calcium accumulation. We were unable to back-translate the clinical 
endotoxin-capsaicin model into BALB/c mice; however, a primed, peripherally targeted 
LPS challenge potentiated capsaicin-induced mechanical hypersensitivity in a population 
of BALB/c mice. However, we found that consecutive intraplantar injections result in 
attenuated capsaicin-induced mechanical hypersensitivity, an effect reversed by both 
classical and non-classical opioid antagonists (-)- and (+)-naltrexone. Further, (-)- and (+)-
naltrexone produced an extended and potentiated capsaicin-induced mechanical 
hypersensitivity. The effect of naltrexone appeared to be dependent on the state of 
nociceptive activity at the time of application. We also present a systematic review of the 
literature analysing capsaicin-induced animal pain models in order to better inform future 
research decisions. Therefore, we present a study investigating the TLR4/TRPV1 
functional interaction in vitro and in vivo; finding TLR4 alters TRPV1 function. Our 
results agree with previous studies which postulate both a direct physical interaction and 
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indirect interaction via intracellular calcium-induced signalling and/or pro-inflammatory 
mediators. Therefore, we present evidence suggesting the interaction between TLR4 and 
TRPV1 warrants further investigation as a relevant neuroimmune signalling element in 
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Chapter 1. An Introduction to pain and neuroimmune signalling 
This chapter provides background to pain signalling, highlighting interactions with 
classically immune systems and their impacts on pain perception. This includes a basic 
introduction to pain and the mechanisms of nociceptive signal transduction, followed by an 
introduction to commonly utilised animal models of pain. Neuroimmune interactions will 
then be introduced in the context of altering nociceptive transmission. The information 
presented will highlight the consequences of neuroimmune interactions and their 
importance to chronic pain. This will give relevance to a review of the relationship 
between toll-like receptor 4 (TLR4) and transient receptor potential cation channel 
subfamily V member 1 (TRPV1), presented in chapter 2. 
 
1.1 Definition of pain  
Pain, and pain related diseases remain a leading cause of disability and disease burden 
globally (Kassebaum et al., 2017). Defined as an “unpleasant sensory experience 
associated with actual or potential tissue damage or described in terms of such damage” by 
The International Society for the Study of Pain (Merskey et al., 1979). As such, pain is 
viewed as an individual’s experience, separating it from the physiological process in which 
noxious stimuli are processed by the nervous system, known as nociception. Pain generally 
serves a protective purpose, warning of potential tissue damage. However, pain can 
become maladaptive, persistent and without purpose; referred to as either pathological or 
chronic pain, which has profound negative impacts on individuals and society (Cao et al., 
2008; Painaustralia, 2019). 
 
1.1.1 Acute Pain 
Acute pain is also referred to as physiological pain, and can be further categorised into 
either nociceptive or inflammatory pain (Cao et al., 2008; Costigan et al., 2009). Acute 
pain is transient, with a protective purpose, alerting individuals to potentially damaging 
stimuli, thereby guarding against tissue damage (Cao et al., 2008). As such, acute pain is 
mediated by high threshold sensory neurons which can respond to external chemical, 
mechanical or thermal stimuli, as well as internal danger signals, such as those generated 
following muscle cramp or myocardial infarction (Millan, 1999; Woolf et al., 2007). 
Inflammatory pain serves to aid healing following tissue damage (Costigan et al., 2009). 
To achieve this, inflammation results in reduction of thresholds required to activate 
sensory neurons (Huang et al., 2006). This results in the affected area becoming more 
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sensitive, and therefore protected (Huang et al., 2006). Typically, both nociceptive pain 
and inflammatory pain abate following removal of stimulus or resolution of tissue damage 
(Costigan et al., 2009). However, either long term changes in the sensory pathway, or 
chronic inflammatory conditions can result in persistent, pathological pain. 
 
1.1.2 Pathological and chronic pain 
Pathological pain no longer serves a purpose to protect and/or support healing (Costigan et 
al., 2009). Pathological pain can be divided further into neuropathic pain (associated with 
damage or dysfunction to the nervous system, e.g. trauma, diabetic neuropathy, 
postherpetic neuralgia), cancer pain, dysfunctional pain (no identifiable inflammation or 
damage, e.g. fibromyalgia, irritable bowel syndrome) and aforementioned inflammatory 
pain (e.g. rheumatoid arthritis). A number of pain types fall into multiple categories (e.g. 
HIV pain, lower back pain) (Cao et al., 2008; Chwistek, 2017; Costigan et al., 2009; 
Feldman et al., 2019; Grace et al., 2014; Hadley et al., 2016; Uebelacker et al., 2015; Urits 
et al., 2019). Collectively these conditions fall under the overarching umbrella of chronic 
pain. Chronic pain is often defined in terms of pain duration, commonly, that which lasts 
longer than three months (Treede et al., 2019). While often the result of disease or injury, it 
is considered a separate condition which represents a significant personal trauma and wider 
economic burden (Costigan et al., 2009; Kassebaum et al., 2017; Painaustralia, 2019). 
Estimated to affect 20% of the global population, in Australia chronic pain affects 3.24 
million people (Goldberg et al., 2011; Painaustralia, 2019). In Australia alone, the 
estimated cost is $139.3 billion annually (2018), accounting for treatment, lost 
productivity, care/aid, and loss in quality of life; this figure is predicted to reach $215.6 
billion by 2050 (Painaustralia, 2019).  
 
Common chronic pain symptoms include spontaneous pain generation (ongoing pain), 
painful responses to innocuous stimuli (allodynia), and exaggerated responses to noxious 
stimuli (hyperalgesia) (Milligan et al., 2009). Allodynia generated by dynamic mechanical 
stimuli, such as putting on clothing or brushing against furniture is considered particularly 
debilitating and can present in 20 – 40% of neuropathic pain patients (Hansson, 2003; 
Mogil, 2009). In neuropathic pain patients, cold allodynia is the second most commonly 
reported form of allodynia (Hansson, 2003). Studies indicate elicited pain sensitivities 
(allodynia or hyperalgesia) of mechanical and thermal sources present in 64 and 38% of 
patients respectively (Backonja et al., 2004). However, spontaneous pain, both continuous 
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and paroxysmal, is the primary complaint in chronic pain patients and consists of stabbing, 
shooting, and burning sensations which are associated with the highest reported pain scores 
in routinely administered pain intensity questionnaires (Backonja et al., 2004). Commonly, 
individuals also report abnormal tingling (paraesthesia) and numbness (Hansson, 2003). As 
mentioned above, these symptoms along with associated anxiety, decreased motivation, 
depression and fatigue cause a significant decrease in quality of life (Loeser, 2000). 
 
Unfortunately, current therapeutic options provide limited efficacy; it is estimated only one 
in four patients experience over 50% pain relief (Nightingale, 2012). Common therapeutics 
include non-steroidal anti-inflammatory drugs (NSAIDs), antidepressants, anticonvulsants 
and opioids, which along with questionable efficacy all present side effects making them 
less than ideal options. Pregabalin and duloxetine, a commonly administered 
anticonvulsant and antidepressant respectively offer questionable efficacy and side effects 
including sedation, dizziness, dry mouth, constipation and nausea (Saarto et al., 2010). 
NSAIDs only offer short term relief and are associated with gastrointestinal symptoms 
(pain, diarrhoea), dizziness, headaches and tiredness (Roelofs et al., 2008; Ryder et al., 
2005). The efficacy of opioids is also questionable in chronic pain, and when administered 
present challenges in the form of diminished efficacy over time, nausea, sedation, 
constipation, risk of addiction and opioid-induced pain (Baldini et al., 2012; Reinecke et 
al., 2015). A number of topically applied agents are also used, examples include lidocaine 
and capsaicin patches; however repeated and painful application processes respectively 
result in limited uptake of these therapies (Nightingale, 2012). It is clear that for such a 
significant health problem, treatment options must be improved with a push for improved 
efficacy. This is a major catalyst behind increased research effort into understanding the 
underlying physiology of generation and maintenance of chronic pain states. 
 
1.2 Pain mechanisms 
1.2.1 Peripheral and central nervous systems 
The somatosensory system is responsible for converting signals from noxious stimuli into 
pain sensations. Separated into two anatomically separate systems; the peripheral (PNS) 
and central (CNS) nervous systems communicate in order to detect visceral or peripheral 
stimuli and process it in higher brain regions (D'Mello et al., 2008; Woolf et al., 2007). 
The peripheral nervous system is composed of sensory primary afferent neurons known as 
nociceptors, which convert noxious stimuli into electrical impulses, initiating nociceptive 
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signalling (Woolf et al., 2007). These neurons are pseudo-unipolar, with cell bodies 
located in dorsal root ganglia (DRG) or trigeminal ganglia (TG) for skin and visceral or 
orofacial innovation respectively. Either side of the cell body, long axonal process extend 
distally to peripheral sites and centrally into the spinal cord from DRG or the spinal tract 
nucleus from TG (Huang et al., 2013). Primary afferent neurons can be subdivided into C-, 
Ad- and Ab-fibres. The majority of nociceptors are the small diameter, un-myelinated and 
therefore slow conducting C-fibres; medium diameter, thinly myelinated Ad-fibres are also 
involved in nociceptive signalling (Woolf et al., 2007). C-fibres have a high-threshold for 
activation, while Ad-fibres have a lower, intermediate threshold which makes these neuron 
classes ideal for detecting high intensity noxious signals. Ab-fibres are large diameter, 
highly myelinated, fast conducting neurons responsible for detection of non-noxious low 
intensity stimuli including touch, pressure and vibration (Millan, 1999). Non-neural cells 
considered part of the peripheral nervous system include Schwann cells, responsible for 
myelination and neural nutrition; and satellite glia located at the ganglion, which 
communicate with neurons and influence activity by inducing changes in receptor 
expression and neuropeptide release (Catala et al., 2013; Huang et al., 2013). 
 
Neural components of the CNS include the spinal cord (SC), brainstem and brain; while 
microglia, astrocytes and oligodendrocytes make up the non-neural components (D'Mello 
et al., 2008; Milligan et al., 2009). Input from the PNS is transferred to the CNS at the 
dorsal horn of the spinal cord from the DRG, while the medullary dorsal horns of the 
trigeminal spinal tract nucleus receives input from the TG (Huang et al., 2013). The grey 
matter of the spinal cord is subdivided into 10 sections (laminae) containing numerous cell 
types, including nociceptive-specific (NS), low-threshold (LS), wide dynamic range 
(WDR) neurons and interneurons (Basbaum et al., 2009; D'Mello et al., 2008; Millan, 
1999; Steeds, 2016). Sensory information is processed in the dorsal horn region which 
includes the first 6 laminae, as well as the tenth (grey matter around central canal) 
(D'Mello et al., 2008; Millan, 1999). NS cells are primarily found in the most superficial 
laminae, I and II (specifically the superficial section known as outer laminae II (II0)) and 
only respond to nociceptive input from C- and Ad-fibres; a smaller number are present in 
deeper laminae; IV, V, VI and X (Basbaum et al., 2009; Millan, 1999; Todd, 2002). These 
deeper laminae also contain LS cells which only respond to input from Ab-fibres, and 
WDR cells which are able to respond to all types of peripheral input from light touch to 
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noxious mechanical and thermal (D'Mello et al., 2008; Steeds, 2016). Therefore, 
nociceptive signals alone are processed in the most superficial laminae, while all neuron 
types can signal through deeper laminae. Excitatory (glutamatergic) and inhibitory 
(GABAergic, glycinergic) interneurons make up a significant proportion of dorsal horn 
neurons influencing the activity of NS and WDR cells and are therefore important in 
output from the dorsal horn (D'Mello et al., 2008; Maxwell et al., 2007). Inhibitory 
interneurons play multiple important roles; including preventing spontaneous excitatory 
firing, separating different signalling modalities (e.g. low-threshold vs nociceptive) and 
preventing spatial spread of nociceptive input to maintain somatotopic representation 
(Cioffi, 2018). Higher structures involved in nociceptive transmission include the 
parabrachial nuclei (PB) and periaqueductal grey (PAG) of the brainstem, thalamus 
(ventrocaudal, medial), and numerous cortical regions (primary and secondary 
somatosensory, insular, anterior cingulate and prefrontal) (D'Mello et al., 2008). The 
details of these pathways will be discussed further in section 1.2.2.  
 
Astrocytes are the most abundant cell type in the CNS. Connected by gap junctions, 
astrocytes support neuron function. They also encapsulate the synapse and are closely 
associated with capillaries enabling them to become a signalling pathway between 
neurons, astrocytes and capillaries. This allows modulation of water balance, synaptic 
transmission, blood flow, and potassium and glutamate homeostasis (Haydon, 2001; 
Milligan et al., 2009; Ransohoff et al., 2012). Microglial cells are considered macrophage 
cells of the CNS and constitute approximately 10% of all cells (Ransohoff et al., 2012). 
The first line of defence against homeostatic changes including invading pathogens, 
microglia survey their environment by extending and retracting philopodia (Cao et al., 
2008; Nimmerjahn et al., 2005). Like astrocytes, microglia are intimately linked with the 
synapse providing support for synaptic transmission (Cao et al., 2008). Oligodendrocytes 
are primarily involved in myelination of CNS axons, while also assisting neural 
communication and modulating neuronal function (Cao et al., 2008; Milligan et al., 2009). 
 
To maintain its delicate chemical composition while preventing entry of neurotoxic plasma 
components, pathogens and blood cells, the blood brain barrier (BBB) isolates the CNS 
from peripheral tissues (Sweeney et al., 2019). Endothelial cells form continuous non-
fenestrated capillaries and the innermost layer. Pericytes incompletely cover the 
endothelial layer and are embedded in a basement membrane; to which astrocytes, linked 
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by gap junctions attach. Peripheral and central immune cells in the form of macrophages 
and microglia are also present at the BBB (Sharif et al., 2018; Sweeney et al., 2019). 
Further, epithelial cells at the choroid plexus form the blood-CSF (BCSF) barrier and 
arachnoid membrane (surrounding brain and SC) (Abbott et al., 2010). These sites are 
important for the infiltration of peripheral immune cells during injury and/or disease, the 
importance of which will be discussed in section 1.4. 
 
1.2.2 Nociception – neural pathways 
Specific neural pathways receive nociceptive signals and relay them to higher brain 
centres; each pathway is responsible for different sensory aspects of pain, related to its SC 
origin and final destination (Tracey et al., 2007). All nociceptive signals begin outside the 
CNS, synapsing with either NS, LS or WDR cells, known as second order projection 
neurons. Numerous tracts originate from these second order neurons, with major outputs 
being from laminae I and V (Basbaum et al., 2009). Major tracts include the spinothalamic 
and spinoreticular tracts, of which the majority of second order neurons cross-over 
(decussate) to the white matter on the opposite (contralateral) side of primary afferent 
stimulation; before projecting to higher CNS sites (Millan, 1999; Tracey et al., 2007; Yam 
et al., 2018). A majority of the ascending tracts synapse at the thalamus before reaching 
cortical regions including the primary and secondary somatosensory cortices; the insula, 
anterior cingulate and prefrontal cortex (D'Mello et al., 2008; Millan, 1999). Sending the 
signal to multiple cortical areas allows differentiation of nociceptive input, from sensory 
discriminative aspects (e.g. location, intensity, sharp/diffuse) to autonomic and 
affected/emotional aspects of pain (D'Mello et al., 2008; Yam et al., 2018). Multiple 
ascending tracts enter the thalamus only after synapsing or sending offshoots at brain stem 
sites, including the periaqueductal grey (PAG), reticular formation, rostral ventral medulla 
(RVM) and tectum (Kendroud et al., 2020; Yam et al., 2018). From these brainstem sites, 
along with the thalamus, further ascending tracts connect the hypothalamus and limbic 
system (Kendroud et al., 2020). Nociceptive input from visceral organs follows the same 
ascending routes, which is often the reason for referred pain, as the brain interprets visceral 
input as the somatic input entering at the same spinal cord level (Steeds, 2016). Trigeminal 
nociceptors relay information from the orofacial region (head, face, intraoral), entering the 
CNS at the brainstem (pons, medulla). From here, second order neurons synapse at the 




Descending pathways play an important role in nociceptive transmission. Signals from the 
brainstem influence activity at the SC level, both facilitating and inhibiting nociceptive 
transmission (D'Mello et al., 2008; Millan, 1999; Tracey et al., 2007). Two important 
regions are the PAG and RVM. The PAG receives input from the spinothalamic tract, 
thalamus, hypothalamus, limbic system and cortex (D'Mello et al., 2008; Steeds, 2016). 
PAG neurons then excite cells of the RVM, an important site for integrating spinal cord 
descending influence. RVM projections return to the dorsal horn and generally inhibit 
transmission of nociceptive signals by modulating neurotransmitter release and altering 
activity of inhibitory interneurons, mechanisms of which are discussed in section 1.2.4. 
(Millan, 1999; Steeds, 2016). Further to the PAG-RVM system, the dorsal reticular 
nucleus (DRt) and ventrolateral medulla (VLM) also exert descending modulation 
(Heinricher et al., 2009). Similarly to the PAG-RVM system, these descending tracts can 
communicate directly with primary and secondary neurons as well as dorsal horn 
interneurons to influence pain outcomes (Cioffi, 2018). 
 
1.2.3 Signal generation and transmission 
Nociceptors detect noxious stimuli due to the array of surface ion channels and receptors at 
their exposed peripheral terminals; the type and amount of which determine which 
stimulus, be it heat, chemical or mechanical, excites the nociceptor (Woolf et al., 2007). 
Nociceptors can be classified as high-threshold mechanoreceptors, responding to intense 
mechanical stimuli; thermal receptors, responding to thermal (hot or cold) stimuli; and 
polymodal receptors, responding to mechanical, thermal and chemical stimuli (Basbaum et 
al., 2009; Kendroud et al., 2020). Major channel types include transient receptor potential 
(TRP), acid sensing ion channels (ASICs) and two pore background potassium channels 
(K2P) (e.g. TRAAK, TREK-1) (Basbaum et al., 2009).  
 
TRP channels are nonselective cation channels, considered the most important family for 
detection of noxious stimuli due to wide expression profile and polymodal nature. Three of 
the six subfamilies, ankyrin (TRPA), vanilloid (TRPV) and melastatin (TRPM) play 
important roles in nociception (Gonzalez-Ramirez et al., 2017). Detection of thermal 
stimuli is well documented in TRP channels, transient receptor potential cation channel 
subfamily V member 1 (TRPV1), discovered as the receptor for capsaicin, is found on the 
majority of heat sensitive nociceptors, while transient receptor potential cation channel 
subfamily M member 8 (TRPM8) is expressed on the majority of cold sensitive 
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nociceptors (Caterina et al., 1997; Peier et al., 2002). Multiple other TRP channels are 
involved in the detection of noxious heat (TRPV2, TRPV3, TRPV4) and cold (TRPA1) 
(Basbaum et al., 2009; Dhaka et al., 2006). As mentioned, TRP channels are polymodal 
and respond to numerous chemical stimuli including capsaicin, protons, toxins (TRPV1), 
mustard, wasabi, cinnamaldehyde (TRPA1) and menthol (TRPM8) (Basbaum et al., 2009). 
ASICs including ASIC3, ASIC1A and ASIC1B are permeable to cations and implicated in 
nociception. Known for the response to protons produced by tissue ischemia, activation by 
mechanical stimuli and non-proton chemical stimuli has also been observed (Basbaum et 
al., 2009; Wemmie et al., 2013; Yu et al., 2010). Potassium channels present at peripheral 
terminals play a regulatory, rather than faciliatory role in nociceptive firing. Potassium 
channels respond to thermal (TREK-1, -2, TRAAK), mechanical (TREK-1, -2, TRAAK) 
and chemical (TREK-1, TASK-1,- 3.) stimuli (Du et al., 2013; Honore, 2007; Kang et al., 
2005).  
 
Increases in cation influx at the afferent terminals has a depolarising effect on membrane 
potential, in turn activating voltage-gated ion channels critical for propagation of the action 
potential, the frequency of which determines stimulus intensity (Basbaum et al., 2009). 
Voltage gated sodium (NaV) and calcium channels are important for this process, while 
K2Ps and voltage gated potassium channels (Kvs) exert regulatory influence. NaV1.7 and 
1.8 in particular are well characterised due to their high expression levels in C-fibres; with 
altered function resulting in clinical pain disorders erythromelalgia and paroxysmal 
extreme pain disorder (Basbaum et al., 2009; Nassar et al., 2004). Generally, it is NaV 
channels which are activated when the appropriate membrane potential is reached, starting 
the action potential which propagates along the neuron (Yam et al., 2018).  
 
Numerous Kv and K2P channels are associated with nociceptor function; maintaining 
resting potential and therefore nociceptor threshold, repolarising the cell following action 
potential, and as mentioned above, responding to noxious stimuli (Tsantoulas et al., 2014). 
Due to their activity at resting membrane potential, Kv7 (M channels) are considered an 
important element of maintaining resting membrane potential and overall nociceptor 
activation threshold. Enhancing Kv7 activity by altering voltage characteristics reduces 
nociceptive stimulation (Brown et al., 2009). Due to their presence on small diameter 
primary afferents, alongside TRPV1, Kv1.4 is implicated in nociceptive function (Rasband 
et al., 2001). Further, Kv1.4 levels are reduced in neuropathic pain models and implicated 
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in alteration of membrane potential and decreased excitability in glycoprotein 130 deficient 
nociceptors (Langeslag et al., 2014; Rasband et al., 2001). T-type voltage gated calcium 
channels (VGCC) present on the cell body and neuronal dendrites are also important to 
maintenance of resting potential. Knockdown of these low-voltage activated channels 
results in attenuated nociceptive sensitivity following nerve injury; highlighting their 
regulatory role in nociceptive threshold maintenance (Cao, 2006).  
 
Upon reaching the presynaptic terminal, an action potential induces neurotransmitter 
release by activating VGCCs. High threshold N-, Q/T- and R-type VGCCs exist within the 
dorsal horn, with differing distribution across the laminae (Cao, 2006; Zamponi et al., 
2009). Following activation of VGCCs, calcium enters the presynaptic terminal promoting 
fusion of neurotransmitter vesicles to the neuronal membrane. Typically, Ad-fibres release 
glutamate, while C-fibres release various neuropeptide neurotransmitters, including 
calcitonin gene-related peptide (CGRP) and substance P (SP) (Kendroud et al., 2020). 
Glutamate exerts its excitatory effect on multiple receptors once crossing the synapse, 
including; a-amino-3-hydroxy 5-methyl-4-isoxazeloproprionic acid (AMPA), N-methyl-
D-aspartate (NMDA) and G-protein coupled metabotropic receptors (mGluR), inducing 
calcium influx (D'Mello et al., 2008; Stanley, 2016). SP and CGRP bind to neurokinin 1 
receptors (NK-1) and the receptor activity modifying protein 1 (RAMP1) accessory 
protein/calcitonin receptor-like receptor (CRLR) complex respectively, inducing 
intracellular signalling and activating kinases which facilitate glutamatergic transmission 
(Iyengar et al., 2017; Zieglgansberger, 2019). Neurotransmitters must be removed from the 
synaptic cleft in order to stop continued signal transmission. This can be achieved by 
degradation, reuptake by the releasing nociceptor, removal by astrocytes and drifting (Yam 
et al., 2018). Glutamatergic transmission results in excitatory post-synaptic currents 
(EPSCs) in the secondary order projections. Summation of ESPCs results in action 
potential, transmitting the nociceptive signal (Basbaum et al., 2009). 
 
In addition to neurotransmitters, a number of neuromodulatory substances may be released 
by nociceptors depending on the CNS environment. Fractalkine, a chemokine expressed by 
nociceptors is cleaved from the membrane in response to overstimulation (Chapman et al., 
2000; Verge et al., 2004). Adenosine triphosphate (ATP) is released by damaged cells as 
well as during synaptic transmission, modulating excitatory signals by binding presynaptic 
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ATP receptors (P2X), enhancing glutamate release (Li et al., 1998; Nakatsuka et al., 2001). 
Synaptic vesicle release can also promote d-opioid receptors (DOR) to the cell membrane, 
joining µ-opioid receptors (MOR) and cannabinoid receptors (CB1) in an analgesic role at 
the presynaptic terminal (Guan et al., 2005; Woolf et al., 2007). 
 
1.2.4 Descending influence 
As described above, ascending pathways are moderated by descending inhibition and 
facilitation by a PAG-RVM system (Heinricher et al., 2009). The dorsal horn is a key site 
for integration of ascending and descending signals; ultimately it is the dynamic interaction 
of descending inhibitory and excitatory signals which determine nociceptor output to 
higher brain centres. This balance is altered by multiple factors, including illness, injury, 
stress and fear (Heinricher et al., 2009). Activity of pain inhibiting OFF-cells or pain 
facilitating ON-cells in the RVM determines the descending effect on the dorsal horn, with 
low nociceptive thresholds associated with an active ON-cell population and inactive OFF-
cell population (Heinricher, 2016; Heinricher et al., 1989; Ossipov et al., 2010). The 
modulation of each of these RVM cell types by the PAG is the mechanism of action for a 
number of receptor systems, importantly, opioids and cannabinoids (Maione et al., 2006; 
Maione et al., 2009). Outside of the PAG-RVM system, the areas of caudal medulla, DRt 
and VLM participate in descending modulation. Both systems consist of closed loops with 
the dorsal horn. The DRt receives ascending input and plays a mainly facilitatory role in 
descending modulation (Lima et al., 2002). While the VLM exerts a tonic inhibitory 
function via noradrenergic cells (Tavares et al., 2002). 
 
Endogenous opioids, including b-endorphin, dis-inhibit PAG output neurons, increasing 
OFF-cell firing while inhibiting ON-cells and exerting an inhibitory tone onto the dorsal 
horn (Adams et al., 1986; Fields et al., 1991; Heinricher, 2016). This inhibition is 
associated with an increase in inward potassium conductance at presynaptic GABAergic 
inputs and postsynaptic PAG and RVM GABAergic interneurons (Chieng et al., 1994; Lau 
et al., 2014). An interaction with co-expressed TRPV1 has also been observed in vivo as 
non-analgesic doses of either agonist when co-administered produce analgesia to thermal 





CB1 receptors are also highly expressed in the RVM descending tracts. Excessive 
glutamate production activates glutamate receptor mGlu5, releasing endocannabinoids 
(endogenous cannabinoids), in turn, activating CB1 receptors in the RVM. Activation of 
CB1 receptors reduces GABAergic tone by presynaptic inhibition thereby dis-inhibiting 
OFF cell descending tracts (Lau et al., 2014; Maione et al., 2006). The effect of 
endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) on OFF-cell 
activity is dependent on their relative levels in tissue, therefore can have either a 
facilitatory or inhibitory role (Maione et al., 2006). Their pro-nociceptive effect at low 
doses is thought to involve their CB1 activation on excitatory (glutamatergic) neurons 
(Maione et al., 2006; Marsicano et al., 2003). Like opioid expressing cells within the PAG, 
CB1 receptors are colocalised with TRPV1 which is activated by AEA, resulting in 
immediate analgesia in rat a thermal pain model by activation of OFF cells. Therefore, the 
effects of endocannabinoids in the PAG on descending pain modulation is determined by 
concentrations, relative timing of release and their actions at both CB1 and TRPV1 
receptors (Maione et al., 2006).  
 
Descending projections include serotonergic, glycinergic, GABAergic and noradrenergic 
neurons. Hydroxydopamine (5-HT), also known as serotonin, can be both pro- and anti-
nociceptive depending on which receptor it binds; it is unclear which RVM population is 
serotonergic, or indeed if action is direct or via interneurons (Ossipov et al., 2010). 
Nevertheless, antagonising spinal receptors 5-HT7 and 5-HT3 has both pro- and anti-
nociceptive effects respectively, suggesting relevance of serotonergic tone on the dorsal 
horn (Dogrul et al., 2009). Noradrenergic neurons are not found at either the PAG or 
RVM, however these regions connect with noradrenergic sites, including A5, A6 and A7 
nuclei which project to the spinal cord (Ossipov et al., 2010). Noradrenaline (NE) is 
released by descending neurons and targets a2 and a1-adrenergic receptors. a2-adrenergic 
receptors inhibit pre- and post-synaptic terminals resulting in nociceptive inhibition, while 
a1-adrenergic receptors depolarise inhibitory GABAergic interneurons (Gassner et al., 
2009; Pertovaara, 2006). In addition to the vast literature on 5HT and NE as descending 
neurotransmitters, there is also evidence of direct GABAergic and glycinergic descending 





1.3 Pathological Pain Models 
1.3.1 Neurogenic pain models 
Neurogenic compounds are pain producing and do not directly reflect a particular clinical 
pain state, but recruit nociceptive mechanisms leading to altered pain processing. They can 
also be considered inflammatory pain models due to their neurogenic inflammatory effect 
and are often utilised for investigation of nociceptive mechanisms and as tools for 
screening therapeutic compounds of interest. Capsaicin is widely used in animal and 
human pain models, directly activating TRPV1 channels resulting in spontaneous pain and 
longer lasting (up to 120 min) hypersensitivity (Gilchrist et al., 1996; Hutchinson et al., 
2013). Further to inducing symptoms relevant to pathological pain states; preclinical 
capsaicin models respond to commonly utilised opioid and anti-epileptic drugs (Joshi et 
al., 2006). Similarly, mustard oil is used to elicit spontaneous pain by direct activation of 
TRPA1 channels in human and animal models (Andersen et al., 2017; Laird et al., 2002). 
Bee venom is also utilised to produce short lived spontaneous pain and longer lasting 
hypersensitivity (Lariviere et al., 2000). These compounds directly activate nociceptors 
and allow greater control of pain outcomes. In addition, the procedures are minimally 
invasive, and pain induced is transient in comparison to other pain models mentioned here, 
improving ethical considerations (Joshi et al., 2006). While neurogenic compounds result 
in relevant behavioural outcomes and are attenuated by known analgesics, the overall 
clinical relevance to pathological pain is questionable given they do no replicate clinical 
pathophysiological events. 
 
1.3.2 Inflammatory pain models 
Numerous immune stimulating substances are used to induce inflammatory pain. TLR4 
agonist lipopolysaccharide (LPS) is commonly used, which does not produce spontaneous 
pain behaviours but induces pain hypersensitivity in clinical and preclinical animal models 
(Calil et al., 2014; Maier et al., 1993; Wegner et al., 2014). Similarly, intrathecal human 
immunodeficiency virus-1 envelope glycoprotein, gp120 is used to induce thermal and 
mechanical hyperalgesia (Milligan et al., 2001b). Complete Freund’s adjuvant (CFA) and 
carrageen represent commonly administered immune driven pain mediators. CFA and 
carrageen are commonly administered into the hind-paw producing peak hypersensitivity 
between 6-8 h post administration; carrageen-induced sensitivity persists compared to CFA 
(Cunha et al., 2005; Ren et al., 1999). Similarly, zymosan can be administered into the 
hindpaw for short lasting (6 h) sensitivity, or centrally to induce mechanical 
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hypersensitivity lasting weeks (Milligan et al., 2003; Sweitzer et al., 1999). Formalin, 
commonly administered subcutaneously, causes both spontaneous pain and mechanical 
hypersensitivity lasting 60 min (Choi et al., 2003; Sweitzer et al., 1999). Less common 
inflammatory mediators include lithium chloride, picrotoxin, and kainite (LaBuda et al., 
2000; Maier et al., 1993; Oliveras et al., 1996). Similar to neurogenic compounds, these 
compounds don’t reflect clinical pathophysiology in terms of causation and timeframes. 
However, they can be useful for understanding mechanisms associated with inflammatory-
induced nociceptive signalling changes. Further, many of these models are carried out over 
longer time periods, a disadvantage to both subject and experimenter compared to 
neurogenic models.  
 
There are however inflammatory pain models which aim to replicate clinical disease 
pathophysiology. Arthritis models are often used as a screen for compounds ready for early 
clinical trials (Berge, 2011). These models include antigen-induced arthritis (AIA), 
collagen-induced arthritis (CIA), and monosodium iodoacetate arthritis (MIA). Models of 
arthritis can induce mechanical and thermal hypersensitivity upwards of 30 days (Boettger 
et al., 2008; Ebbinghaus et al., 2012; Fernihough et al., 2004; Inglis et al., 2007). Multiple 
behaviours are observed in arthritis models which are potentially relevant in clinical 
situations, including weight bearing and limb movement (Gregory et al., 2013). Other 
examples of preclinical inflammatory models aimed at specific clinical pathologies include 
remifentanil administration to replicate opioid-induced hyperalgesia (OIH), incision 
models imitating post-surgical pain and meningeal inflammatory stimulation to mimic 
migraine (Aguado et al., 2018; Melo-Carrillo et al., 2013; Pogatzki et al., 2002).  
 
1.3.3 Neuropathic pain models 
Neuropathic pain models are developed to recreate the pathophysiological mechanisms 
following nervous system damage. Damage to peripheral nerves is a common method of 
inducing neuropathic pain hypersensitivity, resulting in common clinical sensitivity 
changes (Campbell et al., 2006). Multiple nerve ligation models exist due to multiple 
attempts to create a standardised approach (Berge, 2011). Chronic constriction injury 
(CCI) of the sciatic nerve is commonly performed, inducing thermal and mechanical 
hypersensitivity up to 4 weeks (De Leo et al., 1997). Ligation of spinal nerve roots (SNL) 
causes similar hypersensitivity (up to 35 days) (Arruda et al., 2000; Hashizume et al., 
2000; Kim et al., 1992). Similar time frames are observed following partial sciatic nerve 
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ligation (PSNL) (Seltzer et al., 1990). Spinal cord hemisection is a form of spinal cord 
injury (SCI) used to create mechanical hypersensitivity lasting 6 weeks (Peng et al., 2006). 
Spared nerve injury (TST), transecting the common peroneal and tibial nerves, results in 
significantly greater duration of sensitivity, (upwards of 200 days) for mechanical, heat 
and cold stimuli (Decosterd et al., 2000). Less common techniques, include sciatic 
cryoneurolysis, sciatic nerve transection and facial nerve ablation albeit with varying 
timeframes owing to the nature of injury (De Leo et al., 1994; Kiefer et al., 1993; 
Rotshenker et al., 1992). A significant downside to this approach is that it is in contrast to 
clinical trials of neuropathic pain, which don’t use subjects with comparable lesions. 
Instead, they more frequently include patients with port-herpetic neuralgia and diabetic 
neuropathies (Finnerup et al., 2010; Rice et al., 2008). This approach makes it difficult to 
compare clinical and preclinical outcomes. Finally, these models report elicited 
behavioural sensitivities, ignoring the significant clinical symptom of spontaneous pain. 
 
Neuropathic pain results from numerous clinical pathologies, the pathophysiology of 
which are recreated in preclinical pain models in an attempt to overcome the relevance 
issues of above models which utilise traumatic lesions. Diabetic neuropathy is one such 
example, including the streptozotocin-diabetic model, numerous diabetic mouse strains and 
diet-induced diabetes (Ahlgren et al., 1993; Obrosova, 2009; Wuarin-Bierman et al., 1987). 
Chemotherapy-induced neuropathic pain (CINP) models are widely used, utilising multiple 
drugs including paclitaxel, vincristine, cisplatin and bortezomib (Flatters et al., 2004; 
Robinson et al., 2015; Yan et al., 2015). Cancer pain models are also commonly utilised, 
inoculating tumour cells to specific target areas (Jaggi et al., 2011; Shimoyama et al., 
2002). Whether these models reflect clinical symptoms is questionable however (Berge, 
2011; Gregory et al., 2013). While the exact mechanisms underlying the generation of 
pathological pain remain elusive, these models, along with the clinical disease mimicking 
inflammatory models, currently offer the best chance of bridging the knowledge gap. 
 
1.3.4 Measurable Outcomes 
All models require measurable outcomes from which researchers can infer pain. As 
mentioned above, spontaneous pain is clinically the most significant symptom of 
pathological pain; many neurogenic and inflammatory models monitor spontaneous 
behaviours, including flinching, biting, tail flick, blinking and altered body position/or 
movement (Gregory et al., 2013; Kemper et al., 1998; Laird et al., 2001a; Liu et al., 2013; 
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Sakurada et al., 1992). Pain sensitivities are monitored by eliciting responses to mechanical 
or thermal stimuli. Common tests for mechanical sensitivity include the von Frey test and 
paw withdrawal thresholds which apply a static force to the hindpaw (Gilchrist et al., 1996; 
Gregory et al., 2013; Otuki et al., 2005). Thermal tests include withdrawal from hot or cold 
surfaces and water, commonly used are the Hargreaves test (light source), hot/cold plate 
tests, tail withdrawal/flick tests and acetone application (Gregory et al., 2013; Honda et al., 
2008; Ko et al., 1998; Negri et al., 2006; Yalcin et al., 2009). While these observations are 
relevant to clinical symptoms, the relevance is often limited, and some clinical symptoms 
are ignored altogether. For example, spontaneous behaviours mentioned above are induced 
by direct neuronal stimulation or inflammation, dissimilar to non-evoked spontaneous pain 
in clinical chronic pain patients (Backonja et al., 2004; Hansson, 2003). Similarly, static 
mechanical testing ignores clinical instances of allodynia induced by dynamic stimulation. 
Further, paraesthesia (abnormal sensations) and sensory loss are ignored in animal pain 
models (Hansson, 2003). Consideration of these less explored, yet clinically relevant 
symptoms may provide greater context to the relevance of currently utilised models. 
 
1.4 Neuroimmune pain 
1.4.1 Neuroimmune background 
As described earlier, the nervous system contains numerous non-neural cell types 
including satellite glia, Schwann cells, astrocytes, microglia and oligodendrocytes, which 
are important for maintaining nervous system homeostasis (Greenhalgh et al., 2020; Huang 
et al., 2013; Stevens, 2003). Following injury or illness, astrocytes and microglia are 
considered the major responsive cell types of the CNS, and along with CNS infiltrating 
peripheral monocytes and T-cells are involved in identifying and removing pathogens and 
repairing associated damage (Ransohoff et al., 2012). This involves release of immune 
mediating cytokines, chemokines and neurotrophic factors which instigate changes in 
surrounding glia and neurons (Grace et al., 2014; Greenhalgh et al., 2020). This 
communication is referred to as neuroimmune signalling and ultimately leads to alteration 
in processing of nociceptive signals in both the PNS and CNS following illness or injury 
(Grace et al., 2014). The three major contributors are neurons (pre- and post-synaptic 
terminals), astrocytes and microglia which form a tetrapartite synapse, an important site for 
central neuroimmune communications (De Leo et al., 2006). Outside of the CNS, 
important neuroimmune communication occurs at peripheral nerve terminals influenced by 
peripheral immune responses and neuropeptide release (Baral et al., 2019). As such, 
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neuroimmune signalling is a bidirectional relationship between neural and non-neural 
elements to affect outcomes of nociceptive input (Baral et al., 2019; Cao et al., 2008). 
 
1.4.2 Immunologically active glia 
Glial cells are able to respond to illness and injury due to the plethora of pattern 
recognition receptors (PRRs) they express. PRRs recognise molecular epitopes released by 
damaged and stressed endogenous cells known as DAMPs (danger associated molecular 
patterns), as well as exogenous pathogens known as PAMPs (pathogen associated 
molecular patterns) (Takeuchi et al., 2010). Commonly expressed PRRs include toll-like 
receptors (TLRs) and NOD-like receptors (NLRs). Glia also express receptors which 
detect neuropeptides released by nociceptors and postsynaptic neurons including SP, 
glutamate, CGRP, ATP, fractalkine, prostaglandins (PGs) and nitric oxide (NO) (Cao et 
al., 2008).  
 
Constitutively expressed membrane receptors are key to initiating microglial responses and 
include TLRs, purinergic receptors and fractalkine receptors (CX3CR1) (Cao et al., 2008). 
Microglia respond rapidly following stimulation, resulting in morphological changes 
(stratified to ameboid appearance), increased proliferation, altered migration and 
phagocytosis, and changes in gene expression. This includes changes in cell-surface 
molecules including, complement receptor 3 (CD3), major histocompatibility complex 
(MHC) class 1 and 2, PRRs and numerous cytokine and chemokine receptors (Hanisch, 
2002; Olson et al., 2004). Further to changes in receptor expression, multiple soluble 
factors are released, including cytokines; interleukins (IL-1b, IL-6, IL-8, IL-10, IL-18 IL-
2) and tumour necrosis factor α (TNFα), chemokines (incl. CCL2, CCL5, M-CSF), NO, 
ATP and PGs (Hanisch, 2002; Inoue, 2006; Li et al., 2003; Ransohoff et al., 2012).  
 
Evidence suggests the molecular signals released following afferent damage is key to 
engaging microglial signalling, of which ATP plays a significant role. ATP is an important 
microglia “reactivator;” binding P2-type purinergic receptors (Basbaum et al., 2009). 
P2X4, P2X7 and P2Y are expressed on microglia and upregulated following activation. P2 
receptors are cation channels, activation therefore increases intracellular calcium, 
promoting activation of p38 mitogen-activated protein kinase (MAPK) (Trang et al., 
2012). p38 MAPK activity following P2X4 activation results in release of brain-derived 
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neurotrophic factor (BDNF), while IL-1b and cathepsin S are released following P2X7 
activation (Clark et al., 2010; Clark et al., 2007; Trang et al., 2009).  
 
CX3CR1, the fractalkine receptor is another cation channel upregulated in microglia, 
activation of which results in increased intracellular calcium and increased p38 MAPK 
(Chapman et al., 2000; Verge et al., 2004; Zhuang et al., 2007). CX3CR1 in the CNS is 
restricted to microglia and considered to have neuroprotective function in uninjured 
tissues, supporting neuronal and microglial survival in neurotoxic environments (Cardona 
et al., 2006). Cathepsin S, released by microglia following ATP stimulation, cleaves 
fractalkine from the presynaptic membrane, resulting in a positive feedback loop further 
enhancing microglia responses, providing a mechanism by which fractalkine signalling 
contributes to the pathological pain state. Indeed, cathepsin S inhibitor LHVS attenuates 
mechanical hypersensitivity associated with neuropathic pain in rats (Clark et al., 2007). 
Chemotactic cytokine receptor 2 (CCR2) is another receptor upregulated on microglia in 
inflammatory conditions, enhancing chemoattraction, and microglial activation (Abbadie 
et al., 2003; Zhang et al., 2018). 
 
Multiple TLRs (1 - 9) are expressed at low levels on microglia in healthy tissues and 
upregulation occurs rapidly upon activation (Bsibsi et al., 2002; Konat et al., 2006; 
Lehnardt, 2010). TLR activation results in activation of transcription factor nuclear factor 
kappa-light-chain enhancer of activated B cells (NF-kB), leading to transcription of 
interleukin-1 (IL-1) family genes, producing pro forms of IL-1 and IL-18 (Chakraborty et 
al., 2010; Ransohoff et al., 2012). Key to the conversion or pro-IL-1b and pro-IL-18 into 
their active forms (IL-1b, IL-18) is caspase-1, which itself is activated by inflammasomes, 
large structures containing pattern recognition NLRs, adaptor proteins and effector 
caspases (Martinon et al., 2004). Extensively studied in microglia, inflammasome 
(NLRP3) activation is induced by numerous DAMPS and PAMPS including ATP, uric 
acid and bacterial protein and RNA (Halle et al., 2008; Petrilli et al., 2007; Ransohoff et 
al., 2012). Caspase independent cleavage of pro-IL-1b has also been reported in 
neuropathic pain following TNFα-induced microglial activation, by matrix 
metalloprotease-9 (MMP-9) (Kawasaki et al., 2008). Of particular interest due to their 
apparent role in pathological pain are TLR2 and TLR4. In models of nerve injury, 
knockout of both TLR4 and TLR2 produce significant reduction in cytokine output and 
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reduced glial morphological changes, highlighting their role in glial responses to injury 
(Kim et al., 2007; Tanga et al., 2005). TLR4 responds to exogenous ligands including gram 
negative bacterial cell wall component LPS, and endogenous ligands including heat shock 
proteins (HSPs), causing release of proinflammatory cytokines (interferon-g (IFN g), IL-
1b, IL-6 and TNFα) and other immunomodulatory substances including inducible-nitric 
oxide synthase (iNOS) (Nicotra et al., 2012; Olson et al., 2004; Tanga et al., 2005). TLR4 
activation also induces microglial neuroprotective effects including phagocytic repair 
(Glezer et al., 2006). TLR2 activation results in the same pro-inflammatory milieu induced 
by TLR4 although alternate danger signals activate the receptor, including gram positive 
bacterial cell wall components (Kawai et al., 2007b; Kim et al., 2007).  
 
Astrocyte responses are delayed and persist compared to those of microglia in preclinical 
pain models. Changes in astrocyte activation often correlate with induction of altered 
behavioural sensitivity (Hashizume et al., 2000; Ren et al., 2008). Interestingly in contrast 
to astrocytes, microglial stimulation is not always required for persistent pain in animal 
models and human tissues, as observed in rat CINP and clinical HIV tissues (Robinson et 
al., 2014; Shi et al., 2012). In contrast to microglia, astrocytes constitutively express only 
few TLRs; in humans TLR 2 and -3 have been detected, while TLR2, -3, -4, and -9 have 
been reported in murine astrocytes (Bowman et al., 2003; Bsibsi et al., 2002; Gorina et al., 
2009). Following stimulation of TLRs and NLRs astrocytes produce inflammatory 
cytokines IL-1b and IL-6, and chemokines CCL2, CXCL1, CXCL10 and CXCL12 
(Ransohoff et al., 2012). Similar to microglia, cleavage of pro-IL-1b in astrocytes is 
mediated by MMP-2, however at later time points associated with its relatively late 
response (Kawasaki et al., 2008). This cleavage of pro-IL-1b is also observed in satellite 
glia with comparable timing (Kawasaki et al., 2008). In further contrast to microglia, 
expression of MHC in astrocytes is low, which brings into question their in vivo 
significance to antigen presentation. However there is strong evidence that astrocytes are 
heavily involved in T-cell activation (Tian et al., 2012). Along with microglia, astrocyte-
induced chemokines recruit T-helper cells (Th1, Th2), promote recruitment of T regulatory 
cells (Treg) via cytokine transforming growth factor b (TGF- b) and CXCL1, while also 
releasing anti-inflammatory IL-10, capable of suppressing T cell and microglia activation 




Upregulation of gap junction proteins is observed in CINP, CCI and SCI pain models 
(Chen et al., 2014; Cronin et al., 2008; Robinson et al., 2015). Of particular importance is 
connexin 43 (CX43), upregulated in aforementioned pain models, inhibition of which 
results in reversal of mirror image allodynia, brief attenuation of ipsilateral thermal 
hyperalgesia and improved recovery times (Cronin et al., 2008; Spataro et al., 2004). These 
results suggest that astrocytic communication influences distant synapses, potentially 
through release of pro-inflammatory cytokines IL-1 and IL-6 (Spataro et al., 2004). 
Further, CX43 forms hemichannels following nerve injury, allowing release of numerous 
neuromodulator substances including ATP, glutamate and CXCL1, exacerbated by the 
concurrent upregulation of CX43 (Chen et al., 2014; Huang et al., 2012; Ji et al., 2019). 
 
Glutamate transporters (GLT1, GLAST) constitutively expressed on astrocytes and 
important for maintaining glutamate homeostasis at the synapse, are downregulated in 
preclinical pain models. PSNL and CINP models report astrocytic downregulation of 
GLT1 and GLAST in rats (Robinson et al., 2015; Xin et al., 2009). While minocycline pre-
treatment prevents decreases in glutamate transport in a CIPN model (Robinson et al., 
2015). Interestingly, SC analysis shows an initial upregulation in GLAST and GLT-1 4 
days after CCI, followed by downregulation at 14 days. PSNL initiates expression of GLT-
1 and GLAST in microglia, potentially explaining rapid increases in SC glutamate 
transporters, while delayed downregulation is associated with later responding astrocytes 
(Sung et al., 2003).  
 
It is clear that activation of typically immune receptors and associated signalling can alter 
the neuromodulatory elements surrounding neurons. These include changes to glutamate, 
cytokine, chemokine, ATP, NO, cathepsin S and PG levels. In addition to DAMPs and 
PAMPs, elements released by/from neurons, such as SP, glutamate, fraktaline and ATP 
also stimulate glia to induce further changes. It is now important to understand how these 
neuroimmune interactions alter nociceptive transmission, both centrally and in the 
periphery.  
 
1.4.3 Neuroimmune interactions – peripheral sensitisation 
Peripheral sensitisation results in increased excitability of nociceptors, causing 
hyperalgesia and allodynia within their receptive field (Grace et al., 2014). Excitability 
changes are a result of lowered activation thresholds, by a process known as sensitisation. 
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Sensitisation can result from numerous mechanisms, including; upregulation of, or altered 
ion channel kinetics (increased receptor activation for a given stimulus), and changes in 
thresholds for NaV opening (Campbell et al., 2006). Immune activation in the periphery, or 
release of immune modulating neurotransmitters and neuropeptides from nociceptor 
terminals contribute to peripheral sensitisation.  
 
Peripheral inflammation, including neuronal injury results in secretion of monocyte-
chemoattractant protein 1 (CCL2) and leukemia inhibitory factor (LIF), recruiting 
macrophages to the injury site, a key step in the process of Wallerian degeneration 
(Sugiura et al., 2000; Tofaris et al., 2002). Further recruitment of mast cells, basophils, 
fibroblasts, neutrophils, T- and B-cells and Schwann cells produces a proinflammatory 
milieu along with resident endothelial cells, neurons and keratinocytes (Basbaum et al., 
2009; Woolf et al., 2007). Often concurrently, multiple nociceptor inputs result in action 
potential propagation along collateral axon branches to the periphery releasing 
neurotransmitters which contribute to the inflammatory milieu (Yam et al., 2018). This 
milieu contains a multitude of potential neural sensitisers including cytokines, chemokines, 
PG, nerve growth factor (NGF), SP, CGRP, bradykinin, NE, 5-HT, glial derived 
neurotrophic factor (GDNF), TNFα, activin, prokineticin, proteases, protons, NO and ATP 
(Basbaum et al., 2009; Woolf et al., 2007; Yam et al., 2018). Sensitising agents bind their 
respective receptors initiating intracellular signalling, of which important regulators 
include; protein kinase C (PKC), protein kinase A (PKA), phospholipase C (PLC), 
phosphoinositide 3-kinase (PI3K), ERK- and p38- MAPK (Cheng et al., 2008; Yam et al., 
2018).  
 
PKC, PKA and PI3K are implicated in phosphorylation of TRPV1 receptors, increasing 
their response to chemical stimuli (Varga et al., 2006; Zhang et al., 2005). Similarly, PKC 
activation following bradykinin stimulation sensitises TRPA1 channels to cold stimuli 
(Bautista et al., 2006). Mechanical sensitivity induced by NGF, which binds to receptor 
tyrosine kinase (TrkA) and neurotrophin receptor p75, is attenuated by inhibitors of PLC, 
ERK and PI3K (Malik-Hall et al., 2005). TNFα, acting on TNFR1 causes modulation of 
NaV channels via activation of p38 MAPK, facilitating channel opening (Jin et al., 2006). 
These studies also highlight the key effector channels in peripheral sensitisation, namely 
TRP and NaV channels. Of which TRPV1, TRPA1 and NaV-1.7, -1.8 and -1.9 contribute 
significantly to peripheral sensitisation (Amaya et al., 2006; Caterina et al., 2000; del 
 
 21 
Camino et al., 2010; Kerr et al., 2001; Nassar et al., 2004; Varga et al., 2006). Membrane 
channel activity is also altered by lipid membrane components which can be altered by 
these intracellular signalling effectors. Hydrolysis of phosphatidylinositol 4,5-bisphospate 
(PIP2) by bradykinin- and NGF-induced PLC activation releases TRPV1 from PIP2 
mediated inhibition (Chuang et al., 2001).  
 
While the primary role of cytokines in peripheral sensitisation is the potentiation of the 
inflammatory response, there is evidence of direct effects. Nociceptors express a variety of 
classical immune receptors including those for TNFα and IL-1b (Opree et al., 2000). 
Direct sensitisation of nociceptors by TNFα and IL-1b has been reported. TNFα induces 
joint sensitivity in the rat knee joint via p38 MAPK, which is associated with increased 
excitability of excised DRG neurons (Richter et al., 2010). IL-1b reduces rat nociceptor 
thresholds to noxious heat, potentiating accumulation of intracellular calcium (Obreja et 
al., 2002). Both TNFα and IL-1b produce mechanical hypersensitivity following 
intraplantar injection in mice lasting up to 5 h, in the case of IL-1b however this was via 
downstream PG release (Cunha et al., 2005). Further, IL-1b is shown to increase 
expression of NGF, resulting in increased surface expression of TRPV1 and sensitisation 
of NaV channels in rat DRG neurons (Binshtok et al., 2008; Ebbinghaus et al., 2012; 
Kanaan et al., 1998; Lindholm et al., 1987).  
 
Upregulation of ion channels TRPV1 and TRPA1 on injured nociceptors is associated with 
increased hot and cold sensitivity respectively in neuropathic pain models (Hudson et al., 
2001; Katsura et al., 2006b). Likewise, rat and mouse models of inflammatory pain report 
upregulation of NaV1.7 and NaV1.8 in DRG neurons as well as NaV1.3 in the rat and 
NaV1.9 in mice (Black et al., 2004; Strickland et al., 2008). Further to ion channels, there 
is also upregulation of neurotransmitters, neuropeptides and cytokines (SP, CGRP, BDNF, 
TNFα and IL-1b) in nociceptors following inflammation and/or nociceptive activity 
(Cheng et al., 2008). Upregulation of CGRP, BDNF and P2X3 has also been reported in 
uninjured nociceptors following nerve ligation (Fukuoka et al., 2001; Fukuoka et al., 1998; 
Tsuzuki et al., 2001) Inflammation and nerve injury also result in both upregulation and 




Neurotransmitters released in the periphery act at multiple targets to induce an 
inflammatory response and drive neurogenic inflammation. SP and CGRP both act at 
vasculature promoting neurogenic inflammation by inducing permeability, oedema and 
NO release (Baral et al., 2019). SP targets monocytes and macrophages inducing IL-1b, 
IL-6 and TNFα release (Cunin et al., 2011; Lotz et al., 1988). In contrast, CGRP also 
induces anti-inflammatory effects including release of IL-10. The overall impact of these 
contradictory mechanisms on nociceptive outcomes is yet to be elucidated (Baliu-Pique et 
al., 2014; Baral et al., 2019). SP also acts directly at mast cells resulting in degranulation, 
releasing numerous nociceptor effector substances including histamine, leukotrienes, 
TNFα, tryptases and PG (Baral et al., 2019; Lewin et al., 1994). 
 
Peripheral nerve injury can induce increased firing of the injured nociceptor population or 
in the surrounding uninjured nociceptors away from their peripheral terminals, known as 
afterdepolarisation or ectopic discharge (Blumberg et al., 1984; Djouhri et al., 2006; Liu et 
al., 2002). Not classical nociceptive action potentials, this ectopic firing results from 
abnormal membrane excitability at the site of injury. Proposed mechanisms include TNFα 
released from Schwann cells, altered activity of potassium and calcium channels, 
hyperpolarisation-activated current and Ca2+-activated chloride currents (Hilaire et al., 
2005; Lee et al., 2005a). Like inflammation at peripheral terminals, the resulting 
sensitisation results in reduced activation thresholds due to altered membrane surface 
molecules and function, upregulation of neurotransmitters, and spontaneous firing. 
 
1.4.4 Neuroimmune interactions – central sensitisation 
Central sensitisation is the common mechanism responsible for multiple chronic pain 
states, associated with decreased activation thresholds in nociceptive projection neurons 
and increased responsiveness, resulting in a state of neuronal excitability within the spinal 
cord (Costigan et al., 2009; Grace et al., 2014). This change is mediated by afferents 
supplying the region, associated inflammatory responses and changes to descending input 
(Campbell et al., 2006). Central sensitisation can be broadly broken down into neural 
plasticity which is functional and protective, and neuroimmune components present in 





Neural inputs to the spinal cord can be considered homosynaptic (input from a single 
synapse) or heterosynaptic (input from multiple synapses) on the second order neuron 
(Latremoliere et al., 2009). Intense, repetitive, sustained high frequency homosynaptic 
input such as spontaneous firing following nerve injury results in “wind-up”; and long-
term potentiation (LTP). Wind-up results in a prolonged response lasting tens of seconds, 
while LTP amplifies subsequent stimulations and can last for several hours (Campbell et 
al., 2006; Dickenson et al., 1987; Ji et al., 2003; Latremoliere et al., 2009). NMDA 
receptors which are usually inactive, become active after sustained glutamate, SP, CGRP 
and BDNF release from nociceptors alters the receptor pore. The resulting increased 
calcium influx boosts synaptic efficiency and consequently amplifies the signal to produce 
this LTP effect (Mayer et al., 1984). Increased calcium influx boosts synaptic efficiency by 
activating kinases (PKC, PKA, ERK, Ca2+/Calmodulin-dependant protein kinase CaMKII) 
which induces changes in NMDA and AMPA activation kinetics and surface expression 
(Latremoliere et al., 2009). Long term synaptic changes can result from activation of 
transcription factors, upregulating expression of NK1 and TrkB (Latremoliere et al., 2009). 
Heterosynaptic input is responsible for interactions between large magnitude C-fibre inputs 
and low threshold input from mechanoreceptors (Ab-fibres) (Campbell et al., 2006; Ji et 
al., 2003). Multiple C-fibre inputs alter the activity of the postsynaptic membrane as 
described above, augmenting the response to a secondary synapse. Therefore, 
heterosynaptic activity is responsible for secondary hyperalgesia and allodynia, whereas 
homosynaptic inputs can only increase responses to noxious input of the same synapse and 
contribute to primary hyperalgesia (Latremoliere et al., 2009). In pathological pain this 
functional plasticity is augmented by continuous neuroimmune interaction at the 
tetrapartite synapse.  
 
The importance of neuroimmune interactions to generation of central sensitisation is 
highlighted by the attenuation of neuropathic pain by glial and inflammatory attenuator 
propentofylline (Raghavendra et al., 2003). As described above, glial activation following 
nerve injury and inflammation results in release of a proinflammatory milieu. TNFα, IL-1b 
and IL-6 are all implicated in spinal mediated nociceptive alteration correlating with 
nociceptive hypersensitivity in numerous injury and inflammatory-induced preclinical pain 
models, and chemically-induced pain in clinical models (Arruda et al., 2000; De Leo et al., 
1997; Hutchinson et al., 2013; Peng et al., 2006; Raghavendra et al., 2004; Sweitzer et al., 
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1999). Further highlighting their importance, antagonism of TNFα, IL-1b and IL-6 activity 
reverses pain hypersensitivity (Arruda et al., 2000; Milligan et al., 2003; Peng et al., 2006). 
It should be noted that centrally administered IL-6 produces both pro- and anti-nociceptive 
effects seemingly dependent on the nociceptive stimulation type, complicating our 
understanding of its role in nociception (Choi et al., 2003; Flatters et al., 2003). As 
mentioned above, p38 MAPK is believed to be a key integrator of multiple stimuli 
resulting in cytokine release. Inhibitor of p38 MAPK, CNI-1493, blocks the pro-
inflammatory pain inducing cytokine responses and reverses thermal and mechanical 
hypersensitivities (Milligan et al., 2001a; Milligan et al., 2003). Decreased phosphorylation 
of p38 MAPK has been directly associated with decreased dorsal horn TNFα expression 
and mechanical hypersensitivity (Peng et al., 2006). Inflammatory associated increases in 
NGF also facilitate central nociceptive signalling by increasing NMDA receptor activity 
(Lewin et al., 1994). 
 
As in the periphery, both glia and neurons express pro-inflammatory cytokine receptors 
(Vitkovic et al., 2000). As discussed above this direct activation causes further cytokine 
release and proliferation in glia. TNFα application to superficial lumbar spinal cord results 
in increased spontaneous firing in WDR neurons (Onda et al., 2002). TNFα induces a 
change in membrane conductance by altering calcium channel function, similar 
mechanisms have been proposed for changes in neuronal excitability by IL-6 and IL-1b 
(Qiu et al., 1998; van der Goot et al., 1999; Wilkinson et al., 1996). IL-1b also induces 
central cyclooxygenase-2 (COX-2), important for the production of PG in the SC (Samad 
et al., 2001). Centrally, PG facilitates presynaptic neuropeptide release, including SP and 
CGRP (Vasko, 1995). Microglial release of TNFα is associated with increased synaptic 
glutamate due to its effect on astrocytes. This mechanism involves PG release from 
astrocytes, which in an autocrine and paracrine fashion induces glutamate release from self 
and surrounding astrocytes. This signal is self-propagating leading to further increases in 
TNFα, PG and glutamate resulting in an excited synaptic environment (Bezzi et al., 2001). 
Astrocytes further amplify this feedback loop, releasing CXCL12 which binds to astrocyte 
and microglial CXCR4 receptors further increasing TNFα, and further increasing 
glutamate levels (Bezzi et al., 2001). Bradykinins further augment glutamatergic release 
from presynaptic terminals, which appears to depend on TRPA1 mediated calcium influx 
(Bautista et al., 2006; Kosugi et al., 2007; Wang et al., 2005). Bradykinins also alter 
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AMPA and NMDA receptors at postsynaptic terminals increasing spontaneous currents 
(Wang et al., 2005).  
 
A number of factors released from both neuronal and non-neuronal sources can reduce 
inhibitory input in the dorsal horn. Downregulation of MORs following nerve injury 
results in decreased inhibition by endogenous opioids (Kohno et al., 2005). ATP-induced 
microglial BDNF release following nerve injury downregulates potassium chloride co-
transporters (KCC2), altering the ionic gradient and altering GABA receptor function to 
induce depolarisation, thus reducing inhibitory and enhancing excitatory tone (Coull et al., 
2005; Coull et al., 2003). Effects on glycinergic inhibition have been observed in an 
inflammatory pain model. PG, acting at the PGE2 receptor alters strychnine-sensitive 
glycine receptor (GlyR) function in a PKA-dependant mechanism. This results in the 
excitatory interneurons and secondary projection neurons which express GlyR becoming 
unresponsive to glycinergic input inducing both mechanical and thermal hypersensitivity 
(Harvey et al., 2004). Finally, injury-induced apoptosis due to glutamate toxicity in the 
dorsal horn results in the loss of GABAergic inhibitory interneurons (Scholz et al., 2005). 
 
Outcomes of central sensitisation therefore depend on the relationship of multiple 
excitatory and inhibitory processes which are impacted by neuronal and classically 
immune input. Although neural elements of central sensitisation alone account for 
relatively short-term hypersensitivity, neuroimmune interaction can lead to long lasting 
pathological pain. Despite this knowledge, the key mechanisms for generating and 




Evidence presented here clearly highlights the importance of neuroimmune interaction in 
the alteration of nociceptive signal transmission. The consequences of these interactions 
can result in centrally and peripherally mediated alterations in pain sensitivity contributing 
to chronic pain. Preclinical pain models typically target either the neuronal mechanism, 
evidenced by numerous neurogenic pain models; direct immune stimulation, or unspecific 
activation of elements of neuroimmune signalling via nerve injury. The most relevant 
options are those models which aim to mimic clinical pathophysiology. One potential 
improvement in this space are models which independently, and therefore controllably 
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stimulate each of the elements involved in neuroimmune signalling. This will allow further 
mechanistic investigation with behavioural outcomes, as well as offer the possibility of 
investigating how timing and duration of each signalling modality independently affects 
long term nociceptive outcomes. Due to the unreliability of therapeutics to combat chronic 
pain; further research into the clinical importance of neuroimmune interactions is required. 
This thesis will now provide an investigation into a potentially clinically relevant 





























Chapter 2: Introducing toll-like receptor 4 and transient receptor potential cation 
channel subfamily V member 1 
This chapter introduces the clinically relevant neuroimmune interaction between toll-like 
receptor 4 (TLR4) and transient receptor potential cation channel subfamily V member 1 
(TRPV1). Each receptor is introduced individually in relation to their role in pain, before a 
discussion of their functional interaction. Along with the opening chapter, the information 
presented will highlight the importance of continued research into the mechanisms and 
relevance of the interaction and frame the aims of this thesis.  
 
2.1 Toll-like receptor 4 (TLR4)  
TLR4 is a transmembrane innate immune receptor responsible for initiating inflammatory 
signal cascades. TLR4 is expressed in multiple tissue types including; respiratory, urinary 
and digestive epithelia, endothelial cells, cardiac myocytes, peripheral and central myeloid 
cells (e.g. glia, macrophages) and peripheral and central neurons (Buchanan et al., 2010; 
Ferraz et al., 2011; Frantz et al., 1999; Ghosh et al., 2015; Helley et al., 2015; Kielian, 
2006; Smolinska et al., 2008; Taylor et al., 2004). Activation can occur by interaction with 
a number of danger and pathogen associated molecular patterns (DAMPs/PAMPS), 
including heat shock proteins (HSPs), yeast cell wall components, protozoan glycolipids 
and viral envelope proteins (Lee et al., 2007; Ohara et al., 2013; Ransohoff et al., 2012). 
However, the most well-known and widely used agonist is the gram-negative bacterial cell 
wall component lipopolysaccharide (LPS) (Poltorak et al., 1998; Shimazu et al., 1999).  
 
2.1.1 Structure 
TLR4 consists of an extracellular region containing a leucine rich repeat domain and 
intracellular region containing a toll/interluekin-receptor-1 (TIR) domain (Buchanan et al., 
2010; Hashimoto et al., 1988). An extracellular binding partner, myeloid differentiation 
factor 2 (MD2) is required for agonist binding (Shimazu et al., 1999). While co-receptor 
CD14 and extracellular LPS binding protein (LBP) act to chaperone LPS to the 
TLR4/MD2 complex; CD14 dramatically increases sensitivity to LPS (Delude et al., 1995; 
Janova et al., 2016; Zanoni et al., 2011).  
 
2.1.2 Signal transduction 
LPS binding induces dimerisation of the TLR4/MD2 complex, recruiting TIR domain 
containing adaptor proteins which interact with the TIR domain of TLR4. Two distinct 
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signalling pathways are involved in TLR4 signal transduction, each with separate TIR 
containing adaptor proteins. Myeloid differentiation primary response protein 88 (MyD88), 
and MyD88-adaptor protein (MAL) (also known as TIR domain-containing adaptor 
protein (TIRAP)) associate with TLR4 to initiate the MyD88 dependent pathway, known 
as the early phase response (Buchanan et al., 2010; Horng et al., 2002). While TIR 
domain-containing adapter inducing IFNb (TRIF) and TRIF-related adaptor molecule 
(TRAM) are recruited to induce the late response phase MyD88 independent pathway. 
Evidence from a microglial (BV2) cell line suggests initial increases in 
phosphatidylinositol 4,5-bisphosphate (PIP2) following LPS promotes TIRAP translocation 
to the membrane (Nguyen et al., 2013). Similarly, another study concluded PIP2 is key for 
facilitating MyD88 interaction with the TLR4 complex by binding and mediating TIRAP 
membrane translocation; MyD88 engineered to bind PIP2 does not need TIRAP to activate 
the MyD88 dependent pathway (Kagan et al., 2006). Activation of the MyD88 dependent 
pathway occurs mainly at the plasma membrane, and TLR4 association with 
TIRAP/MyD88 induces translocation of transcription factors nuclear factor kappa-light-
chain enhancer of activated B cells (NF-kB) and activator protein 1 (AP-1). Transcription 
factor translocation occurs after a chain of kinase activations including, IL-1R-associated 
kinases (IRAKs), TNF receptor-associated factor 6 (TRAF6), transforming growth factor 
b-activated kinase 1 (TAK1), mitogen activate protein kinases (MAPKs) (JUN N-terminal 
kinase (JNK), p38, extracellular signal related kinases (ERKs)) and the IkB kinase (IKK) 
complex (Fig. 2.1). This pathway induces transcription of proinflammatory cytokines and 
chemokines including tumour necrosis factor a (TNFa) and CCL2 (Kawai et al., 2007a; 
Kielian, 2006; Molteni et al., 2016). In contrast, the MyD88 independent pathway occurs 
in the cytoplasm following TLR4/MD2 internalisation (Buchanan et al., 2010; Tanimura et 
al., 2008). This pathway leads to nuclear translocation of transcription factors interferon 
regulatory factor 3 (IRF3) and NFkB/AP-1 via TRIF/TRAM activation of TRAF3 and 
TRAF6 respectively (Fig. 2.1). IRF3 promotes interferon (IFN)-b  synthesis and further 
production of type 1 IFNs which counteract the pro-inflammatory NFkB outcomes 
(Buchanan et al., 2010; Kielian, 2006). CD14 is important for modulating responses by 
inducing TNFb mediated negative feedback and for TLR4 internalisation following LPS 
activation, suggesting it is important for induction of the MyD88 independent pathway 






Figure 2.1: TLR4 Signalling Cascade Highlighting MyD88 Dependant and 
Independent Pathways. LPS binding involves LBP, CD14, MD-2 and TLR4. Orange and 
green proteins represent signalling cascades unique to MyD88 dependant and independent 
pathways respectively. Dark blue represents proteins common to both pathways resulting 
























In addition to the pathways described above, TLR4 activation induces a host of 
intracellular changes which influence the pro-inflammatory outcome. These include 
changes in intracellular calcium, expression of microRNAs (miRNAs) and activity of 
multiple kinases. LPS binding causes increases in cytosolic calcium in mouse dendritic 
cells and DRG neurons, from both intracellular stores and extracellular sources upon 
activation of calcium release activated calcium channels (CRAC) (Grobner et al., 2014). 
Despite this data some discussion persists around LPS being the true initiator of these 
calcium changes (Salter et al., 2009). Nevertheless, it is a phenomenon also observed in 
human bladder and mouse lung epithelial cells (Song et al., 2007; Tauseef et al., 2012). 
Multiple NFkB dependent miRNAs have been identified following TLR4 activation, 
including miR-145, miR-146 and miR-348. miRNA influence at multiple points of the 
NFkB signalling cascade negatively regulates the pro-inflammatory response (O'Neill et 
al., 2011; Taganov et al., 2006).  
 
TLR4 mediated increases in protein kinase A and C (PKA, PKC), and calcium dependent 
increases in phospholipase C (PLC) and phosphoinositide 3-kinase (PI3K) following LPS 
have been reported (Cabral et al., 2015; Kim et al., 2015). PI3K is important for activation 
of the serine/threonine kinase, Akt, and production of IL-1b, TNFa and macrophage 
activating factor-2 (MAF-2) (Ojaniemi et al., 2003). While PLC-induced diacylglycerol 
(DAG) increase correlates with rapid NFkB translocation in mouse lung epithelial cells 
(Tauseef et al., 2012; Yamamoto et al., 1997). LPS results in calcium dependent activation 
of Src kinase associated with production of oxidants in a mouse macrophage (RAW264.7) 
cell line (Check et al., 2010). Activation of Src, as well as other members of the Src 
tyrosine kinase (STK) family, Fyn and Yes, are reported to last between 5 and 60 min 
following LPS administration in human lung microvascular epithelial cells, reversed by 
TLR4 small interfering (si)RNA-induced knockdown (Gong et al., 2008). Highlighting 
their role in TLR4 outcomes, antagonising STK activity inhibits output of TLR4 induced 
pro-inflammatory mediators in human and murine macrophages, including; TNFa, IL-8, 
IL-10, CXCL10 and inducible nitric oxide synthase (iNOS) (Lee et al., 2005b; Smolinska 
et al., 2008). In this case, cytokine and chemokine outcomes were independent of NFkB 
activation and ERK, JNK and p38 phosphorylation, although modulation of AP-1 was 
observed, suggesting an effect on the MyD88 independent pathway (Smolinska et al., 
2008). Another STK member, Lyn kinase, is important for phosphorylation of the TIR 
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domain and endotoxin induced signalling (Medvedev et al., 2007). Altogether, this 
evidence suggests kinase activity is an important regulator of the TLR4 signalling system. 
It appears further mechanistic elucidation of kinase activation following TLR4 ligand 
binding is necessary due to the varied evidence of TLR4-induced intracellular calcium 
elevation. 
 
2.1.3 TLR4 and pain 
Change in pain sensitivity is associated with TLR4 activity through a number of 
mechanisms, including peripheral and central sensitisation, and direct nociceptor TLR4 
activation. Neuronal subsets express TLR4, MD2 and CD14, which can be directly 
influenced by TLR4 agonists (Ochoa-Cortes et al., 2010; Tse et al., 2014). In mouse dorsal 
root ganglia (DRG) neurons, LPS increases both the generation of action potentials 
following electrical stimulation and the expression of IL-1b, TNFa and cyclooxygenase -2 
(COX-2) in a MyD88 dependent fashion (Ochoa-Cortes et al., 2010; Tse et al., 2014). LPS 
also induces calcium influx in rat trigeminal (TG) and DRG neurons; the number of DRG 
neurons responding to LPS increases above 10 ng/mL (Diogenes et al., 2011; Li et al., 
2015). In addition to LPS, HSP70 binding to TLR4 expressing TG neurons is a suggested 
mechanism of action for referred tongue pain during tooth pulp inflammation; while 
chemotherapy agent paclitaxel increases presynaptic glutamate release, an effect blocked 
by TLR4 antagonist LPS-RS in mice spinal cord (SC) slices (Ohara et al., 2013; Yan et al., 
2015).  
 
Indirect effects of TLR4 have been widely reported following systemic and peripheral LPS 
administration. Intravenous (i.v.) LPS (4 ng/kg) reduces pain thresholds to electrical, 
mechanical and cold stimulation in humans (de Goeij et al., 2013). While lower doses (0.4 
ng/kg) produce mechanical visceral hypersensitivity (Benson et al., 2012). Similarly, 0.4 
ng/kg i.v. produces peripheral mechanical hypersensitivity which interestingly is 
dependent on anatomical location, observed on the back and shoulder, and only observed 
at the calf or neck at higher doses (0.8 ng/kg) (Wegner et al., 2014; Wegner et al., 2015). 
This opens the interesting possibility of anatomically distinct nociceptive processes 
involving TLR4. Similarly, a mouse nerve injury model of orofacial pain produced 
widespread TLR4 dependent pain sensitivity at distant sites (hind paw) but not at the 
vibrissae pad, again suggesting region specific nociceptive mechanisms (Hu et al., 2017). 
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In the clinical examples above, peak pro-inflammatory cytokine levels (IL-6, IL-8, IL-10, 
TNFa) occurred between one and three hours post LPS, correlating with peak hyperalgesia 
at 3 h for all anatomical locations tested (Benson et al., 2015; Wegner et al., 2014). 
Peripheral application of between 30 and 300 ng of LPS induces mechanical 
hypersensitivity 3 h after intraplantar (i.pl.) injection into the mouse paw. This involves 
nociceptor sensitisation by MyD88 dependent increases in IL-1b, TNFa and CXCL1 (Calil 
et al., 2014). Further, two intraperitoneal (i.p.) (0.2 mg/kg) or intracerebroventricular 
(i.c.v.) (0.2 mg) doses of LPS produce a priming effect, whereby the second dose 24 h later 
produces increased mechanical and thermal hypersensitivities when compared to the initial 
dose (Cahill et al., 1998). Intrathecally (i.t.) applied LPS induces mechanical 
hypersensitivities correlated with astrocytic and microglial derived TNFa (Saito et al., 
2010). 
 
TLR4 has been implicated in the development and maintenance of multiple neuropathic 
pain models. I.t. delivery of TLR4 antagonists LPS-RS, (+)-naloxone and (+)-naltrexone 
reverse mechanical hypersensitivity 14 days following chronic constriction injury (CCI) 
for up to 3 h (Hutchinson et al., 2008). Likewise, systemic application of (+)-naloxone 
reverses mechanical hypersensitivity for up to 3 h. This attenuation was correlated with 
reduction of microglial marker CD11b, but not astrocyte marker GFAP, following 
sustained (4 day) delivery of (-)- or (+)-naloxone (Hutchinson et al., 2008). Another study 
correlated CCI-induced mechanical hypersensitivity with increased spinal cord and DRG 
TLR4 expression (Jurga et al., 2016). Interestingly 3 days of spinal cord stimulation 
attenuates CCI-induced TLR4 and NFkB expression, tissue IL-1b, IL-6 and TNFa, and 
associated mechanical hypersensitivity (Yuan et al., 2014). Use of peroxisome proliferator-
activated receptor gamma (PPAR-γ) antagonist to reverse CCI hypersensitivity is also 
correlated with decreased spinal cord IL-1b, TNFa and TLR4 mRNA (Jia et al., 2016). 
Paclitaxel treatment causes chemotherapy-induced neuropathic pain (CINP) and is 
associated with TLR4 activity. TLR4 and MyD88 expression in DRG neurons are 
increased at 1- and 7-days , while TRIF is upregulated at 7 days; corresponding with the 
observed mechanical hypersensitivity beginning 7 days post paclitaxel administration (Li 
et al., 2014). Both LPS and MyD88 antagonists result in attenuation of paclitaxel-induced 
mechanical hypersensitivity; although interestingly LPS antagonism results in reduced 
DRG MyD88 but not TRIF, suggesting an alternative source. Interestingly, increased 
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TLR4 expression has been observed from days 1 to 21 following paclitaxel administration 
in typically late responding astrocytes, but not microglia (Li et al., 2014). Finally, TLR4 
signalling is also implicated in joint inflammation associated hyperalgesia, diabetic 
neuropathy, opioid-induced hyperalgesia, postoperative pain, bone cancer pain, and 
migraine models (Aguado et al., 2018; Chen et al., 2017a; Guerrero et al., 2016; Lan et al., 
2010; Su et al., 2018; Xing et al., 2018). 
 
In addition to the activation of peripheral immune mechanisms, centrally activated glia 
play an important role in the action of TLR4 at the spinal cord level. Briefly mentioned 
above, upregulation of microglia and astrocyte TLR4 levels in paclitaxel CINP and CCI 
correlate with observed mechanical hypersensitivity (Bettoni et al., 2008; Li et al., 2014; 
Tanga et al., 2005). Further, paclitaxel-induced CINP reduces surface expression of glial 
transporters, glial glutamate transporter 1 (GLT1) and glutamate aspartate transporter 
(GLAST) on astrocytes, effects which are reversed by LPS-RS (Yan et al., 2015). 
Knockdown of TLR4 by i.t. siRNA administration reduced microglial activation and 
development of bone cancer pain (Lan et al., 2010). While a spinal nerve transection pain 
model shows that microglial and astrocyte activation markers are significantly reduced in 
TLR4 knockout animals compared to wildtype, correlating with attenuation of mechanical 
and thermal hypersensitivity (Tanga et al., 2005). Finally, in a skin and muscle incision 
pain model, TLR4 upregulation in astrocytes and microglia at 10 days, correlates with peak 
mechanical hypersensitivity (Sun et al., 2015b). It is evident that the action of TLR4, 
whether indirect by the action of pro-inflammatory signalling, or direct binding of neuronal 
TLR4, is influential to preclinical and clinical nociceptive outcomes. 
 
2.2 Transient receptor potential cation channel subfamily V member 1 (TRPV1) 
TRPV1 is a non-selective cation channel belonging to transient receptor potential (TRP) 
channel family and vanilloid subfamily (Zheng, 2013). The receptor was first classified in 
1997 by Caterina and colleagues as vanilloid receptor 1 (VR1), a receptor for capsaicin, 
the pungent ingredient of chilli peppers, and resiniferatoxin (RTX), an ultrapotent 
capsaicin analogue from Euphorbia plants (Moroccan cactus) (Caterina et al., 1997; 
Szallasi et al., 1989). Initial cloning of the receptor also revealed it was activated by heat 




TRPV1 is found on numerous cell types including; keratinocytes, cardiomyocytes, oral and 
gastric epithelium, mast cells, thymocytes, T-cells, fibroblasts, pancreatic islet cells, 
hepatocytes, lung epithelium, urothelial cells, male germ cells, microglia and peripheral 
and central neurons (Akiba et al., 2004; Amantini et al., 2004; Bertin et al., 2014; Birder et 
al., 2001; Biro et al., 1998; Denda et al., 2001; Dvorakova et al., 2001; Jang et al., 2012; 
Kato et al., 2003; Kido et al., 2003; Lowin et al., 2015; Mezey et al., 2000; Mizrak et al., 
2008; Wadachi et al., 2006). We will be focussing on TRPV1 effects related to pain and 
nociceptive processing. Compared to other tissue types mentioned, TRPV1 is abundant on 
primary afferent neurons as seen by expression in dorsal, trigeminal and nodose ganglia; 
where it is expressed on small diameter C-fibres and medium diameter Ad-fibres 
responsible for detection and transduction of nociceptive stimuli (Brito et al., 2014; Jang et 
al., 2012; Kunert-Keil et al., 2006; Szallasi et al., 2007). Within the CNS, TRPV1 is 




The TRPV1 channel is a homo-tetramer with an internal pore consisting of an external 
selectivity filter and a lower gate (Cao et al., 2013). Each monomer consists of an 
intracellular TRP domain at the C-terminal end, 6 transmembrane domains and an 
intracellular ankyrin repeat segment at the N-terminal end. A pore forming loop is present 
between transmembrane domains 5 and 6, forming part of the pore and influencing 
selectivity (Liao et al., 2013; Nilius et al., 2007). Channel opening threshold is altered by 
changes in phosphorylation state and the availability and/or activity of potentiating or 
negative regulators which will be discussed in detail below. 
 
2.2.2 TRPV1 in pain literature 
Activation of TRPV1 is widely used to study pain physiology and analgesic efficacy. In 
this respect TRPV1 provides an interesting juxtaposition, where activation results in 
spontaneous pain and extended hypersensitivity or analgesia, depending on dose and 
duration of stimulation (Holzer, 1991; Laird et al., 2001a; Menendez et al., 2004; Rashid et 
al., 2003a; Sakurada et al., 1992). The importance of TRPV1 in the generation of thermal 
hypersensitivity has been highlighted in multiple knockout models, while sensitivity to 
mechanical stimulation is also observed following channel activation (Caterina et al., 2000; 
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Cavanaugh et al., 2009; Davis et al., 2000; Ren et al., 1994). Further, centrally and 
peripherally acting TRPV1 antagonist AS1928370 attenuates spontaneous capsaicin-
induced pain and mechanical hypersensitivity associated with spinal nerve ligation (SNL), 
highlighting the role of TRPV1 in physiological and pathological pain (Watabiki et al., 
2011).  
 
The importance of TRPV1 in pathological pain is highlighted in numerous preclinical pain 
models. TRPV1 is upregulated in CFA-induced inflammatory pain, opioid-induced 
hyperalgesia, dextran sulfate sodium-induced colitis, CFA-induced orofacial pain and 
spinal cord injury (SCI) (Amaya et al., 2003; Lapointe et al., 2015; Vardanyan et al., 2009; 
Watase et al., 2018; Wu et al., 2013). In contrast, total numbers of TRPV1 expressing 
neurons remain unchanged or decrease following CCI (Malek et al., 2014; Malek et al., 
2015). Blockade of TRPV1 in CFA-induced orofacial pain leads to attenuation of head 
withdrawal thresholds to mechanical and thermal stimuli (Watase et al., 2018). Likewise, 
blocking TRPV1 in a model of orthodontic pain reduced expression and mouth wiping 
behaviour (Gao et al., 2016). While TRPV1 antagonists attenuate mechanical 
hypersensitivity in a paclitaxel CINP model (Li et al., 2015). Centrally, TRPV1 
upregulation has been observed in mouse prelimbic and infralimbic structures following 
spinal nerve injury (SNI), with antagonism of TRPV1 at these sites resulting in attenuation 
of mechanical hypersensitivity (Giordano et al., 2012). While centrally administered 
TRPV1 antagonists block postsynaptic TRPV1 activity and attenuate mechanical 
allodynia, suggesting TRPV1 is an important element in the disinhibition of SC 
GABAergic inhibitory interneurons (Kim et al., 2012).  
 
Clinically, TRPV1 activation by capsaicin is potentiated in patients with unilateral sciatica 
and rheumatoid arthritis, consistent with upregulation observed in preclinical studies 
(Shenker et al., 2008; Sumracki et al., 2012). TRPV1 upregulation is also observed in 
human tissues from irritable bowel syndrome patients (Akbar et al., 2008). There is 
abundant literature to suggest TRPV1 plays a significant role in both physiological and 
pathological pain. Characterising the key mechanisms with which TRPV1 contributes to 






2.2.3 Activation and agonists 
In addition to capsaicin and RTX, direct activation is possible via natural exogenous 
agonists including; inhibitor cystine knot peptides (component of spider venom), piperine 
(component of black pepper), eugenol (component of clove oil), gingerols, shogaols, 
zingerone (components of ginger) and camphor (component of camphor trees) (Table 2.1) 
(Iwasaki et al., 2006; Liu et al., 1996; Siemens et al., 2006; Yang et al., 2003). Direct 
activation can occur by a number of endogenous ligands, including: polyamines (e.g. 
spermine) and lipid compounds comprising biogenic amines (including endocannabinoids 
anandamide (AEA) and N-arachidonoyl dopamine (NADA)), oxygenated eicosatetraenoic 
acids (e.g. oleoylethanolamide (OEA)) and lipoxygenase products (e.g. 12-(S)-
hydroperoxyeicosatetraenoic acid (12-(S)-HPETE)) (Table 2.1) (Ahern, 2003; Ahern et al., 
2006; Brito et al., 2014; Hwang et al., 2000; Toth et al., 2003; Vriens et al., 2009; Zygmunt 
et al., 1999). While not considered a direct activator, protons can sensitise the channel by 
binding directly, allowing the temperature threshold to drop below physiological 
temperatures at low enough pH (< 5.6) (Tominaga et al., 1998). Acidification produced by 
osteoclast activity in bone cancer models is associated with TRPV1 mediated pain 
sensitivity (Ghilardi et al., 2005). Similarly, basic conditions following ammonia 
application sensitise the channel, although through unknown mechanisms theorised to 
involve deprotonation of key residues (Dhaka et al., 2009). In lieu of direct agonist 
binding, TRPV1 activation can result from temperatures above 43°C, however this 
threshold can be reduced (sensitised) by proton binding and multiple intracellular pathways 
detailed below (Caterina et al., 1997).  
 
Capsaicin is a widely utilised TRPV1 agonist and warrants further introduction. Consisting 
of an aromatic ring, amide bond and hydrophobic side chain, capsaicin binds an 
intermembrane region between transmembrane domain 3 and 4 (Elokely et al., 2016; Yang 
et al., 2015). Capsaicin elicits an initial burning sensation in mammals followed by a 
period of increased sensitivity, followed by a period of desensitisation resulting from 
depletion of neurotransmitters, calcium-induced cytotoxicity and calcium-induced receptor 
desensitisation (Caterina et al., 2001). As a result of its contradictory effects on 
nociception, capsaicin has a number of applications from self-defence (pepper spray) to 
analgesic agents (Szallasi et al., 1999; Szallasi et al., 2007). Currently, capsaicin is used to 
treat multiple pain conditions, including post herpetic neuralgia, diabetic neuropathy, 
arthritis and post-surgical pain (Baranidharan et al., 2013; Szallasi et al., 2007). Capsaicin-
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induced pain models are utilised in both clinical and preclinical pain studies due to its 
ability to produce observable spontaneous pain behaviours and produce symptoms 
associated with both peripheral and central sensitisation (Hutchinson et al., 2013; Kinnman 
et al., 1995; Laird et al., 2001a). Measurable sensitisation effects include induction of 
primary and secondary hypersensitivities and visible neurogenic flare responses (Aykanat 
et al., 2012; Hutchinson et al., 2013; O'Neill et al., 2012; Tominaga et al., 1998; Willis, 
2002).  
 
  Table 2.1: Naturally occurring TRPV1 agonists 
Exogenous 
Camphor (Xu et al., 2005) 
Capsaicin (Caterina et al., 1997) 
Eugenol (Yang et al., 2003) 
Gingerol (Dedov et al., 2002) 
Inhibitor cystine knot (ICK) peptides (Siemens et al., 2006) 
Piperine (McNamara et al., 2005) 
Resiniferatoxin (RTX) (Caterina et al., 1997) 
Shogaol  (Iwasaki et al., 2006) 
Zingerone (Witte et al., 2002) 
Endogenous 
5-(S)-hydroxyeicosatetraenoic acid (5-(S)-HETE) (Hwang et al., 2000) 
12-(S)-hydroperoxyeicosatetraenoic acid (12-(S)-HPETE) (Hwang et al., 2000) 
15-(S)-hydroperoxyeicosatetraenoic acid (15-(S)-HPETE) (Hwang et al., 2000) 
15-(S)-hydroxyeicosatetraenoic acid (15-(S)-HETE) (Hwang et al., 2000) 
Anandamide (AEA) (Zygmunt et al., 1999) 
Leukotriene B4 (LTB4) (Hwang et al., 2000) 
N-arachidonoyldopamine (NADA) (Huang et al., 2002) 
Oleoylethanolamide (OEA) (Ahern, 2003) 









As mentioned above, the activity of TRPV1 is altered by multiple phosphorylation events. 




Kinase activity induced by inflammatory mediators and/or calcium influx are a key 
contributing factor of TRPV1 activation and therefore nociceptive outcomes. PKC, PKA 
and Ca2+-calmodulin dependant kinase II (CaMKII) phosphorylate key sites resulting in 
receptor activation and sensitisation. PKC and CaMKII mediate receptor function by 
phosphorylating key serine (S502, S800) and threonine (T704) residues (Bhave et al., 
2003; Numazaki et al., 2002). Mutation of S800 alone results in attenuation of capsaicin-
induced spontaneous pain and inflammatory muscle pain (Joseph et al., 2019). While S502 
and T704 phosphorylation by CaMKII is required for capsaicin binding (Jung et al., 2004). 
PKA phosphorylates serine (S502, S116), and threonine (T117, T370) residues (Bhave et 
al., 2002; Mohapatra et al., 2003, 2005). Upregulation of PKA, PKC and CaMKII in 
TRPV1 positive cells is observed following CCI in rats (Malek et al., 2015). While 
downregulation of PKC and PKA and the subsequent effect on TRPV1 has been associated 
with the analgesic effect of electroacupuncture (Yang et al., 2017). Scaffolding protein A-
kinase anchoring protein 150 (AKAP150) in rodents (human orthologue AKAP79) is 
crucial to the function of PKA and PKC (Faux et al., 1997; Jeske et al., 2008; Jeske et al., 
2009; Zhang et al., 2008). Src kinase similarly acts to lower activation threshold by 
phosphorylation of tyrosine residue Y200 (Jin et al., 2004; Zhang et al., 2005). In addition 
to phosphorylation, kinase activity is associated with increased TRPV1 activity by 
mediating translocation of the receptor to the cell membrane. PKC is associated with 
increased TRPV1 surface expression by promoting SNARE-mediated exocytosis 
(Morenilla-Palao et al., 2004). While forskolin induced cyclic adenosine monophosphate 
(cAMP)-dependant PKA activity has been associated with rapid cell membrane insertion 
of TRPV1, although further mechanistic analysis of this pathway is required (Vetter et al., 
2008).  
 
Dephosphorylation of the aforementioned TRPV1 residues is associated with decreased 
TRPV1 activity known as receptor desensitisation. Short term, desensitisation can be 
categorised as either acute desensitisation, resulting in reduced response due to prolonged 
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agonist exposure; and tachyphylaxis, a reduction in response to repeated agonist 
applications (Vyklicky et al., 2008). Literature suggests these responses result from the 
balance between numerous phosphorylation and dephosphorylation events induced by 
calcium. Highly phosphorylated in its resting state; decreased phosphorylation of TRPV1 
is observed following capsaicin application (Bhave et al., 2002). Highlighting the role of 
calcium-induced desensitisation, solutions replacing calcium with barium do not result in 
desensitisation of TRPV1 following capsaicin exposure. Interestingly, piperine agonism 
does result in desensitisation under these conditions, suggesting alternate mechanisms 
depending on agonist binding site (Gunthorpe et al., 2000; McNamara et al., 2005). 
Following from this, direct calcium application alone reduces capsaicin-induced current, 
the same effect is not seen following direct magnesium application (Rosenbaum et al., 
2004). Calcium dependant messenger protein Calmodulin (CaM) binds two sites on the 
TRPV1 monomer, an N-terminal and a C-terminal region, both of which are important to 
channel desensitisation (Numazaki et al., 2003; Rosenbaum et al., 2004). In low 
intracellular calcium conditions, CaM in a calcium independent fashion binds at the C-
terminal site, however ATP outcompetes CaM for the N-terminal ankyrin repeat domain 
(Lishko et al., 2007; Vyklicky et al., 2008). Due to increased intracellular calcium (such as 
following TRPV1 activation), CaM activity is altered, leading to binding both N and C- 
terminal sections, altering receptor configuration, resulting in desensitisation (Lishko et al., 
2007; Vyklicky et al., 2008). Fluorescence resonance energy transfer (FRET) shows CaM 
also interferes with the association of AKAP150 and TRPV1. CaM mediated disruption 
AKAP150/TRPV1 interaction is associated with decreased capsaicin-induced calcium 
accumulation in Chinese hamster ovary cells (Chaudhury et al., 2011). Another regulator 
of desensitisation is the calcium and CaM dependent protein phosphatase 2b (calcineurin), 
which produces acute desensitisation and tachyphylaxis of TRPV1 (Jung et al., 2004; 
Mohapatra et al., 2005). Calcineurin desensitisation is hypothesised to depend on relative 
levels of calcineurin dephosphorylation and PKA and CaMKII phosphorylation events 
(Jung et al., 2004; Mohapatra et al., 2005). In addition to phosphorylation events, Fas-
associated factor 1 (FAF1), co-expressed on primary afferents and associated by physical 
interaction, attenuates TRPV1 responses to acids, thermal and chemical stimuli (Kim et al., 
2006). Longer lasting desensitisation results from receptor internalisation and degradation 
as observed following extended capsaicin application in TRPV1 expressing HEK293FT 
cells and DRG neurons. This action is mediated by calcium dependent PKA 
phosphorylation of S116 and a clathrin mediated endocytosis pathway (Sanz-Salvador et 
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al., 2012). The kinases mentioned above are activated by multiple inflammatory mediators 
which are discussed individually below.  
 
2.2.4.2 Lipids 
Lipid regulation of TRPV1 function is controversial due to the contrasting in vitro 
literature which centres around the role of PIP2. Evidence suggesting that PIP2 interactions 
are inhibitory, report calcium dependent activation of PLC and subsequent hydrolysis of 
PIP2 into inositol triphosphate and DAG, releases TRPV1 from lipid mediated inhibition. 
This results in potentiation of TRPV1 responses to low pH, capsaicin and heat (Chuang et 
al., 2001; Prescott et al., 2003). In contrast, multiple studies in HEK393 cells and primary 
DRG neurons report that PIP2 is required for channel sensitisation, and is an important 
component of recovery of channel function following desensitisation (Klein et al., 2008; 
Stein et al., 2006; Sun et al., 2015a; Ufret-Vincenty et al., 2015; Yao et al., 2009). This 
mechanism also involves PIP2 hydrolysis by calcium dependent PLC action, resulting in 
the breakdown of an interaction between the proximal C-terminal region of TRPV1 and 
PIP2. This PIP2/TRPV1 separation prevents the desensitising binding action of calmodulin 
(CaM) to both C- and N-terminal domains (Kwon et al., 2007; Lishko et al., 2007). 
Similarly to the CaM mechanism discussed above, ATP is critical to re-sensitisation, 
responsible for PIP2 resynthesis by phosphatidylinositol-4-kinase activity (Liu et al., 2005). 
One study reports both an inhibitory and sensitising effect of PIP2 based on the 
concentration of capsaicin administered. In this case the authors suggest any inhibitory 
effect is likely to be indirect due failure to observe the inhibition in excised patches 
(Lukacs et al., 2007). Membrane protein phosphoinositide interacting regulator of TRP 
(Pirt) has been proposed as an important competent of PIP2 regulation. Pirt is associated 
with both the C-terminus of TRPV1 and PIP2, and is a critical component of PIP2 mediated 
enhancement of heat- and capsaicin-induced currents in DRG neurons (Kim et al., 2008). 
Although the weight of evidence points to PIP2 sensitisation of TRPV1, more study is 




Binding of prostaglandin E2 (PGE2) and I2 (PI2) to their respective receptor’s EP and IP, 
reduce the temperature threshold of TRPV1 to below physiological temperature. This 
effect is PKC and PKA mediated depending on the receptor type activated (Moriyama et 
 
 41 
al., 2005). Disruption of AKAP79/150 following EP or IP activation abolishes 
prostaglandin sensitisation effects on TRPV1, highlighting the importance of PKA/PKC 
activity (Zhang et al., 2008). TRPV1 sensitisation by PGE2 is responsible for increased 
spontaneous pain in a model of chemotherapy-induced mucositis (Yamaguchi et al., 2016). 
 
2.2.4.4 Nerve growth factor (NGF) and bradykinin 
Highlighting their importance to nociceptive transmission, both bradykinin and NGF 
produce thermal hypersensitivity following intraplantar injection (Chuang et al., 2001). 
NGF activation results in potentiation of TRPV1 responses to capsaicin stimulation 
through multiple mechanisms. The major mechanism is activation of a PI3K/PKCd/Src 
kinase mediated phosphorylation (Zhang et al., 2005). PI3K associates with TRPV1, 
forming a complex with TrkA (NGF receptor), which once activated by NGF results in 
PIP2 phosphorylation to PIP3, promoting TRPV1 trafficking to the cell membrane (Stein et 
al., 2006; Stratiievska et al., 2018). Another sensitisation pathway, common to both NGF 
and bradykinin activation involves PLC and PKCe activity, resulting in receptor 
phosphorylation (Cesare et al., 1999; Zhang et al., 2005). This same pathway is implicated 
in the PIP2 hydrolysis scenarios mentioned above. Therefore, continued TrkA activation 
inhibits recovery of the desensitised channel (Liu et al., 2005). Finally, an NGF-induced 
PI3K/ERK pathway is also implicated in capsaicin-induced thermal sensitivity (Zhuang et 
al., 2004).  
 
2.2.4.5 Serotonin and dopamine 
Serotonin (5-HT) is implicated in the sensitisation of TRPV1 following visceral capsaicin 
administration by promoting CaMKII activity (Qin et al., 2010). This is corroborated by 
work in TG neurons reporting 5-HT increases capsaicin-induced calcium accumulation and 
CGRP release, attenuated by targeting peripheral 5-HT receptors (Loyd et al., 2011). In 
contrast, dopamine is associated with reduced TRPV1 current induced by capsaicin. 
Inward current is attenuated by inhibition of CaMKII, but not PKC or PKA (Chakraborty 
et al., 2015). 
 
2.2.4.6 Opioids 
Activation of µ- and d-opioid receptors (MOR, DOR) have been linked with TRPV1 
sensitisation via recruitment of scaffolding protein b-arrestin 2. Coimmunoprecipitation 
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reveals an interaction between TRPV1 and b-arrestin 2 in rat TG neurons, while siRNA 
knockdown potentiates and reduces desensitisation to capsaicin by modulating PKA 
phosphorylation (Por et al., 2012). Activation of MOP with DAMGO and morphine in TG 
neurons results in b-arrestin 2 recruitment and dissociation from TRPV1. This is associated 
with potentiated capsaicin responses and TRPV1 dependent thermal hypersensitivities 
following chronic DAMGO and morphine exposure (Rowan et al., 2014a; Vardanyan et 
al., 2009). Interestingly, DOP agonist SNC80 produced comparable results in rats but not 
mice, suggesting species specific effects (Rowan et al., 2014b). In contrast, short term 
morphine administration potentiates capsaicin-induced TRPV1 desensitisation (Endres-
Becker et al., 2007; Shaqura et al., 2014). Centrally, TRPV1 and MOP interaction has been 
reported in the rostroventral medulla (RVM), simultaneous activation resulting in reduced 
ON-cell tone, inhibited by both TRPV1 and MOP antagonists (Maione et al., 2009). 
 
2.2.4.7 Cytokines 
Cytokines are responsible for activating kinase pathways leading to upregulation and 
sensitisation of TRPV1 attributed to increases in pain sensitivity. IL-6 induces 
upregulation of TRPV1, as well as activation of the Janus activated kinase (JAK)/PI3K 
signalling pathway and subsequent receptor sensitisation, associated with mechanical 
hypersensitivity in a bone cancer pain model (Fang et al., 2015). IL-1b is also associated 
with upregulation of TRPV1 in arthritis pain models, correlating with increased thermal 
hypersensitivity (Ebbinghaus et al., 2012). TRPV1 dependent thermal hypersensitivity 
resulting from increased IL-1b is associated with prostaglandin and PKC activity (Russell 
et al., 2009). Similarly, TNFa results in TRPV1 upregulation in cultured DRG neurons in 
an ERK dependent mechanism (Hensellek et al., 2007). A TNFa-induced upregulation of 
TRPV1 expression is found in CINP models, thermal and mechanical hypersensitivity are 
attenuated by both TRPV1 and TNFa inhibitors (Wang et al., 2018). Interestingly, 
blockade of TRPV1 in orthodontic pain models results in reduced IL-1b secretions in 




Activation of numerous other receptor types also influence TRPV1 thresholds. Purinergic 
P2Y receptor activation by ATP results in reduction of temperature threshold in both 
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HEK293FT cells and rat DRG neurons, dependent on PKC activation (Kress et al., 1999; 
Tominaga et al., 2001). Protease-activated receptor 2 (PAR2), co expressed with TRPV1 in 
rat DRG neurons also causes PKC dependent sensitivity changes. Increasing responses to 
protons, capsaicin and reducing temperature threshold upon stimulation in TRPV1/PAR2 
co-expressing HEK293FT cells (Dai et al., 2004). Similarly, activation of prokineticin 
receptors (PKR1, PKR2), sensitises thermal hypersensitivity and potentiates capsaicin 
responses (Negri et al., 2006). 
 
 
2.3 TLR4 / TRPV1 interaction 
Potentiation of capsaicin responses following immune activation was discovered prior to 
the capsaicin receptor itself. Rat vagus nerve exposed to LPS for 5 h showed potentiated 
capsaicin-induced calcitonin gene related peptide (CGRP) content, correlating with 
increased capsaicin-induced CGRP release from excised trachea. Interestingly this effect 
was not observed following a 2 h LPS treatment and was blocked by IL-1b and COX 
inhibitors (Hua et al., 1996). The timing and effect of antagonising pro-inflammatory 
mediators suggests an indirect relationship of LPS on capsaicin effects. In a study 
investigating headache mechanism, systematic LPS decreased the incidence of a multitude 
of intracisternal capsaicin-induced immobilisation behaviours, which did not correlate with 
increased neuronal activation marker, c-Fos (Kemper et al., 1998). This data suggests the 
potentiated behavioural effects are not related to changes in c-Fos and that the output of 
capsaicin sensitive neurons was increased by LPS. As above, a 5 h LPS incubation was 
required to observe these changes, suggesting an indirect effect resulting from LPS 
stimulation (Kemper et al., 1998). Following discovery and characterisation of TLR4 and 
TRPV1, these studies lead to the exploration of a potential functional interaction between 
the two receptors. Functional TLR/TRP relationships have been proposed for other 
receptor types. TLR4 activation indirectly results in activation of transient receptor 
potential cation channel subfamily C member 6 (TRPC6) due to LPS-induced DAG 
production (Tauseef et al., 2012). 
 
While the above examples suggest indirect, immune sensitisation and kinase activation 
events, the possibility of direct TRP and TLR interactions have previously been observed. 
Coimmunoprecipitation reveals an interaction between TLR7 and TRPA1, enhanced by 
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TLR7 and TRPA1 agonist miRNA lethal-7 (let-7b). Further, TLR7 and TRPA1 are 
colocalised in mouse DRG neurons (Park et al., 2014). This interaction induces functional 
consequences; let-7b activated TRPA1 mediated inward currents are enhanced by co-
expression of TLR7 in HEK293FT cells. This potentiation is unaffected by blocking 
common intracellular mediators (PKA, PKC, PLC) and TRPA1 currents are reduced in 
TLR7 deficient DRG neurons (Park et al., 2014). Taken together, this data suggests a 
functional relationship between TLR7 and TRPA1, although further studies are required to 
ascertain a potential direct protein-protein interaction. Investigation of a TLR4/TRPV1 
relationship in vitro and in vivo has attempted to clarify the nature of a potential interaction 
with mixed results.  
 
2.3.1 Nociception - TLR4/TRPV1 in vitro 
In vitro studies reveal expression of TLR4 in TLR4/TRPV1 co-expression systems is 
capable of modulating TRPV1 activity. Expression of TLR4 with TRPV1 in HEK293FT 
cells increases the amplitude of capsaicin responses and magnitude of calcium 
accumulation (Min et al., 2014). This mechanism is postulated to involve direct 
interactions between TRPV1 and the TIR domain of TLR4. An interaction which prevents 
internalisation and desensitisation of TRPV1 (Min et al., 2018). Contradicting this finding, 
evidence shows TRPV1 desensitisation to a second capsaicin stimulation in TLR4/TRPV1 
co-expressed HEK293FT cells, a phenomenon not observed in cells expressing TRPV1 
only (Li et al., 2015). It should be noted that this study introduced the whole TLR4 
receptor complex, including MD2 and CD14, which were not co-expressed in the studies 
mentioned above. The same paper reported that short LPS (15 min, 10 ng/mL) exposure 
potentiated inward currents in HEK293FT cells co-expressing TLR4 and TRPV1, as well 
as the chemotherapy and TLR4 stimulating agent paclitaxel (Li et al., 2015). Therefore, in 
engineered overexpression systems, the presence of TLR4 potentiates TRPV1 responses. 
 
Multiple studies investigating primary cultures have shown that TLR4 activation is able to 
alter the function of TRPV1. A 15 min LPS stimulation of rat trigeminal neurons produces 
potentiation of capsaicin evoked calcium accumulation and CGRP release attenuated by 
antagonising TLR4 (Diogenes et al., 2011; Ferraz et al., 2011). These and other studies 
reveal co-expression of TLR4 and TRPV1 in rat TG, DRG and human dental pulp and 
DRG neurons (Diogenes et al., 2011; Ferraz et al., 2011; Li et al., 2015; Wadachi et al., 
2006; Wu et al., 2019). The short LPS incubation times of these and engineered co-
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expression studies contrasts the previously discussed interaction in rat vagus nerves and 
suggests the possibility of a direct receptor interaction as postulated by studies in 
HEK293FT cells. 
 
2.3.2 Pain – TLR4/TRPV1 in vivo 
Preclinical pain models have given greater relevance to the in vitro results discussed 
above. The chemotherapy agent paclitaxel increases TRPV1 sensitisation in a TLR4 
dependant manner in a rat CINP model, as well as excised human and rat DRG neurons (Li 
et al., 2015). Similar to the rat TG studies above, increased TRPV1 mediated calcium 
responses in the presence of paclitaxel were attenuated when TLR4 antagonist LPS-RS 
was co-administered in DRG culture. Paclitaxel not only induces nociceptor changes, but 
spinal changes; ex vivo studies show an increased rate of miniature excitatory postsynaptic 
currents (mEPSCs) to a second application of capsaicin following paclitaxel treatment, an 
effect blocked by LPS-RS. Although, no changes in spontaneous EPSCs (sEPSCs) were 
observed suggesting the paclitaxel effect was on pre-, not post-synaptic terminals (Li et al., 
2015). In contrast, long term paclitaxel effects on postsynaptic TRPV1 responses were 
reported due to increased sEPSCs 7 days following paclitaxel treatment (Li et al., 2015). 
Comparable findings are observed in a 2,4,6-trinitrobenzine sulfate (TNBS)-induced colitis 
model. TLR4 knockout results in attenuated TRPV1 expression, consistent with the above 
theory that TLR4 prevents internalisation and thus desensitisation of TRPV1 (Wu et al., 
2019). Upregulation of TLR4 in WT mice is associated with increased TRPV1 expression 
and visceral hypersensitivity. Excised DRG neurons also revealed that the inflammatory 
conditions predictably potentiated capsaicin-induced current, however, responses from 
TLR4 knockout animals were significantly attenuated in both TNBS and control animals, 
suggesting TLR4 expression alone is responsible for increasing capsaicin responses (Wu et 
al., 2019).  
 
Evidence of functional and relevant TLR4/TRPV1 interaction in humans has been 
established in a clinical capsaicin model (Hutchinson et al., 2013). In this case, potentiation 
of mechanical allodynia and hyperalgesia was observed at three hours, but not two hours or 
directly following intravenous low dose (0.4 ng/kg) LPS. Interestingly this effect was 
anatomically variable, observed on the forearm but not the forehead. Further, the timing of 
potentiation correlated with peak levels of serum IL-6 (Hutchinson et al., 2013). Therefore, 
the mechanisms of action here appears to be one of inflammatory mediated receptor 
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sensation, rather than the rapid changes observed in primary DRG, TG and HEK293FT 
cultures. 
 
2.3.3 Outside pain literature 
Outside of pain literature, but within the sensory space, there have been increasing 
investigations regarding the role of TLR4/TRPV1 interactions in chronic itch. Increases in 
TLR4 expression are associated with increased histamine-induced itch. While histamine-
induced calcium currents are potentiated by LPS in DRG neurons of animals with 
increased TLR4 expression (Ji et al., 2018). Similarly, histamine-induced calcium signals 
are reduced in TLR4-deficient neurons. These results suggest histamine mediated itch is 
altered by TLR4’s impact on TRPV1 function (Min et al., 2014). Stroke models have also 
investigated the role of TLR4 and TRPV1. TLR2 and -4 are increased around the infarct, 
interestingly TRPV1 antagonism both reverses infarct volume and reduced TLR2 and -4 
expression. This suggests the possibility that TRPV1 can modulate TLR4 expression 
(Hakimizadeh et al., 2017). TRPV1 modulation of TLR4 function has also been observed 
in macrophages and salivary gland epithelial cells where capsaicin application attenuates 




Neuroimmune interactions play an important role in pathogenesis of chronic pain and 
warrants further investigation to uncover novel therapeutic targets. Improving the 
relevance of preclinical models to screen novel targets would be an important step. TLR4 
and TRPV1 represent receptor targets which are important in multiple pathological pain 
models and neuronal tissues. Further, multiple studies have highlighted a potential 
functional interaction whereby TLR4 mediates TRPV1 functional changes. The interaction 
involving TLR4 and TRPV1 offers a potential novel neuroimmune mechanism with 
clinical relevance in pathological pain states, the nature of this mechanism is the focus of 
current research. Further characterisation of the TLR4/TRPV1 interaction is required, 
including a greater understanding of mechanisms leading to direct and rapid receptor 
sensitisation. Rapid increases in receptor sensitivity are observed following LPS 
application, while the presence of TLR4 alone is also proposed to alter channel activity by 
direct protein-protein interaction. TLR4 activation by LPS results in increased levels of 
multiple kinases (PKC, PKA, PI3K, Src) as well as intracellular calcium, all of which are 
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associated with increased TRPV1 activity due to alteration in receptor phosphorylation and 
cell membrane expression. Potential direct and rapidly induced TLR4-dependent routes of 
TRPV1 sensitisation are presented in Figure 2.2 based on the literature of each receptor 
presented above. Investigation of both rapid, and proinflammatory driven sensitisation is 
required to understand the potential role in generation and/or maintenance of central 
sensitisation and pathological pain. The importance of each receptor to pathological pain 
states and central sensitisation suggests the interaction warrants further investigation in this 
context. Ultimately, novel mechanisms which influence central sensitisation are potential 















Figure 2.2: Proposed mechanisms of direct and rapid TLR4 induced TRPV1 
sensitisation. (A) Direct interaction proposed between the TIR domain of TLR4 and 
TRPV1. (B) LPS-induced increase in enzymatic activity (Src, PKA, PKC, PLC) alters 
TRPV1 sensitisation. (C) LPS-induced increase in enzymatic activity (PKC, PKA, PI3K) 
results in increased trafficking of TRPV1 to the cell membrane. Green represents actions 
resulting in receptor sensitisation; red represents actions resulting in receptor 
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Thesis Aims and Hypotheses 
The introductory chapters highlight that further research is required to ascertain the exact 
nature of a TLR4/TRPV1 functional interaction. It is clear that sensitisation of the TRPV1 
channel occurs through multiple agents induced by inflammation. The timing of 
potentiated capsaicin responses in multiple in vivo studies correlates with the induction of 
pro-inflammatory responses, suggesting an indirect mechanism of receptor sensitisation. 
However, in vitro studies point to a much shorter LPS incubation altering TRPV1 function. 
Further, both in vitro and in vivo studies suggest the presence of TLR4 alone, in the 
absence of activation, alters TRPV1 function. The nature of this relationship could be any 
one of a number of candidates, from physical interaction, alteration of scaffolding proteins, 
the fast activation of multiple relevant kinases, or alteration of membrane lipid 
composition. Understanding this relationship will help improve our understanding of 
neuroimmune interactions important in the generation and maintenance of chronic pain 
states. 
 
The aim of the first research chapter is to further investigate mechanisms surrounding the 
rapid induction of sensitisation in vitro. This involves creating a TLR4/TRPV1 co-
expression system and assessing TRPV1 in the presence and absence of TLR4. Further, we 
aim to reproduce previously observed short term agonist-induced sensitisation in order to 
target multiple intracellular components which are potentially responsible. Based on the 
literature presented above, we hypothesise we will see a TLR4 dependent potentiation of 
capsaicin-induced intracellular calcium in TLR4/TRPV1 expressing HEK293FT cells. We 
then expect agonism of TLR4 with LPS will induce rapid (< 20 min) potentiation of 
calcium responses compared to vehicle treated TLR4/TRPV1 expressing cells. Further we 
hypothesise that antagonism of TLR4 signalling will inhibit potentiation, as will inhibition 
of TRPV1 acting protein kinases (PKA, PKC). 
 
The second major aim relates to understanding the mechanisms underlying LPS-induced 
potentiation of capsaicin sensitivity in humans. A significant obstacle in the chronic pain 
field is the preclinical to clinical translation and relevance of preclinical pain models. One 
exciting possibility, given the clinical endotoxin-capsaicin model, is a unified preclinical, 
clinical model. Such a paradigm would offer the unique possibility of studying central 
cellular and molecular changes associated with both preclinical and clinical behavioural 
outcomes. We aim to reproduce the clinical endotoxin-capsaicin model in a preclinical 
 
 50 
BALB/c mouse model. Following the creation of the model we aim to investigate if key 
mechanisms are central or peripheral by targeted TLR4 antagonism. Further we aim to 
characterise central glial activity and pro-inflammatory cytokine levels. We hypothesise 
that systemic endotoxin will potentiate mechanical hypersensitivity in a BALB/c mouse 
model, associated with an inflammatory response and glial activation. 
 
In conjunction with this second aim, we will present a systematic review discussing the use 
of capsaicin in pain models. We hope such a review will help inform our decisions and 
interpretations of a BALB/c endotoxin-capsaicin model. Likewise, the review will assist 
future researchers and inform decisions to help improve the use and relevance of capsaicin 
in preclinical pain models. 
 
Achieving these aims will further our understanding of potentially important neuroimmune 
interactions, and their role in pain sensitivity. Further, we hope to produce a novel 
neuroimmune pain model which targets both immune and neural elements separately to 
produce heightened pain sensitivity. This will create a unified clinical and preclinical 
model, a unique situation in pain literature. We hypothesis that TLR4 plays a critical role 
in TRPV1-induced pain and these investigations will improve understanding of the 
TLR4/TRPV1 interaction, it’s importance to pain hypersensitivities, and relevance as a 
















Chapter 3. Activation and antagonism of toll-like receptor 4 signalling potentiates 




Interaction between nociceptive signalling and the immune system is becoming 
increasingly relevant in the search for novel therapeutics to treat chronic pain. Two 
receptor types in particular have been repeatedly implicated in the generation and 
maintenance of chronic pain in preclinical models. These are the innate immune receptor, 
toll-like receptor 4 (TLR4), and the neuronal ion channel, transient receptor potential 
cation channel subfamily V member 1 (TRPV1). Recently, a functional relationship 
between these receptors has been reported in clinical and preclinical models. We utilise a 
dual overexpression model in HEK293FT cells in an attempt to understand the mechanism 
of this interaction. We report potentiated intracellular calcium and altered influx dynamics 
in cells expressing both TLR4 and TRPV1 compared to TRPV1 only, including increased 
rate of calcium accumulation (p < 0.0001). TLR4 antagonists LPS-RS, (+)-naloxone, 1J 
and TAK-242 do not affect calcium influx dynamic but do increase intracellular calcium 
accumulation. Likewise, short term (18 min) but not long term (4 h) stimulation of TLR4 
with LPS does not affect calcium influx dynamic, but produces increased calcium 
accumulation in TLR4/TRPV1 expressing HEK293FT cells. TLR4 is able to alter the 
function of the TRPV1 receptor independent of TLR4 signalling events raising the 





Chronic pain represents a significant worldwide health problem, affecting an estimated 
20% of adults globally, with an estimated economic impact in 2010 of between $560 and 
635 billion in the United States (Goldberg et al., 2011; Loeser, 2012). Changes in ion 
channel sensitivity are associated with increased neural excitability and symptoms of 
chronic pain (Gonzalez-Ramirez et al., 2017). Increasing evidence implicates transient 
receptor potential cation subfamily V member 1 (TRPV1) in mechanical and thermal 
hypersensitivities; as a result, research has focussed on improving understanding 




A neural receptor found centrally and peripherally, TRPV1 is activated by endogenous and 
exogenous ligands (e.g. anandamide, capsaicin) as well as environmental factors including 
temperature and pH (Brito et al., 2014; Caterina et al., 1997; Szallasi et al., 2007). 
Sensitisation and/or increased expression of TRPV1 leading to increased neuronal 
excitability occurs in the presence of numerous inflammatory mediators including 
interleukins (IL-1, IL-6), prostaglandins (PGs), bradykinins, adenosine triphosphate (ATP) 
and nerve growth factor (NGF) (Chuang et al., 2001; Fang et al., 2015; Hensellek et al., 
2007; Moriyama et al., 2005; Tominaga et al., 2001; Zhang et al., 2005). Use of knockout 
models and expression studies reveal its importance in the maintenance of numerous pain 
phenotypes including morphine-induced thermal hyperalgesia, orofacial pain, orthodontic 
pain and complete Freund’s adjuvant (CFA)-induced inflammatory pain (Amaya et al., 
2003; Gao et al., 2016; Vardanyan et al., 2009; Watase et al., 2018). 
 
The importance of neuroimmune interactions on neural sensitivity is becoming 
increasingly evident; and the role of innate immune toll-like receptors (TLRs) in particular, 
which are heavily linked to chronic pain (Lacagnina et al., 2017; Nicotra et al., 2012). 
TLR3, 4, 5 and 7 have all been implicated in pain via upregulation in pain models or 
presence on primary afferent nociceptors. (Chen et al., 2017b; Lacagnina et al., 2017; Qi et 
al., 2011; Shi et al., 2017). The most intensively studied is TLR4, well known for its 
detection of gram-negative bacterial cell wall component lipopolysaccharide (LPS). TLR4 
antagonists LPS-RS and (+)-naloxone reverse neuropathic pain in rat models, while low 
dose LPS produces location-specific hypersensitivities in clinical trials (Hutchinson et al., 
2008; Jurga et al., 2016; Lewis et al., 2012; Wegner et al., 2014). TLR4 has also been 
implicated in direct neural activation (Chiu et al., 2013). Unsurprisingly, due to anatomical 
proximity and their apparent roles in pain hypersensitivities, a functional relationship 
between TLR4 and TRPV1 has been proposed.  
 
LPS potentiates capsaicin-induced neural responses in a number of primary cell and ex 
vivo models including rat vagus nerve, dorsal root and trigeminal ganglia (Diogenes et al., 
2011; Ferraz et al., 2011; Hua et al., 1996). Hutchinson et al. revealed the clinical 
relevance of a TLR4/TRPV1 interaction, reporting low-dose endotoxin potentiates 
mechanical hypersensitivity following intradermal forearm application of capsaicin 
(Hutchinson et al., 2013). The timing of potentiation creates questions around the nature of 
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the TLR4/TRPV1 interaction. Clinical potentiation and ex vivo vagus nerve studies suggest 
an indirect relationship via increased production of proinflammatory mediators (Hua et al., 
1996; Hutchinson et al., 2013). While primary cell and overexpression system studies 
suggest potentiation after a much shorter stimulation period (15 min), suggesting a more 
direct interaction (Diogenes et al., 2011; Ferraz et al., 2011; Li et al., 2015).  
 
Despite the apparent clinical implications of a TLR4/TRPV1 interaction, the exact nature 
of this relationship is yet to be determined. This study aims to further define the functional 
relationship between TLR4 and TRPV1 by exploring changes in TRPV1 function in the 







Human TRPV1 cloned into a PcDNA 3.1 D-V5/His6 TOPO mammalian expression vector 
was kindly donated by Dr. Christopher Reilly of the University of Utah, USA (Reilly et al., 
2003). GibcoTM Hanks’ Balanced Salt Solution (HBSS) – supplemented with calcium, 
magnesium and glucose; phenol red and sodium pyruvate free, purchased from 
ThermoFisher (NSW, AUS, cat#: 14025). 1M HEPES purchased from Sigma-Aldrich 
(NSW, AUS), diluted to 25 mM in HBSS. Lipopolysaccharide (LPS) from Escherichia 
coli 0111:B4 purified by phenol extraction purchased from Sigma-Aldrich (Castle Hill, 
NSW). (+)-Naloxone and 1J were kindly provided by Dr Kenner Rice (Chemical 
Biological Research Branch, National Institute on Drug Abuse and National Institute on 
Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD), solubilised 
to 10 mM in 100% DMSO. LPS from Rhodobacter sphaeroides (LPS-RS) purchased from 
Invivogen (CA, USA), solubilised to 100 µg / mL in 1X PBS. CLI-095 (TAK-242) 
purchased from Invivogen (CA, USA), solubilised to 10 µM in 1X PBS. Capsazepine 
purchased from Sigma-Aldrich (NSW, AUS) and solubilised to 5 mM in 100% DMSO. 
Capsaicin purchased from Sigma-Aldrich (NSW, AUS), solubilised to 50 mM in 100% 
DMSO. ViafectÔ purchased from Promega (WI, USA). Fluo-4AM purchased from 
Thermo Fisher (NSW, AUS), solubilised to 1 mM in 100% DMSO. 
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3.3.2 Cell culture 
Human embryonic kidney 293-FT (HEK293FT) cells were purchased from Life 
Technologies (VIC, AUS), HEK293FT cells stably expressing TLR4 and accessory 
proteins (CD14 and MD2) (TLR4 cells) were purchased from InvivoGen (CA, USA). 
HEK293FT and TLR4 cell lines were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 4.5 g/L glucose, (10%) (w/v) fetal bovine serum (FBS), 2 
mM L-glutamine, 50 U/ml penicillin and 50 mg/mL streptomycin. TLR4 cell line was 
further supplemented with 100 µg/mL normocin, 50 µg/mL hygromycin, and 10 µg/mL 
blasticidin as per the manufacturer’s protocol.  
 
3.3.3 TRPV1 transient transfection 
Cells were plated in 96 well clear bottom black cell culture plate (plate-based assay) or 8 
well ibidi ibiTreat µ-Slide 8 well (live-cell assay) 24 h prior to transfection. All cell types 
were plated in basic media (antibiotic free DMEM supplemented with 4.5 g/L glucose, 
(10%) (w/v) fetal bovine serum (FBS), 2 mM L-glutamine) in a total volume of 200 µL. 
HEK293FT and TLR4 cell lines were plated at 25000 and 45000 cells/well respectively. 
Transfection was carried out 24 h after plating when cells were 60-80% confluent using 
ViaFectÔ as per the manufacturer’s protocol. ViaFectÔ was used at a ratio of 6:1 (6 µL/1 
µg DNA), 80 ng of DNA was added to each well. Cells were used for plate based or live 
cell calcium assay 24 h post transfection. 
 
3.3.4 Fluo-4AM calcium assay  
Supernatant was aspirated and 200 µL of HBSS added. 150 µL of supernatant was 
removed and replaced with 150 µL, repeated for a total of three washes – all remaining 
supernatant was removed during the final wash. 50 µL of 3 µM Fluo-4AM in HBSS + 25 
mM HEPES was added to each well and left to incubate in the dark for 45 min at room 
temperature (RT). Fluo-4AM was removed and the cells were washed as above. Following 
the removal of the last wash step, 90 µL (96 well) or 150 µL (8 well) HBSS + 25 mM 







3.3.4.1 Plate reader  
BMG FLUOstar OPTIMA was used for plate-based calcium assays and preheated to 37°C 
before all experiments. The plate was added immediately following the addition of 90 µL 
HBSS + 25 mM HEPES and read 18 min after removal of Fluo-4AM to allow appropriate 
de-esterification (timing optimised in pilot studies). Fluorescence was measured at 2 s 
intervals for 32 s (exc. 485, em. 520) per well with a maximum of 16 wells per run, 10 µL 
of capsaicin or vehicle was injected at 5.5 s. 
 
3.3.4.2 Live cell  
Olympus FV3000 Confocal and associated FV31S-SW viewer software (Ver2.3) was used 
to record live cell calcium flux. Slides were added to the preheated stage (37°C) following 
addition of 150 µL HBSS + 25 mM HEPES and allowed to sit for 18 min to allow 
appropriate de-esterification prior to the addition of capsaicin. Imaging was initiated, and 5 
s later 150 µL of 1 µM capsaicin was administered via PE10 tubing attached to a 30G 
needle and 1 mL syringe. Total image time was 40 s per well. ImageJ software (Ver 2.0.0-
rc-69/1.52p) was used to analyse fluorescence changes in responding cells. 
 
3.3.5 Antagonist assays 
Capsazepine (10 µM), (+)-naloxone (200 µM), and 1J (10 µM) were applied to cells after 
removal of the final wash. TAK-242 (1 µM) and LPS-RS (200 ng/mL) were applied 1 and 
3 h respectively, prior to the first HBSS wash and re-applied during the 45 min Fluo-4AM 
incubation and following the final wash in HBSS + 25 mM HEPES to ensure total pre-
treatment time of 2 and 4 h respectively. 
 
3.3.6 Endotoxin – capsaicin study 
An 18-min LPS pre-treatment; 10, 100 or 1000 ng/mL in HBSS + 25 mM HEPES was 
added after the final wash in HBSS + 25 mM HEPES. For the 4 h pre-treatment; 10, 100 or 
1000 ng/mL LPS in basic media was added to cells 3 h prior to the first wash and re-







3.3.7 Assessment of TLR4 function 
Transfection of HEK293FT and TLR4 cell lines was performed as above. 24 h following 
transfection, supernatant was removed and cells treated with LPS in basic media (100 µL - 
100 ng/mL) or vehicle (media only) for 4 h. 80 µL of supernatant was removed, and IL-8 
content was measured using an ELISA kit (BD-Bioscience, Cat#555244, USA) according 
to the manufacturer’s instructions. Due to the high concentrations of IL-8 in the 
supernatant, samples were diluted (1:25) in assay diluent so they did not exceed the 
detection limits (samples receiving LPS-RS were the exception (1:2)). 
 
3.3.8 Analysis 
GraphPad Prism (Ver 8.2.0) was used to analyse all data. To compare AUC, time to 
maximum intensity and linear regression slope between HEK293FT and TLR4 expressing 
cell lines, two-way ANOVA with Sidak’s multiple comparisons test was performed. To 
compare intensity over time from plate reader experiments two-way ANOVA with 
Geisser-Greenhouse correction and Tukey’s multiple comparison test was performed. All 
other AUC and ELISA data was analysed by one-way ANOVA with Tukey’s multiple 
comparisons test. An unpaired two-tailed t-test was used to compare linear regression slope 





3.4.1 TLR4 alters TRPV1 dependent capsaicin responses in HEK293FT cells 
Capsaicin induces a sudden TRPV1 dependent increase in Fluo-4AM signal in cells 
transfected with TRPV1 (Fig. 3.1A, B). Post hoc analysis following two-way ANOVA 
revealed that TLR4 cells have significantly higher AUC at 50 (p < 0.05) and 0.5 µM (p < 
0.001) compared to HEK293FT cells, no differences are observed at the lower 
concentrations tested. Time to maximum fluorescence intensity was significantly reduced 
for all concentrations tested (Fig. 3.1D), while the rate of intensity increase calculated by 
the slope from baseline to maximum was significantly higher in TLR4 expressing cells at 
50 µM (p < 0.0001), 0.5 µM (p < 0.0001), and 50 pM (p < 0.05) but not 50 fM (Fig. 3.1E). 
ELISA results confirmed functionality of TLR4 in cells expressing TRPV1 (Fig. 3.1F). 
Post hoc analysis revealed LPS-RS significantly attenuated LPS-induced IL-8 responses in 
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both TRPV1 and empty vector control transfections (p < 0.0001) (Fig. 3.1F). Interestingly, 
the TRPV1 antagonist capsazepine also attenuated the IL-8 response in both TRPV1 (p < 
0.0001) and empty vector controls (p < 0.001). No significant difference in IL-8 response 
between TRPV1 and empty vector transfected cells was observed (p = 0.81). Together, 
these results indicate an altered TRPV1 dependant capsaicin-induced calcium influx 
















Figure 3.1: TLR4 alters TRPV1 dependent capsaicin responses in HEK293FT cells. 
Capsaicin dose response (50 µM, 0.5 µM, 50 pM, 50 fM) in TLR4/TRPV1 (A) and 
TRPV1 expressing cells (B) with AUC comparison (C). Comparison of time to peak 
fluorescence intensity (D) and rate of intensity increase (E). (F) TLR4 functionality 
confirmation in TRPV1 transfected cells by human IL-8 ELISA. n = 4 for calcium assay 
studies, n = 5 for ELISA results. Error bars represent SEM, dotted vertical line represents 
time of capsaicin injection. * = p < 0.05, ** = p < 0.01, **** = p < 0.0001 for 
TLR4/TRPV1 vs TRPV1 expressing cells. #### = p < 0.0001 for LPR-RS + LPS vs LPS 
only cytokine response for respective transfections. &&& = p < 0.001, &&&& = p < 









3.4.2 Live cell calcium analysis reveals a population of fast responding TLR4/TRPV1 
HEK293FT cells.  
Live cell images reveal a rapid increase in calcium accumulation following capsaicin 
treatment in TRPV1 and TLR4/TRPV1 expressing cells. The rate of intensity increase 
varies within the population (Fig. 3.2). Linear regression of baseline to maximum intensity 
revealed a significant difference between the mean slope of TLR4/TRPV1 (5.3 ± 0.5) and 
TRPV1 (3.5 ± 0.3) cells (p < 0.001). Distribution of the two populations suggests a 
separate population with unique response characteristics may exist within the TLR4 
responders (Fig. 3.2C). 
 
 
Figure 3.2: Live cell analysis reveals a fast responding population within the 
TLR4/TRPV1 cell line. Example recoding of TLR4 (A) and HEK293FT (B) cells 
transfected with TRPV1 at baseline, 1, 10 and 40 s following capsaicin administration (500 
nM). (C) Violin plot comparing linear regression slope (baseline to max.) of the two 
populations of cells showing median, 1st and 3rd quartiles. Representative single cell 
fluorescent changes for TLR4/TRPV1 (D) and TRPV1 expressing HEK293FT cells (E). A, 
B, D and E represent one trial only. n = 5 recordings for violin plot (n = 326 & 356 
individual capsaicin responders from TLR4/TRPV1 and TRPV1 populations respectively). 
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3.4.3 TLR4 antagonists potentiate capsaicin-induced calcium accumulation in 
TLR4/TRPV1 expressing HEK293FT cells. 
TLR4 antagonists LPS-RS, (+)-naloxone, TAK-242 and 1J were administered to assess the 
potential action of TLR4 on TRPV1 function. Two-way ANOVA revealed an effect of 
time (F(1.9, 28.9) = 2393, p < 0.0001) and interaction (F(60, 225) = 2.3, p < 0.0001) but not 
treatment (F(4, 15) = 2.0, p = 0.15) when capsaicin fluorescence intensity plots were 
analysed (Fig. 3.3A). Multiple comparisons revealed no significant differences at all time 
points for LPS-RS, TAK-242 and 1J compared to capsaicin only. (+)-Naloxone showed 
increased fluorescence intensity at 12 s post capsaicin but at no other time point (Fig. 
3.3A). Comparison of AUC analysis by one-way ANOVA revealed that all TLR4 
antagonists; LPS-RS (p = 0.012), TAK-242 (p = 0.0017), 1J (p = 0.0025) and (+)-naloxone 
(p < 0.0001) produced a significant increase compared to vehicle treated cells (Fig. 3.3B). 
Unlike all other antagonists, LPS-RS produced a significant intensity increase over vehicle 
cells in the absence of capsaicin from 14 s post addition of vehicle until the end of 
recording (Fig. 3.3A). This difference was observed in AUC analysis in LPS-RS treated 
cells (p = 0.0011), no statistical differences were observed between vehicle treated cells 
and all other antagonists tested; (+)-naloxone (p = 0.873), TAK-242 (p = 1.0), 1J (p = 1.0) 
(Fig. 3.3B). These results suggest TLR4 antagonist activity increases overall capsaicin-






Figure 3.3: TLR4 antagonists potentiate capsaicin-induced calcium accumulation in 
TLR4/TRPV1 expressing HEK293FT cells. (A) Intensity changes induced by capsaicin 
(500 nM) in the presence of TLR4 antagonists LPS-RS (200 ng/mL), (+)-naloxone (200 
µM), TAK-242 (10 µM) and 1J (10 µM). (B) AUC analysis of intensity plot in (A). n = 5 
for capsaicin-vehicle and vehicle-vehicle treated cells, n = 4 for all other groups except 
cells administered 1J (n = 3). Error bars represent SEM, dotted vertical line represents time 
of capsaicin injection. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 for 
(+)-naloxone + capsaicin (A) and antagonist + capsaicin (B) vs vehicle + capsaicin treated 










3.4.4 Endotoxin potentiates capsaicin-induced calcium accumulation following 18 min 
but not 4 h pre-treatment. 
Representing the range of LPS doses previously found to potentiate TRPV1 responses; 10, 
100 or 1000 ng/mL LPS was administered 18 min or 4 h prior to capsaicin (Ferraz et al., 
2011; Li et al., 2015; Wu et al., 2019). After an 18 min pre-treatment a two-way ANOVA 
revealed significant effect of time (F(1.9,23.2) = 387, p < 0.0001) but not treatment (F(3,12) = 
1.0, p = 0.4) or interaction (F(45,180) = 1.4, p = 0.05) when capsaicin treated data was 
analysed (Fig. 3.4A). Two-way ANOVA of cells not treated with capsaicin reveals a 
significant effect of time (F(2.0, 24.0) = 119, p < 0.0001), treatment (F(3,12) = 6.9, p = 0.006) 
and interaction (F(45,180) = 5.9, p < 0.0001) (Fig. 3.4A). Post hoc analysis revealed no time 
point differences between LPS-capsaicin and vehicle-capsaicin treated cells (Fig. 3.4A). 
Significant differences were observed for 1000 ng/mL LPS-vehicle compared to vehicle-
vehicle treated cells from 20 s onwards (Fig. 3.4A). AUC analysis revealed a significant 
difference between 1000 ng/mL (p < 0.01) and 100 ng/mL (p < 0.0001) LPS-capsaicin and 
vehicle-capsaicin treated cells (Fig. 3.4C). Likewise, compared to vehicle-vehicle treated 
cells, AUC analysis revealed significant difference with 1000 ng/ml LPS-vehicle (p < 
0.001) and 100 ng/ml LPS-vehicle (p < 0.001) groups (Fig. 3.4C). Following a 4 h pre-
treatment two-way ANOVA revealed significant effect of time (F(1.6, 19.7) = 353, p < 
0.0001). However, no significant effect of treatment (F(3,12) = 0.2, p = 0.9) or interaction 
(F(45,180) = 0.4, p = 1.0) was found when capsaicin treated data was analysed (Fig. 3.4B). 
Two-way ANOVA of cells not treated with capsaicin reveals a significant effect of time 
(F(2.1,25.3) = 104, p < 0.0001) and interaction (F(45,180) = 1.8, p = 0.004) but not treatment 
(F(3,12) = 2.5, p = 0.1). Post hoc analysis revealed no time point differences between 
vehicle-capsaicin and all LPS-capsaicin groups, or vehicle-vehicle and all LPS-vehicle 
groups (Fig. 3.4B). AUC analysis revealed a significant difference between 100 ng/mL 
LPS-vehicle and vehicle-vehicle treated cells (p < 0.05) (Fig. 3.4D). Despite this increase, 
there were no differences due to LPS treatment in capsaicin treated cells (Fig. 3.4D). 
Therefore, the shorter 18 min, but not 4h pre-treatment, resulted in potentiated capsaicin-
induced calcium accumulation. However, LPS alone induced increased calcium 






Figure 3.4: Endotoxin potentiates capsaicin-induced calcium accumulation following 
18 min but not 4 h pre-treatment in cells expressing TLR4 and TRPV1. Intensity 
changes induced by capsaicin (500 nM) pre-treated with LPS for 18 min (A) or 4 h (B). 
AUC of intensity plot for 18 min (C) and 4 h (D) pre-treatment. n = 4 for all groups. Error 
bars represent SEM, dotted vertical line represents time of capsaicin injection. # = p < 
0.05, ## = p < 0.01, for 1000 ng/mL - VEH vs VEH - VEH. * = p < 0.05, ** = p < 0.01, 















Neural sensitisation resulting in pain hypersensitivity leads to symptoms of chronic pain. 
TRPV1 plays an important role in nociception and hypersensitivity; it’s relationship with 
immune receptor TLR4 is a potentially important neuroimmune interaction contributing to 
receptor sensitisation. Here we show that TLR4/MD2/CD14 (TLR4), co-expressed in 
HEK293FT cells with TRPV1, alters the dynamics of calcium influx following capsaicin 
exposure. The presence of TLR4 increased the rate of calcium accumulation when 
compared to un-transfected controls (Fig. 3.1). This agrees with similar studies in 
TLR4/TRPV1 expressing HEK293FT cells which showed increased calcium influx when 
compared to ionomycin control treatments (Min et al., 2018; Min et al., 2014). In contrast 
to these studies, we did not observe a sustained calcium difference for the duration of 
recording, although we used a different (non-ratiometric) calcium indicator and a 20-fold 
lower capsaicin concentration. It should also be noted that these studies do not mention co-
expressing TLR4 associated CD14 and MD2. Primary cell patch clamp studies report 
similar findings in mouse DRG neurons; TLR4 knockout tissue shows decreased current 
density when compared to wild-type (WT) controls (Wu et al., 2019). Itch studies have 
postulated increased TRPV1 mediated histamine-induced itch is potentiated in older (75 
day) compared to younger (45 day) mice as a result of increased DRG expression of TLR4 
(Ji et al., 2018). Upregulation of TLR4 in vivo is also associated with increased capsaicin 
responses in models of inflammatory pain; paclitaxel-induced neuropathy and TNBS-
induced colitis (Ji et al., 2018; Li et al., 2015; Wu et al., 2019). Our live cell analysis 
reveals a fast responding population of TLR4/TRPV1 cells, resulting in significantly 
higher calcium accumulation rate following capsaicin when compared to TRPV1 
expressing cells (Fig. 3.2). These separate populations potentially explain the fluorescence 
ratio slope differences observed between TLR4/TRPV1 and TRPV1 expressing 
HEK293FT cells in a plate reader assay. 
 
These unstimulated effects strengthen a proposed direct protein-protein interaction 
between TRPV1 and TLR4. The toll-interleukin receptor 1 (TIR) domain of TLR4 has 
been proposed as a potential site of interaction. TLR4 mutants without a TIR domain, 
expressed with TRPV1, results in decreased capsaicin responses compared to wild-type 
TLR4, whose responses resemble TRPV1 only expressing HEK293FT cells (Min et al., 
2018). TIR domain potentiates TRPV1 activity by blocking activation-induced 
desensitisation (Min et al., 2018). It is unclear however if the interaction is direct; no 
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interaction between TIR domain containing proteins and TRP channels has been 
previously reported. While the authors identifying the TIR/TRPV1 interaction 
acknowledge unidentified intermediary proteins may be involved in the observed 
potentiation of TRPV1 activity (Min et al., 2018). One potential intermediary is 
cytoplasmic scaffolding protein A-kinase anchoring protein 79 (AKAP79) (rodent 
orthologue AKAP150), which is important to the sensitising effect of protein kinase A and 
C (PKA, PKC) on TRPV1 (Faux et al., 1997; Jeske et al., 2008; Jeske et al., 2009; Zhang 
et al., 2008). TLR-TRP interactions have been observed previously, co-
immunoprecipitation revealed an interaction between TRPA1 and TLR7 which potentiates 
TRPA1 induced inward current, suggesting a physical interaction (Park et al., 2014). 
Further research is required to confirm a protein-protein interaction between TLR4 and 
TRPV1. Detection of unmodified protein interactions in tissues remains elusive due to the 
unreliability of available TLR4 antibodies (McCarthy et al., 2017). Advances in protein-
protein interaction assays such as bioluminescence resonance energy transfer (BRET) have 
the potential to improve our understanding using overexpression models (Dimri et al., 
2016). 
 
TLR4 antagonists were applied to identify potential TLR4 signalling effects. Interestingly, 
at concentrations which inhibit LPS-induced IL-8 release in TLR4 cells, all antagonists 
showed increased calcium accumulation analysed by AUC when compared to vehicle 
treated cells (Fig. 3.3). (+)-Naloxone is the opioid inactive stereoisomer of opioid 
antagonist (-)-naloxone, and a TLR4 antagonist; its mechanism of action requires further 
investigation (Lewis et al., 2012). Like (+)-naloxone, (+)-naltrexone is an opioid inactive 
stereoisomer of an opioid antagonist, and TLR4 antagonist. Unsurprisingly its analogue IJ, 
modified for increased potency and decreased cytotoxicity, resulted in the same significant 
increase as (+)-naloxone (Fig. 3.3) (Selfridge et al., 2015). LPS-RS prevents many 
endotoxin sources from interacting with MD-2 (Gaikwad et al., 2015; Kutuzova et al., 
2001). While TAK-242 inhibits the association of TLR4 with adaptor molecules 
toll/interleukin-1 receptor domain-containing adaptor protein (TIRAP) or toll/interleukin 1 
receptor domain-containing adaptor protein inducing interferon-b-related adaptor molecule 
(TRAM) by binding a cysteine residue (C747) in the intracellular TIR domain (Matsunaga 
et al., 2011; Shirey et al., 2020). As interfering with this conserved region potentiates, 
rather than inhibits capsaicin-induced calcium accumulation, it is unlikely this represents 
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an important residue for a potential protein-protein interaction between TLR4 and TRPV1. 
Further, it suggests that TIRAP or TRAM don’t facilitate an interaction. Taken together 
these results reveal blocking external and internal signalling components of the TLR4 
signalling cascade causes an increase in calcium influx following capsaicin. This is in 
contrast to Diogenes et al. who did not report an antagonist effect on capsaicin response, 
either calcium accumulation or CGRP release from rat TG neurons (Diogenes et al., 2011).  
 
To further elucidate mechanism, we tested the widely reported endotoxin-capsaicin 
paradigm where LPS potentiates TRPV1 dependent calcium responses. Studies using rat 
TG and mouse DRG report potentiated capsaicin responses (Ca+2 influx, CGRP release and 
current density) following 5 and 15 min LPS treatments (Diogenes et al., 2011; Ferraz et 
al., 2011; Wu et al., 2019). Importantly, antagonism of TLR4 reversed the effect in rat TG 
neurons and the potentiated capsaicin responses were not observed in DRG neurons from 
TLR4 knockout mice (Diogenes et al., 2011; Wu et al., 2019). Due to limitations with 
calcium detection by Fluo-4AM, we were unable to replicate this timing exactly but 
applied capsaicin after an 18 min LPS incubation. We observed potentiation at 1000 and 
100 but not 10 ng/mL LPS (Fig. 3.4). In contrast, potentiation of inward current has been 
observed after 10 ng/ml LPS over a similar timeframe in TLR4/TRPV1 overexpressing 
HEK293FT cells; although the serotype used was not reported in this case (Li et al., 2015). 
In the same study, activation of TLR4 by chemotherapeutic agent paclitaxel over the same 
time period produced TRPV1 potentiation (Li et al., 2015). This effect is in contrast with 
primary cell studies which concluded 20 and 200 ng LPS did not potentiate a response, and 
between 2 and 200 µg/mL were required (Diogenes et al., 2011; Ferraz et al., 2011; Wu et 
al., 2019). This result is not unexpected given in vitro TLR4 overexpression models are 
likely to show greater sensitivity to LPS. Given the low dose of LPS (0.4 ng/kg) which 
produced potentiated capsaicin-induced pain behaviours in the clinical model, this data 
further strengthens the argument of immune mediator driven rather than direct receptor 
interaction causing potentiation in the clinical setting. This in vitro data further supports 
the hypothesis that early consequences of TLR4 signalling cause rapid sensitisation of 
TRPV1. Together with our antagonist data, we may also suggest that conformational 
changes induced by binding at TLR4 can affect TRPV1 function if a protein-protein 




Potentiation of capsaicin responses caused by longer term LPS stimulation have been 
observed in rat ex vivo and behavioural studies (5 hr LPS treatment) as well as clinical 
studies (3.5 hr LPS) (Hua et al., 1996; Hutchinson et al., 2013; Kemper et al., 1998). 
Interestingly a clinical endotoxin-capsaicin study observed potentiation at 3.5 h but not at 
earlier time points (2 h) using a low dose of endotoxin (Hutchinson et al., 2013). In 
contrast animal studies required a much higher LPS concentration to observe a potentiated 
capsaicin response (Hua et al., 1996; Kemper et al., 1998). Nevertheless, in both cases the 
changes were associated with inflammatory cytokines. In humans, the timing of 
potentiation correlated with peak IL-6, while blockade of cyclooxygenase-2 (COX-2) and 
IL-1b activity reversed potentiation in ex vivo rat trachea (Hua et al., 1996; Hutchinson et 
al., 2013). Our in vitro studies were unable to replicate potentiation over a range of LPS 
concentrations despite producing a detectable inflammatory response (Fig. 3.1, 4). Despite 
the IL-8 increase we observed in our overexpression system, perhaps the gamut of 
inflammatory mediators known to sensitise TRPV1 were not present in our homogenous 
single cell culture system. While verifying the function of TLR4 in our TLR4/TRPV1 
overexpression system, TRPV1 antagonist capsazepine reduced IL-8 output. TRPV1 
antagonism with AMG9810 has been shown to decrease TLR2 and TLR4 expression in rat 
stroke models suggesting TLR4/TRPV1 relationship is not one-way, potentially explaining 
our result (Hakimizadeh et al., 2017). Like TLR4’s impact on TRPV1, the potential impact 
of TRPV1 on TLR4 function requires further investigation. 
 
LPS caused significant increases in calcium accumulation past 20 seconds in vehicle 
treated cells after an 18 min pre-treatment at 1000ng/mL, a result also observed following 
LPS-RS pre-treatment (Fig. 3.3, 4). While not significant, the same situation is observed 
after 4 h of LPS treatment (Fig. 3.4). Increase in baseline calcium levels, a phenomena 
previously observed in microglia could potentially explain enhanced neuronal excitability 
following LPS treatment (Hoffmann et al., 2003; Tzour et al., 2017). Multiple studies 
suggest LPS alone is capable of exciting nociceptive neurons, increasing action potential 
generation following long and short term exposure (Diogenes et al., 2011; Ochoa-Cortes et 
al., 2010; Tzour et al., 2017). Interestingly the same effects were not observed in cells not 
co-expressing TRPV1 (Sup. Fig. 3.1). Similar results have been observed in nodose and 
trigeminal ganglion neurons, where calcium influx following LPS treatment are 
independent of TLR4 expression and dependant on expression of ion channel TRPA1 
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(Meseguer et al., 2014). These increases potentially explain the increased calcium 
accumulation observed following capsaicin treatment. However, increased calcium 
accumulation in LPS-vehicle treated cells did not correlate with potentiated responses in 
LPS-capsaicin treated cells following 4 h pre-treatment. Further investigation is required to 
ascertain if these effects are mediated by TRPV1, TLR4 or both in combination.  
 
In the present study we have shown cells expressing TLR4, MD-2 and CD14 have altered 
TRPV1 mediated calcium influx dynamic following stimulation with capsaicin. Antagonist 
investigation reveals the effect is unlikely to be connected to TLR4 signalling. We were 
able to observe a potentiated capsaicin induced calcium accumulation following short term 
administration of LPS at 1000 and 100 ng/mL but not following a longer-term 
administration as previously observed in primary cell lines. More investigation into a 
potential physical interaction between the receptors is required to fully understand this 
mechanism. Both a potential physical interaction and secondary effect of TLR4 signalling 
on TRPV1 function play a role in neuronal hypersensitivity, and further insight could 
















3.6 Supplementary figures 
 
 
Supplementary Figure 3.1: Endotoxin effects on intracellular calcium in TLR4 
expressing HEK293FT cells are observed following short, but not long term 
incubations. Intensity changes induced by capsaicin (500 nM) pre-treated with LPS for 18 
min (A) or 4 h (B). AUC of intensity plot for 18 min (C) and 4 h (D) pre-treatment. n = 4 
for all groups. Error bars represent SEM, dotted vertical line represents time of capsaicin 











The next section of this thesis will relate to our second aim and focus on the generation of 
a preclinical endotoxin-capsaicin model. The first chapter confirmed a functional 
relationship between the two targeted receptors. Taking into account chapter 3 and 
previous studies we will look to incorporate a second, shorter time point. We begin the 
development of an endotoxin-capsaicin model by delivering a literature review analysing 
the use of capsaicin in preclinical animal models utilising behavioural assessment. The 
review began as a means of understanding the best approach to back-translate the clinical 
model into a rodent model. As a consequence, we have been able to analyse the capsaicin 
literature, providing a valuable resource for future researchers utilising capsaicin-induced 
behavioural pain assessment. 
 
 
Chapter 4. Review: The use of capsaicin as a pro-nociceptive stimulus in animal pain 




Animal models of pain have been instrumental in advancing our understanding of pain 
mechanisms. However, translating this understanding into positive clinical outcomes has 
been lacking, with pain remaining a significant worldwide burden. As a result, researchers 
are having to re-evaluate their use of animal models in pain research, aiming to improve 
clinical relevance and improve therapeutic options. One commonly used model of pain is 
the application of capsaicin, the pungent ingredient of chilli peppers. Capsaicin directly 
activates neurons by activating transient receptor potential cation channel subfamily V 
member 1 (TRPV1), resulting in burning pain and sensitivity to numerous stimuli. This 
review analyses capsaicin use as a pro-nociceptive stimulus in pain literature, reporting on 
its current and historical use. We report species and sex used, routes of administration, 
associated behavioural testing, range of doses and duration of nociceptive hypersensitivity 
induced. We then discuss potential improvements on the use of capsaicin in the context of 
the broader pain literature with the aim of helping to inform the decisions of future 







Capsaicin is an alkaloid recognisable as the main pungent ingredient of chilli peppers 
(Szallasi et al., 1999). It binds transient receptor potential cation channel subfamily V 
member 1 (TRPV1), a heat sensitive non-selective cation channel (Caterina et al., 1997; 
Szallasi et al., 2007). TRPV1 is found on multiple tissues types, including small to medium 
primary afferent neurons known as nociceptors, responsible for the transmission of 
noxious stimuli to produce the sensation of pain (Brito et al., 2014; Szallasi et al., 2007). 
TRPV1 is also activated by protons (low pH), resiniferatoxin, and various endogenous 
ligands including anandamide (Szallasi et al., 2007). Following activation of the receptor, 
cation influx results in action potential generation and nociceptive firing in the peripheral 
nervous system (PNS), ultimately leading to generation of pain sensation in higher brain 
regions (Brito et al., 2014; Sutherland, 2014). This makes capsaicin an excellent compound 
for the study of basic mechanistic questions around nociception both in vitro and in vivo. 
 
In mammals, application of capsaicin leads to a sensation of burning, followed by a period 
of increased sensitivity (sensitisation), and finally a loss of sensation known as 
desensitisation/analgesia (Sawynok, 2005). Desensitisation is likely the result of one or 
multiple of the following factors; a depletion of neurotransmitters (e.g. substance P), 
calcium-induced receptor desensitisation or calcium-induced neuronal ablation (Caterina et 
al., 2001). As a result, capsaicin has multiple practical applications ranging from self-
defence (pepper spray) to therapeutic agents targeting pain (Szallasi et al., 1999; Szallasi et 
al., 2007). Capsaicin has been used as an analgesic for over 100 years, currently a number 
of topical patches are available to treat chronic pain conditions including post herpetic 
neuralgia (PHN), diabetic neuropathy, arthritis and post-surgical pain (Baranidharan et al., 
2013; Szallasi et al., 2007).  
 
The dose, application method and age of the subject all contribute to the effects of 
capsaicin; single, low doses are able to produce nociceptor sensitisation without long term 
desensitising effects (Holzer, 1991). Sensitisation of TRPV1 produces nociceptor 
sensitivity to a number of mechanical and thermal (hot and cold) stimuli (Szallasi et al., 
1999). In clinical studies this sensitisation is referred to as either hyperalgesia, an 
exaggerated painful response to noxious stimuli, or allodynia, a painful response to a 
previously non-noxious stimulus (Ji et al., 2003; Milligan et al., 2009). Capsaicin is able to 
cause sensitisation to areas surrounding the application site, known as secondary 
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hyperalgesia/allodynia as well as at further sites, known as referred hyperalgesia/allodynia 
(Kinnman et al., 1995; Laird et al., 2000; Willis, 2002). Mice lacking TRPV1 do not 
develop thermal hyperalgesia following capsaicin administration, highlighting the 
importance of the receptor to this sensitisation event (Caterina et al., 2000). The processes 
by which capsaicin is able to cause sensitisation to secondary areas of tissue are known as 
peripheral and central sensitisation (Carlton et al., 2001; Dai et al., 2002).  
 
Peripheral sensitisation is a term given to multiple events on or within neurons of the PNS 
which result in lowered activation threshold and therefore increased chance of firing 
(Grace et al., 2014). Likewise, central sensitisation results in increased neuronal 
excitability, but refers to neurons within the central nervous system (CNS) (Woolf et al., 
2000). These processes are of particular interest to the field of chronic pain, a disease state 
affecting 1 in 5 adults worldwide and costing billions of dollars annually (Goldberg et al., 
2011; Loeser, 2012). Allodynia, hyperalgesia and spontaneous pain are major symptoms of 
many chronic pain types, as such, capsaicin is an interesting option for mechanistic 
investigations (Mogil, 2009). Further to symptomatic similarities, TRPV1 is upregulated in 
multiple preclinical animal models of chronic pain (Rashid et al., 2003a; Rashid et al., 
2003b).  
 
Capsaicin pain models have been described as potential surrogates for models of 
neuropathic pain due to the production of secondary hyperalgesia comparable to nerve 
ligation models, which are both attenuated by the same opioid combinations (Joshi et al., 
2006). Beneficially, capsaicin models are able to reduce time and cost to the experimenter 
and reduce the amount of pain animals endure compared to nerve ligation models. 
However, the relevance of animal models which look to emulate human disease is being 
debated due to the poor translation of results for new therapeutic agents. Numerous 
examples exist of positive preclinical results not translating into successful therapeutic 
agents, including neurokinin-1 (NK1) receptor antagonists, sodium channel and gap 
junction blockers and microglial attenuators (Goadsby et al., 2009; Hill, 2000; Landry et 
al., 2012; Wallace et al., 2002).  
 
Successful examples of translation from preclinical to clinical results exist but are less 
common than the failures. N-type voltage sensitive sodium channel blocker (ziconotide) 
showed promise in rat pain models, which translated into clinical trials and to Food and 
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Drug Administration (FDA) and European Medicines Agency (EMEA) approval. 
However, side effects limit use to individuals experiencing severe pain (Bowersox et al., 
1996; Schmidtko et al., 2010). To a lesser extent aforementioned capsaicin patches are 
another example, however low compliance rates due to multiple painful applications limit 
their success (Baranidharan et al., 2013). Despite these positive outcomes of animal model 
use, there is an obvious need to improve use of animals in respect to finding improved 
clinical therapeutic options.  
 
Behaviour assessed is a crucial element of preclinical models; one potential reason for the 
lack of success in preclinical translation is the use of irrelevant behavioural measures 
(Mogil, 2009). Researchers can observe both stimulus-evoked (elicited) or stimulus 
independent (spontaneous) responses which represent mechanical and thermal 
hyperalgesia/allodynia and spontaneous pain observed in pain patients, making these 
measures seemingly relevant (Vierck et al., 2008). Sufferers of chronic pain report 
sensitivity to thermal and mechanical sensitivities. However, the most prevalent symptom 
is spontaneous pain (Backonja et al., 2004). It is important that researchers consider 
models that mimic these phenotypes in order to measure relevant outcomes. Likewise, 
species selection, dose and location of stimulus application can affect the timing, intensity 
and location of pain (Gregory et al., 2013; Henze et al., 2010; Holzer, 1991). Therefore, 
multiple factors need to be considered when assessing the validity of a pain model to a 
particular condition. 
 
Capsaicin is a valuable tool in which to study pain due to both the pain response it induces 
and the importance of TRPV1 to pain mechanisms. Given the relative efficacy of current 
therapeutics utilising capsaicin, TRPV1 also remains a viable target in pain medicine. To 
improve the clinical relevance of capsaicin research we must understand how capsaicin is 
currently used. This review will explore the use of preclinical capsaicin pain models and 
discuss the relevance of current approaches and potential improvements. We will focus on 
capsaicin use intended to provoke an observable nociceptive response, not intended for 







 4.3 Methods 
 
4.3.1 Research strategy 
The PRISMA statement was used to prepare the following systematic review. Literature 
searches of PubMed and Embase databases were used to identify all eligible studies. 
Search terms included “pain,” “capsaicin”, “behaviour” and related words. Papers used 
were published in English up until February 2018, these were the only limits of the search. 
The exact search string can be found in Table 4.1. Additional eligible studies were 
identified after manually searching the reference lists of included articles. 
 
4.3.2 Systematic review publication selection criteria 
To determine eligibility; titles, abstracts and/or full text were screened. Studies were 
eligible for inclusion if they were an original study which used a preclinical in vivo model 
to assess behaviour following application of capsaicin. Studies were excluded if they (i) 
did not include a vehicle control group in the behavioural assessment, (ii) used capsaicin 
for the purpose of denervation/desensitisation/analgesia; (iii) the behaviours observed were 
not related to pain or pain related behaviour (i.e. drinking).  
 
4.3.3 Systematic review publication data extraction 
The following was extracted from each included study: (i) study characteristics (first 
author, year of publication); (ii) animals used (species, sex, strain), (iii) route of capsaicin 
administration (including anatomical location); (iii) dose of capsaicin used, (iv) 
behavioural test used (including testing time and duration of observed sensitivity post 
capsaicin application), (v) purpose of study (hypothesis/stated aim) and (vi) the role of 
















AND allodynia OR hyperalgesia OR assessment, pain[MeSH Terms] OR animal 
behavior[MeSH Terms] 




AND allodynia OR hyperalgesia 
AND behaviour OR pain assessment OR von Frey test OR Hargreaves OR licking 
OR bite 
























4.4.1 Systematic review search outcomes 
The screening process is described in Figure 4.1. The initial search yielded 540 results, 73 
of which were duplicates and immediately discarded. Upon examination of abstracts a 
further 148 were excluded for not meeting entry criteria, including, studies that were not 
preclinical, reported no vehicle control in capsaicin experiments, used alternative TRPV1 
agonists, included no behavioural assessment following capsaicin and were not primary 
research articles. The remaining 319 articles underwent full text review. 85 additional 
articles were identified based on references while a further 96 were excluded. The majority 
of exclusions were due to primary intentions of capsaicin either being 
denervation/desensitisation or as an analgesic intervention rather than to induce a pro-
nociceptive response. Articles were also excluded for analysing non-pain behaviours (i.e. 
drinking), insufficient reporting and not being primary research articles. 309 articles 










Pubmed: N = 288  Embase: N = 252  
Total: N = 540 
Total: N = 319 
Total: N = 309 
Duplicates: N = 73  
Excluded: N = 96 
N = 12 Poster/abstract 
N = 7 Insufficient reporting 
 
Capsaicin used for:  
N = 51 Denervation/desensitisation 
N = 22 Analgesia/antinociception 
N = 4 Non-Pain related behaviour 
Included: N = 86 
 
Identified by manual search 
Excluded: N = 148  
Did not meet inclusion criteria: 
- Preclinical 
- Vehicle control 
- Use of capsaicin 
- Behavioural assessment 
- Journal Article 




4.4.2 Paper characteristics 
Use of capsaicin in preclinical models to induce nociceptive behaviours increased in the 
latter half of the 1990’s and has remained a constant research interest (Fig. 4.2A). 
Administration, observations and pain testing are primarily focused at peripheral sites 
(90.3%), the remaining minority explore visceral sites (9.7%). Rodent species are the most 
common animal model used, accounting for 93.2% of all identified studies, followed by 
primates of the genus Macaca (mulatta & fuscata) which account for 6.1% (Fig. 4.2D). 
Two studies in pigs were also identified. It should be noted the use of primates has reduced 
with only one incidence in the 5 years prior to this review, while porcine use is relatively 
recent, the first paper published in 2011 (Fig. 4.2B). Interestingly, there has been a shift in 
the last decade towards the use of mice compared to rats (Fig. 4.2B). Sex is unevenly 
distributed amongst studies using rodents with 18% and 10% of mouse and rat studies 
respectively including females. This discrepancy is not present in the smaller number of 
porcine and primate studies. The relative proportion of male and females used in rodent 









Figure 4.2. Study characteristics. Total number of papers by year of publication (A), 










































































4.4.3 Behaviour assessed 
Following capsaicin administration, both the direct impact (spontaneous behaviour) and 
longer lasting sensitisation are assessed. 48% of studies assessed spontaneous behaviours 




Figure 4.3. Study characteristics. Total number of papers by behaviours assessed (A), 
and type of sensitivity assessed (B). 
 
 
4.4.3.1 Spontaneous pain 
Mice are the most common species used to identify spontaneous behaviours following 
capsaicin administration (68.7%) followed by rats (30.8%) and primates (0.5%) (Fig. 
4.3A). 32 different tests were used to quantify spontaneous behaviours (Table 4.2). Five 
techniques require subjective pain scale evaluation, the remaining quantify behaviours by 
number or duration of behaviours, or distance travelled. The most common behaviours 
assessed include movements of the hind paw including licking, flinching, biting, retracting, 
lifting, wiping and grooming (Table 4.2). Paw licking was the assessment first used in 
1992 and remains the most common spontaneous measure following capsaicin (Fig. 4.4A). 
Assessment of spontaneous behaviours for visceral pain (squashing, retracting, licking, 
stretching) originated in 2000 and remain in use and unchanged to the present day (Fig. 
4.4A). No new techniques for spontaneous behavioural assessment have been widely 
adopted in the last decade (Fig. 4.4A). Visceral pain behaviours hunching (2010) and 



































(2010) and flicking (2013) are the most recent to be introduced to the field; none of which 
have been published more than twice. It is clear that mice are favoured in studies assessing 
spontaneous behaviours, and that historical measures of spontaneous pain dominate 
modern capsaicin-pain research. 
 
4.4.3.2 Elicited pain 
Rats constitute the most utilized animal to study elicited pain following capsaicin (58.2%), 
followed by mice (29.7%), primates (10.9%) and pigs (1.2%). 20 different behavioural 
tests have been used to evaluate elicited pain responses (Table 4.2). Mechanical 
stimulation is used more often (61%) than thermal (hot or cold) (39%). Allodynia is more 
commonly reported after mechanical stimulation (75%) compared with hyperalgesia 
(25%). In contrast, hyperalgesia is more commonly reported following thermal challenge 
(77%) than allodynia (23%). Primates account for 84.2% of papers reporting thermal 
allodynia, and 84.2% of papers utilising primates investigate thermal allodynia via water 
immersion withdrawal latency. Commonly used techniques remain those first published 
before 2003 (Fig. 4.4B). The von Frey test was the first elicited pain test used following 
capsaicin (1995) and remains the most utilised, comprising 48.5% of all tests used and 
43.6% of tests used over the past decade. Multiple von Frey techniques have been used, 
‘best of’ techniques arose in the capsaicin literature in 1995 and account for 29.5% of von 
Frey analysis. Von Frey methods assessing mechanical threshold were introduced in 1997 
and account for 64.3% of von Frey analysis. ‘Up Down’ threshold methods are frequently 
used in this analysis, Chaplan et al. 1994 ‘up down’ method is frequently cited, a new 
method (SUDO) was introduced in 2014 and has been published three times in the 
capsaicin literature. Recently introduced von Frey analysis methods include withdrawal 
latency and pain score, which are found in 5 and 2 articles respectively. Air puff (2016), 
cold plate (2013), colorectal distension (2015), dynamic hot/cold plate (2009), thermal 
gradient response (2017), optogenetic stimulus positioning (2017), pinprick (2009), sticky 
tape (2013), mechanical threshold versus reward (2011), withdrawal latency to cold (2014) 
and grip force (2013) tests have been introduced in the last decade. These techniques have 
only been published once, with exception of the pinprick and mechanical stimulus versus 
reward tests (twice). Therefore, in contrast to spontaneous behaviours, rats are most often 
utilised to analyse elicited behaviours, and there is less reliance on rodents overall. 
However, like spontaneous behaviours, novel behavioural assessments have not been 
widely adopted and historical approaches remain the most commonly utilised. The 
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reviewer considers any threshold measurement as testing for allodynia, likewise the use of 
innocuous stimuli. As a result, allodynia was recorded for tests which met these criteria 
regardless of what the authors reported. Inconsistency of behavioural reporting is discussed 
































Table 4.2: Behavioural tests used to classify responses to capsaicin administration in 
preclinical literature. 
Spontaneous Behaviour Incidence (#) Elicited Test Incidence (#) 
Activity Score 4 Acetone 1 
Abdominal Pain Score 1 Air Puff 1 
Blinking 4 Cotton Bud 1 
Biting 20 Cold Plate 1 
Eyes Closed 2 Colorectal Distension 1 
Contractions 2 Dynamic Cold Plate 1 
Distance Travelled 2 Dynamic Hot plate 1 
Escape Behaviour 2 Hargreaves 37 
Eye Movement Score 2 Hot Plate 10 
Exploring 2 Movement (thermal stimuli) 1 
Flicking 1 Position (optogenetics) 1 
Flinching 28 Pin Prick 2 
Grooming 11 Sticky Tape 1 
Guarding 5 von Frey 99 
Hump-backed 1 With. Lat. (radiant heat) 5 
Hunching 1 With. Lat. (rad. heat vs rew.) 3 
Immobilisation 2 With. Lat. (mechanical) 2 
Lifting 13 With. Lat. (water immers.) 27 
Licking 146 With. Thre. (mechanical) 7 
Locomotion Score 3 With. Thre. (mech. vs rew.) 2 
Pain Scale 2   
Rubbing 10   
Retracting 17   
Rearing 1   
Rest 3   
Shaking 12   
Squinting 1   
Squashing 15   
Scratching 10   
With. Lat. 1   





Figure 4.4. First reported use of the most commonly (>10 studies) recorded 
spontaneous behaviours (A) and elicited pain tests (B) following capsaicin in 
preclinical literature.  
 
 
4.4.3.3 Reporting consistency 
Reporting of allodynia or hyperalgesia was inconsistent across the articles reviewed. 
Mechanical threshold showed the greatest reporting inconsistency. Mechanical allodynia is 
reported in 47% of threshold testing with 53% reporting mechanical hyperalgesia. 
Interestingly, of the papers that reported hyperalgesia, 3 also referred to allodynia in the 
introduction and/or concluding remarks. Similarly, there are 3 articles which refer to 
thermal hyperalgesia and allodynia when only using innocuous heat stimuli. Reporting of 
von Frey data also displayed inconsistency. Twenty-three articles using a ‘best of’ von 
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Frey approach report hyperalgesia and allodynia when applying a noxious or innocuous 
stimulus respectively (innocuous stimulus for von Frey is considered a fibre that elicits 
lower than one response per trial). In contrast, nine articles referred to hyperalgesia due to 
increased response rate when testing both innocuous and noxious filaments, with one 
example using only noxious stimuli while reporting allodynia. It should be noted the last 
occurrence of such an inconsistency was 2005. Four articles use the terms allodynia and 
hyperalgesia interchangeably throughout the text, one of which only referring to a single 
stimulus (cotton bud wiping). Ten articles, 9 of which were published post 2010, did not 
classify elicited responses as either allodynia or hyperalgesia, but rather referred to 
‘hypersensitivity’, ‘sensitivity’, ‘withdrawal threshold’ or ‘reactivity.’  
 
4.4.4 Capsaicin administration 
4.4.4.1 Administration route and location 
Route of administration is distinct for peripheral and visceral pain (Table 4.3). Intra-
colonic administration is the most common method of delivery for visceral pain 
assessment accounting for 86.7 and 87% of elicited and spontaneous observations 
respectively, primarily used in mouse models, with three incidences in rats. The intra-
colonic method is the only technique which is utilised to investigate referred (visceral) 
elicited pain using von Frey stimulation of the abdomen. One study utilised intraperitoneal 
administration to induce visceral pain, while two others inject the prostate to investigate 
prostate-specific pain, all of which observe spontaneous behaviours only, using unique 
pain scores (abdominal and eye movement scores respectively).  
 
Peripheral application is more varied. The dominant method is intraplantar, used in 185 
studies (Table 4.3). Intraplantar administration has been utilised in both rat and mouse 
models. Mice usage is dominant in spontaneous observations accounting for 77.2%, which 
differs from elicited studies, 31.8% of which use mice (Table 4.4). Additionally, hind paw 
administration is also achieved via subcutaneous (dorsal aspect) and topical routes, 
accounting for 32% and 15.8% of subcutaneous and topical studies respectively. 
Subcutaneous application is the second most prevalent peripheral administration route, 
accounting for 51 studies. In studies investigating elicited sensitivities, the tail is the most 
common location accounting for 59%, due to this being the dominant method of delivery 
in primates. Hind-paw and vibrissae pad are the most common subcutaneous 
administration sites for studies examining spontaneous behaviour. Topical application 
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accounts for 19 studies, all of which investigate elicited behaviours; with the cheek, tail 
and hind paw being used in multiple studies (Table 4.4). Intraocular administration is the 
only other method present in greater than 10 studies, used to observe spontaneous blinking 
almost exclusively in rats (one study in primates) (Table 4.3, 4). Despite a wide array of 
administration routes and sites it is evident that intraplantar and intra-colonic 
administration are overwhelmingly used for peripheral and visceral pain respectively.  
 
Table 4.3: Frequency of various capsaicin administration routes in experiments 









Intra-Articular (2) 1.3 - 
Intracranial (3) 0.7 1.1 
Intra-Dental (2) - 1.1 
Intradermal (7) 2.0 3.9 
Intramuscular (6) 4.0 1.1 
Intraocular (11) - 6.1 
Intra-Oral (1) - 0.6 
Intraplantar (185) 60.7 68.3 
Intra-Prostatic (2) - 1.1 
Intrathecal (6) 0.7 3.3 
Subcutaneous (51) 18.0 14.4 
Topical (19) 12.7 - 
Visceral Pain 
Intra-Colonic (22) 86.7 87.0 
Intraperitoneal (2) 13.3 4.3 




Table 4.4: Location of capsaicin administration by species and behaviour assessed. 
Three marks indicates species used > 50% of studies, two marks indicates species 





 Spontaneous Elicited 
Location Rat Mouse Mac. Pig Rat Mouse Mac. Pig 
Intra-Articular 
Ankle - - - - ✓✓✓ - - - 
Intra-Colonic ✓✓ ✓✓✓ - - ✓✓ ✓✓✓ - - 
Intracranial 
Cisterna Magna - - - - ✓✓✓ - - - 
I.VL. PAG - - - - ✓ - - - 
Intra-Dental 
Crown Cavity ✓✓✓ - - - - - - - 
Intradermal 
Calf ✓ - - - ✓ - - - 
Cheek - ✓✓✓ - - - - - - 
Neck - ✓ - - - - - - 
Tail - - - - - - - ✓ 
Vibrissae Pad ✓ - - - - - ✓ - 
Intramuscular  
Masseter ✓✓✓ - - - ✓✓✓ - - - 
Plantar - - - - ✓ - - - 
Intraocular  
Cornea ✓✓✓ - ✓ - - - - - 
Intra-Oral  
Tongue ✓ - - - - - - - 
Intraperitoneal ✓ - - - ✓ ✓ - - 
Intraplantar ✓✓ ✓✓✓ - - ✓✓✓ ✓✓ - - 
Intra-Prostatic ✓✓✓ - - - - - - - 
Intrathecal ✓✓ ✓✓ - - ✓ - - - 
Subcutaneous 
Cheek - ✓✓✓ - - ✓✓✓ - - - 
Flank - - - - - ✓ - - 
Hind Paw ✓✓ ✓✓✓ - - ✓✓✓ - - - 
Lip ✓ ✓ - - ✓ - - - 
Tail - - - - ✓✓ ✓ ✓✓✓ - 
Upper Limb - ✓ - - - - - - 
Vibrissae Pad ✓✓✓ ✓ - - ✓✓✓ ✓ - - 
Topical 
Cheek - - - - ✓✓✓ ✓ ✓ - 
Ear - - - - ✓ - - - 
Flank - - - - - - - ✓ 
Hind Paw - - - - ✓✓✓ ✓✓ ✓ - 
Tail - - - - - - ✓✓✓ - 





4.4.4.2 Dose and sensitivity 
Delivery method, species and associated anatomic location are an important contributor to 
dose. Administration to sensitive highly innervated tissues (e.g intrathecal, intraocular and 
intracranial) show lower doses most commonly in the nanogram range (Fig. 4.5). Larger 
tissues including viscera are able to tolerate larger doses, as seen in the case of intra-
colonic, intraperitoneal, intramuscular and topical capsaicin application with doses 
commonly between 100 - 200 micrograms (Fig. 4.5). Well established doses in the 
capsaicin literature include intraplantar doses in both mice (1.6 µg) and rats (10 µg) having 
been used in 51 and 28 studies respectively (Table 4.5). This dose is also often used in 
subcutaneous administration of the dorsal hind paw in mice. Similarly, in Macaques, 
subcutaneous tail administration dose is well established with 10 studies – 63% - using 10 
µg of capsaicin (Table 4.5). Reporting of topical doses is difficult to quantify as 
application of specific volumes is not often stated, instead ‘applied liberally’ is commonly 
used. Duration of reporting following capsaicin administration is highly variable. Well 
established timelines are intra-colonic capsaicin in mice and subcutaneous capsaicin in 



































































Table 4.5: Range of doses and median observation/testing times reported in each 
species. 
Administration 
(incidence) Dose (µg) - (incidence) 
Median Observation/Test 
Duration (min) – 
(incidence) 
 Minimum Median Maximum Spontaneous Elicited 
Rat 
Intra-Articular (2) 100 (2) 100 (2) 100 (2) N/A 20220 (0) 
Intracranial (6) 3.2 E-4 (1) 0.032 (1) 1.8 (1) 6.5 (0) 60 (1) 
Intra-Colonic (3) 200 (3) 200 (3) 200 (3) 20 (2) 50 (1) 
Intra-Dental (5) 3 (1) 100 (2) 150 (1) 60 (2) N/A 
Intradermal (1) 25 (1) 25 (1) 25 (1) 15 (1) 60 (1) 
Intramuscular (8) 1 (1) 100 (5) 100 (5) 3.5 (0) 90 (3) 
Intraocular (9) 0.001 (2) 1 (4) 4 (2) 5 (4) N/A 
Intra-Oral (6) 0.001 (1) 0.55 (0) 100 (1) 10 (1) N/A 
Intraperitoneal (2) 750 (1) 875 (0) 1000 (1) 30 (1) 60 (1) 
Intraplantar (87) 0.3 (1) 10 (28) 1500 (1) 11 (0) 120 (12) 
Intra-Prostatic (4) 0.3 (1) 27.5 (0) 305 (1) 30 (2) N/A 
Intrathecal (9) 0.003 (1) 0.3 (1) 6 (1) 5 (1) N/A 
Subcutaneous (37) 0.1 (1) 3 (5) 500 (2) 20 (2) 60 (3) 
Topical (3) 1.2 (1) 184 (1) 305 (1) N/A 30 (2) 
Mouse 
Intra-Colonic (24) 7.5 (1) 50 (11) 500 (3) 20 (13) 20 (6) 
Intradermal (10) 0.15 (1) 7.5 (0) 40 (1) 30 (2) 120 (1) 
Intraperitoneal (2) 25 (1) 27.5 (0) 30 (1) N/A 180 (1) 
Intraplantar (124) 2 E-6 (1) 1.6 (52) 300 (1) 5 (66) 62.5 (0) 
Intrathecal (5) 0.008 (1) 0.03 (1) 0.06 (2) 10 (1) N/A 
Subcutaneous (27) 1.56 E-3 (1) 1.6 (11) 50 (2) 5 (11) 105 (0) 
Macaque 
Intraocular (1) 1 (1) 1 (1) 1 (1) N/A N/A 
Subcutaneous (16) 10 (2) 100 (10) 320 (1) N/A 15 (6) 
Topical (7) 46 (1) 366 (4) 366 (4) N/A 75 (0) 
Pig 
Intradermal (1) 30 (1) 30 (1) 30 (1) N/A 240 (1) 
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There is no strong correlation in the literature between increasing dose and duration of 
elicited sensitivity. Groups containing greater than 10 studies were analysed for dose - 
duration correlations (Fig. 4.6). Mechanical stimulation in mice and rats and thermal 
stimulation in rats following intraplantar capsaicin showed a positive correlation (0.21 (n = 
29), 0.10 (n = 58) and 0.21 (n = 29) respectively) (Fig. 4.6). R squared values indicate a 
poor fit in each case, 0.05, 0.01 and 0.18 respectively (Fig. 4.6). A similar pattern is 
observed in subcutaneous tail administration in rats (n = 13) and Macaques (n = 14) with a 
positive slope of 0.20 and 0.47 respectively with R squared values of 0.10 and 0.40 
respectively. Mice receiving intra-colonic capsaicin (n = 15) produced a weak correlation 
(R squared = 0.03) and negative slope -0.29 (Fig. 4.6). It is evident that dramatic increases 
in dose have little effect on duration of reported sensitivity. It should be noted that duration 
of sensitivity is often dependent on historically chosen timeframes and behavioural 
experiments are rarely carried out until complete reversal of hypersensitivity. For this 
reason, it is difficult to make concrete conclusions regarding a relationship between dose 
and duration of hypersensitivity and compare doses and responses across species. It is 
evident that researchers are using doses above those necessary to produce hypersensitivity 





























Figure 6. Correlation between dose 
and reported sensitivity due to elicited 
stimulation following capsaicin. 
Correlations included for conditions 
(route of administration + species + 
stimulus type) reported in ³ 10 studies. 
 
I.pl.: Rat - Mechanical
I.pl.:Mouse - Thermal
I.pl.: Mouse - Mechanical
I.pl.: Rat - Thermal
Top.: Rat - Thermal
S.c.: Rat - Mechanical
S.c.: Rat - Thermal
Top.: Macaque - Thermal
I.m.: Rat - Mechanical
I.m.: Rat - Thermal
Top.: Rat - Mechanical
Top.: Macaque - MechanicalI.d.: Rat Mechanical
S.c.: Mouse - Mechanical
S.c.: Macaque - Thermal
I.col.: Mouse - Mechanical
I.col.: Rat - Mechanical
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4.4.5 Sex differences 
For the past two decades between 85 – 90 % of rodent studies published each year used 
male subjects only (Fig. 4.2C). Of all species 77% used male only subjects, 7% used 
female only and 12% used both; 4% of papers did not report sex. Of studies that 
investigated both sexes, 67% did not report sex independent results, 13% reported no sex 
specific effects on capsaicin-induced behaviours and 5% reported an effect of sex. 
 
Of studies which analysed both sexes independently, six studies reported no sex difference 
including two using spontaneous and 6 using elicited (4 mechanical, 4 thermal) responses 
(Carey et al., 2016; Entrena et al., 2009; Hu et al., 2010; Lavand'homme et al., 1999; 
Neubert et al., 2008; Slivicki et al., 2016; White et al., 2014). Two studies show sex 
differences in capsaicin-induced sensitivities using both mechanical and thermal 
stimulation (Barrett et al., 2003; Nasir et al., 2016). Using capsaicin as a pain model to 
examine opioid effects, three studies report greater antinociceptive effects of mixed-
opioids following capsaicin in males (Lomas et al., 2007; Lomas et al., 2008; Saloman et 
al., 2011). Despite the majority of papers reporting no sex effect on capsaicin-induced 
nociception in preclinical models, mixed results in a small sample size suggest more 
investigation is required. This outcome is not aided by low levels of female inclusion, and 
poor reporting of sex independent results in studies which include both sexes.  
 
4.4.6 Capsaicin purpose 
The majority of capsaicin use in preclinical literature aimed to investigate TRPV1 specific 
molecular pain mechanisms (49%). A high proportion of studies (39%) used capsaicin as a 
pain model for screening analgesic compounds. Development of new pain models using 
capsaicin accounted for 9% of all studies. Fewer studies were conducted to understand 
drug/treatment effect mechanism (2%) and discovery of novel TRPV1 antagonists (0.5%). 
One paper was identified as investigating a novel treatment mechanism - involving TRPV1 




Since the discovery of its receptor, capsaicin has been consistently used as a direct pain 
activating agent eliciting an observable behavioural response (Caterina et al., 1997). 
Behavioural responses highlight changes influenced by multiple body systems, adding 
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relevance to in vivo and in vitro cellular and molecular results. Using capsaicin as a 
nociceptive stimulus is most commonly utilised to explore basic physiological questions, 
providing valuable evidence for the role of TRPV1 in pain signalling. Another significant 
utility for capsaicin is as a screening tool for novel therapeutic agents. The relevance of 
capsaicin as a model for drug screening requires further discussion, especially considering 
aforementioned translatability limitations of preclinical pain research. 
 
4.5.1 Species assessed 
Rodent models are overwhelmingly used in preclinical pro-nociceptive capsaicin studies 
involving animal behaviour (91%), in studies investigating spontaneous behaviours this 
rises to 99% (1 primate study being the exception). Considering the lack of successful 
clinical translation, and 40% of papers were investigating novel therapeutic options, it may 
be relevant to consider alternative models. Although infrequently, non-human primates and 
pigs offer ready tested options for thermal and mechanical elicited sensitivities respectively 
following capsaicin (Asad et al., 2016; Di Giminiani et al., 2014; Kupers et al., 1997). 
Larger animal species are part of the wider pain space, as well as pigs and non-human 
primates, dogs have been used to study acute (synovitis) and chronic inflammatory pain 
therapies (natural arthritis) (Brown et al., 2008; Hamilton et al., 2005; Henze et al., 2010). 
A sheep neuropathic pain model has also been developed, evidence the field is actively 
seeking to find potentially more clinically relevant models (Wilkes et al., 2012). Rodents 
absolutely have their place within pain research, offering excellent opportunities for 
mechanistic discoveries. However, novel alternatives should be investigated if screening 
for clinically relevant compounds is a study aim. 
 
4.5.2 Pain type assessed 
Two response types are reported following capsaicin; non-elicited (spontaneous) and 
elicited; the latter comprising allodynia and hyperalgesia from either mechanical or 
thermal stimuli. 64% of studies reported spontaneous data, while 52% reported sensitivity 
to elicited stimuli. In chronic pain; clinical studies report higher prevalence and intensity of 
non-elicited compared to elicited symptoms (Attal et al., 2008; Backonja et al., 2004). The 
prevalence of spontaneous behaviours in capsaicin literature is promising given what is 
being reported in the wider pain community. Between 2000 and 2004 only 10% of animal 
studies published in the journal ‘Pain’ report spontaneous behaviours, thus overlooking 
important mechanisms relevant to clinical pain (Mogil, 2009; Mogil et al., 2004). Further 
 
 95 
to simply reporting on non-evoked behaviours, we must consider which are an appropriate 
representation of pain that may lead to improved clinical outcomes.  
 
In the capsaicin literature 32 different spontaneous behavioural observations were reported. 
Licking was by far the most commonly reported, accounting for 43% of all tests, well 
above the next behaviour, flinching (8%) (Table 4.2). Unfortunately, despite the lack of 
clinical translation in pain literature in general, these historical methods remain the most 
commonly utilised behaviours to judge “pain” in capsaicin models (Fig. 4.4). Discovering 
and introducing different behavioural cues as reliable indicators of spontaneous pain into 
the capsaicin model are needed to improve its relevance in anti-nociceptive drug discovery. 
Facial grimace scores have more recently been used in models with similar duration 
(formalin test, intraplantar mustard oil) (Langford et al., 2010). This type of approach, 
observing responses not directly directed towards the application/injury site is rare in 
capsaicin literature. Two studies using a capsaicin-induced non-bacterial prostatitis model 
have used similar eye movement scores (Chuang et al., 2008; Chuang et al., 2007). The 
capsaicin-induced prostatitis model also reports on locomotion, another potential pain 
score based on automated analysis. As well as locomotion (type and distance) automated 
behavioural analysis can pick up on grooming and gustation behaviours that change based 
on pain state. Locomotion (activity) scores have been used in a single drug discovery 
model; reporting that novel compound AMG0347 decreases activity in the first 30 seconds 
following intrathecal capsaicin (Wu et al., 2008). This result helped confirm the 
compounds activity at TRPV1 but AMG0347 has not yet been used in further pain studies. 
Activity scores (movement, distance and rest time) have also been used in rat intraplantar 
capsaicin models exploring central pathways as well as central and peripheral kinase 
effects, however not in drug discovery studies (Fang et al., 2002; Palecek et al., 2002; Sun 
et al., 2007). Other non-evoked behaviours used in pain literature include burrowing, 
weight bearing and gait analysis, which offer potential alternatives for investigation in 
preclinical capsaicin models (Deuis et al., 2017).  
 
Evoked responses in the capsaicin literature heavily lean on static mechanical allodynia 
and hyperalgesia following von Frey stimulation (49%). However, evoked 
hypersensitivities reported by pain sufferers occurs via both static and dynamic mechanical 
stimuli (i.e. clothes brushing against the skin) (Hansson, 2003; Ochoa et al., 1993). The 
dynamic cotton bud test has been used twice in the capsaicin literature, testing hind paw 
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responses following intraplantar capsaicin to examine the roles of tachykinin receptors 
(NK1) and cation-chloride co-transporters (NKCC1) (Laird et al., 2004; Laird et al., 
2001b). Air puffs have also been utilised in a single model of orofacial pain (intradermal 
vibrissae application) to study the role of protein kinase C gamma (PKCg) expressing 
interneurons in orofacial sensitivity (Peirs et al., 2016). Therefore, despite a much higher 
clinical prevalence (20-40%) only 2% of studies utilising capsaicin tested a dynamic 
stimulus (Hansson, 2003). Thermal sensitivities are tested in 39% of evoked behavioural 
studies following capsaicin (and 47% of drug screening studies using evoked responses). 
Although the symptom does present in clinical trials, sensitivity to heat is not reported as a 
common problem in daily life for neuropathic pain patients (Hansson, 2003; Maier et al., 
2010; Staud et al., 2012). Interestingly, three assays tested cold hyperalgesia following 
capsaicin with mixed results. Dynamic cold plate following topical application of the hind 
paw revealed cold sensitivity based on number of jumps (Yalcin et al., 2009). However, 
standard cold plate tests revealed no capsaicin effect and cold probes show an increase in 
thresholds (Honda et al., 2014; Roberson et al., 2013).  
 
Very few novel techniques have been introduced into the capsaicin animal model 
literature. Three studies introduced operant reward for measuring evoked responses, all of 
which were attempting to develop new models (Neubert et al., 2008; Neubert et al., 2006; 
Nolan et al., 2011; Rohrs et al., 2015). Movement of mice over a thermal gradient surface 
is a unique technique developed to study vasomotor symptoms using capsaicin, with 
capsaicin causing the animals to spend longer at cooler temperature compared to controls 
(Krull et al., 2017). It should also be noted that sensory loss, hypoalgesia, paraesthesia and 
dysesthesias are also symptoms of clinical pain that can be assessed using evoked 
behavioural tests and are not reported here (Hansson, 2003; Maier et al., 2010). Although 
these are rarely tested for in pain literature, they would have been screened out of our 
search with articles using capsaicin for desensitisation and/or analgesia (Mogil, 2009). 
Interestingly, operant and condition-placed preference behavioural analysis produces 
different results when compared to historically utilised evoked behavioural testing. This 
preclinical data correlates with clinical behavioural observations, suggesting these novel 




Capsaicin is overwhelmingly used to elicit peripheral pain, with only 9.7% of studies 
exploring mechanisms of visceral pain. TRPV1 is implicated in numerous visceral pain 
models and importantly is implicated in clinical irritable bowel syndrome and functional 
dyspepsia cases (Akbar et al., 2008; Du et al., 2019; Hammer et al., 2008). The majority of 
studies included here explored visceral pain mechanisms and drug mechanisms associated 
with visceral pain, only 12% used a capsaicin model to assess novel drugs. Interestingly 
92% of studies targeting visceral sites measure non-evoked behaviours involving 
abdominal movements, 100% of intra-colonic capsaicin models assess abdominal licking, 
stretching, squashing and retracting. A significant proportion (54%) of these studies report 
both evoked (colorectal distension, referred mechanical hyperalgesia) and non-evoked 
behaviours, while less than 1% report only evoked behaviours; in complete contrast to the 
peripheral capsaicin studies discussed above. 
 
Lastly, it is prudent to note the inconsistencies in use of pain specific nomenclature within 
the studies analysed. In an attempt to make the animal models seem relevant, clinical 
symptoms of allodynia and hyperalgesia are used to describe behaviours in animal pain 
models. However, due to the inability of animals to self- report, it is difficult to define a 
painful versus non-painful stimulus, leading to researchers describing either allodynia or 
hyperalgesia employing the same behavioural methodology. We observed a growing 
number of publications using the terms; ‘hypersensitivity’, ‘sensitivity’ and ‘reactivity’ 
rather than allodynia and hyperalgesia. In either case, confusion arises from the use of 
multiple terms to describe the same behavioural phenomenon, and the next step is to agree 
upon a universally accepted nomenclature for these behaviours. The author suggests 
hypersensitivity is an appropriate term which would suit the studies using elicited 
behaviours in this review. While the terms allodynia and hyperalgesia absolutely have a 
place in clinical studies, it may be appropriate to find alternatives in preclinical literature to 
eliminate confusion caused by inconsistent reporting. 
 
4.5.3 Dose and capsaicin administration 
Both species and route of administration influence the dose used. Higher doses are 
typically used in larger animals to produce comparable sensitivities to those observed in 
smaller animals. Within the same species, higher doses are used for deeper administration 
(e.g. visceral, intramuscular) compared to superficial application, such as topical or 
intraplantar. An ethical consideration arising from this data is the use of high doses of 
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capsaicin to elicit pain. This data reveals no strong correlation between increasing dose and 
observed length of sensitivity (Fig. 4.6). The strongest correlations were following 
subcutaneous tail administration in primates (R2 = 0.47). In this instance doses 3.5 - 10 
times greater were used to elicit sensitivity lasting only an extra 15 min (Fig. 4.6). This is 
observed in many routes of application and it may be useful to consider when making 
decisions regarding refinement of methods. There were notable exceptions, two studies 
using intraplantar capsaicin in mice reported sensitivity at 24 and 72 h post administration, 
well beyond anything else for the comparable species/administration combination (Chen et 
al., 2009; La et al., 2017). 
 
Larger doses of capsaicin are used to cause denervation and analgesia in adult animal 
studies. A single subcutaneous application can be between 10 and 1000 times greater than 
the median dose observed here, with multiple applications (Miranda et al., 2015; Saade et 
al., 2008). Topical application for desensitisation delivers comparable low doses to studies 
examined here, however multiple applications over multiple days are administered 
(Yamaoka et al., 2007). Likewise, intrathecal doses are comparable but administered for 
extended time periods, up to 24 h (Kamei et al., 2000; Mousseau et al., 1994). 
 
4.5.4 Sex bias 
A greater proportion of chronic pain patients are females and recent evidence suggests 
there may be mechanistic difference in the way sexes process pain (Fillingim et al., 2009; 
Mogil, 2012). Despite this, male subjects remain overwhelmingly the most utilised sex in 
preclinical pain research (Mogil et al., 2005). Capsaicin behavioural studies analysed here 
are typical of what is found in the wider pain community, with 80% of studies using male 
only subjects (Mogil et al., 2005). Of studies which did use both sexes, a large proportion 
(69%) did not report sex independent results or excluded females from behavioural 
experiments. Three papers stated sexes would be evenly distributed and analysed together, 
presumably other studies did the same. Of the small number of studies remaining which 
treated males and females separately there is no consensus on the sex effect of capsaicin-
induced behaviours, which warrants further investigation and greater inclusion of female 
subjects in future studies. Similar contradictory evidence is also found in the clinical 
capsaicin literature (Frot et al., 2004; Jensen et al., 2006). Further emphasising the need for 
the use of both sexes was the increased antinociceptive ability of mixed-opioid analgesics 
in males, observed in multiple studies (Lomas et al., 2007; Lomas et al., 2008; Saloman et 
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al., 2011). The effect of sex on capsaicin sensitivity requires further clarification, this can 
be improved initially by researchers reporting sex independent results when both sexes are 
used. Further, attitudes need to shift in regards to variability imparted by oestrous, and 
researchers should become more open to including female subjects in their studies (Mogil 
et al., 2005). 
 
4.5.5 Limitations 
One of the main drawbacks of using a capsaicin model is the increasingly complicated 
nature of central sensitisation observed in chronic pain. The cross talk between immune 
modulating elements of the CNS (e.g. glia, infiltrating T-cells) and neurons, known as 
neuroimmune signalling, cannot be replicated in models which only use capsaicin (Grace 
et al., 2014). Despite producing comparable behavioural outcomes, capsaicin’s relevance 
to chronic pain is potentially a little superficial. Further, the time frame suggests it does not 
cause prolonged changes from periphery to higher brain regions, again making the model 
different to the theorised mechanisms of chronic pain in humans (Vierck et al., 2008). 
Lastly, blinding of animal experiments is very difficult due to obvious flare response 
elicited by capsaicin, especially for commonly used subcutaneous and intraplantar 
administration. This is perhaps another reason to move away from user evoked behavioural 




Currently, use of animal behaviour is crucial to pain research. It enables researchers to 
answer basic physiological questions, validate model relevance and preclinical molecular 
observations, and assess therapeutic options. No doubt behavioural observation following 
capsaicin administration will continue to be used for these purposes. This systematic 
review will aid in advising decisions on capsaicin dosing, behaviour assessed, sex selection 
and to improve and eliminate inaccurate reporting. These points will improve animal 








Following a review of capsaicin literature, we were ready to attempt a back-translation of 
the clinical endotoxin-capsaicin model. The first step is in line with our original aim, to 
replicate the conditions of the preclinical model. However, due to the results of chapter 3, 
and previous work in primary cells, we also plan to investigate a more directed LPS 
approach. This enables investigation into the relevance of short LPS activation influencing 
TRPV1 activity in vivo. Therefore, the rodent endotoxin-capsaicin model will be 
investigated in terms of both a systematic and localised LPS administration at previously 
examined short (< 20 min) and longer immune activating incubation periods.  
 
 
Chapter 5. A peripherally administrated primed LPS response potentiates capsaicin-
induced mechanical hypersensitivity in BALB/c mice. 
 
5.1 Abstract 
Interactions between immune and neural elements of the nervous system are important 
contributing mechanisms to chronic pain, which represents a significant global disease 
burden. Recently, a functional interaction between innate immune receptor, toll-like 
receptor 4 (TLR4) and neuronal ion channel, transient receptor potential cation channel 
subfamily V member 1 (TRPV1) has been discovered both in vitro and in clinical models. 
The clinical model reports that systematic endotoxin potentiates the effect of intradermal 
TRPV1 agonist, capsaicin. Potentiation of flare responses as well as mechanical allodynia 
and hyperalgesia are observed. Our aim is back-translate this clinical model into a rodent 
model and investigate the molecular and cellular mechanisms behind the response. We 
generated an intraplantar capsaicin pain model that allowed assessment of mechanical 
hypersensitivity to 90 min. Systemic (1 µg, 1 mg/kg) and local (100 ng) lipopolysaccharide 
(LPS) administration did not potentiate mechanical hypersensitivity at multiple time 
points. Interestingly we observed potentiation of capsaicin responses using two separate 
LPS doses administered into the hind-paw; an effect blocked by TLR4 antagonist (+)-
naloxone. However, there appeared to be two populations of responders in this study, 
animals who showed LPS-induced potentiation and animals who showed no potentiation. 
Therefore, we were unable to replicate the clinical endotoxin-capsaicin model but did 
observe a population in which a locally primed endotoxin response results in potentiated 




Effective chronic pain treatment remains elusive, with the condition affecting quality of 
life for billions worldwide (Goldberg et al., 2011; Jacobs, 2005). Current options offer 
poor efficacy and negative side effects including tolerance, potential addiction, 
constipation and drowsiness, impacting on the ability to work, care and drive; necessitating 
the search for novel targets (Jacobs, 2005; Nightingale, 2012; Rogers et al., 2013; Whitten 
et al., 2005). Chronic pain refers to pain that extends past the resolution of injury, typically 
longer than three months, and may result from numerous common insults including nerve 
injury, cancer, chemotherapy, diabetes, surgery and infection (Milligan et al., 2009; 
Nightingale, 2012).  
 
Enhanced neuronal excitability is the cause of several symptoms of chronic pain including 
hypersensitivity to a range of noxious (hyperalgesia) and non-noxious (allodynia) stimuli, 
as well as spontaneous pain (Backonja et al., 2004; Ji et al., 2003; Milligan et al., 2009). 
However, targeting neuronal excitability is the aim of currently underperforming 
pharmaceutical options including opioids, antidepressants and anticonvulsants (Whitten et 
al., 2005). In light of this evidence, the search for novel target mechanisms to treat chronic 
pain has switched away from its neuro-centric stance.  
 
Understanding that both neural and non-neural elements communicate to create an 
environment of enhanced excitability has been an important advance in chronic pain 
science (Grace et al., 2014; Woolf et al., 2000). The peripheral and central nervous systems 
(PNS/CNS) contain multiple interacting cell-types including neurons, glia (astrocytes, 
microglia, oligodendrocytes, satellite glia) and peripheral immune cells. Their interactions 
are collectively referred to as neuroimmune signalling, important in altering neuronal 
excitability in both the PNS and CNS; processes known as peripheral and central 
sensitisation respectively (Grace et al., 2014; Woolf et al., 2000). T-cell knockout, 
blocking glial signalling cascades (e.g. sphingosine-1-phosphate receptor (S1PR1), toll-
like receptors (TLRs), ERK pathway, Src kinase activity), and disrupting 
cytokine/chemokine binding (e.g. interleukin-1 receptor antagonists (IL-1Ra), colony 
stimulating factor 1 (CSF-1) have all attenuated generation or maintenance of pain 
sensitivity in animal models (Guan et al., 2016; Katsura et al., 2006a; Kobayashi et al., 
2015; Lacagnina et al., 2017; Milligan et al., 2001b; Milligan et al., 2003). Targeting 
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neuroimmune interaction has the potential to revolutionise therapeutic outcomes for 
chronic pain.  
 
Despite the importance of neuroimmune mechanisms observed in preclinical studies, there 
has been little clinical impact. Clinical trials which attempt to alter neuroimmune 
communication have not produced promising results. (Huggins et al., 2012; Landry et al., 
2012). However, evidence shows pain sensitivity is altered by disease and inflammatory 
stimuli in humans (Hutchinson et al., 2013; Shenker et al., 2008; Sumracki et al., 2012; 
Wegner et al., 2014). Again, this suggests a lack of relevant mechanistic understanding; if 
neuroimmune targeting therapies are to be introduced, relevant clinical mechanisms must 
be understood. Development of quality clinical and preclinical models of pain which 
encompass both neuro- and immune- molecular mechanisms and aspects of somatosensory 
processing would be an important step forward. 
 
The capsaicin pain model is currently utilised in both the clinical and preclinical literature 
(Kinnman et al., 1995). Capsaicin is the pungent component in chilli peppers and agonist 
of ion-channel, transient receptor potential cation channel subfamily V member 1 (TRPV1) 
(Caterina et al., 1997; Szallasi et al., 2007). It is commonly used due to its ability to 
directly activate pain signalling neurons (nociceptors) and produce symptoms of central 
sensitisation including allodynia, hyperalgesia and spontaneous pain (Aykanat et al., 2012; 
Simone et al., 1989; Tominaga et al., 1998; Wong et al., 2014). Capsaicin also causes 
sensitivity in surrounding (secondary) tissues following intradermal injection, indicative of 
threshold changes within the CNS, and further evidence of central sensitisation (Willis, 
2002). For these reasons the capsaicin model has been likened to neuropathic pain models, 
despite solely targeting neural pain mechanisms (Joshi et al., 2006). 
 
Pain produced by capsaicin is potentiated in individuals diagnosed with unilateral sciatica 
and rheumatoid arthritis, suggesting TRPV1 function is altered in the chronic pain 
environment (Shenker et al., 2008; Sumracki et al., 2012). Evidence of a relationship 
between the immune system and TRPV1 exists and potentially explains these clinical 
results. Activating the innate immune system with gram-negative cell wall component 
lipopolysaccharide (LPS), potentiates TRPV1 response in a the rat vagus nerve and dorsal 
root ganglia neurons (Diogenes et al., 2011; Ferraz et al., 2011; Hua et al., 1996). Along 
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with the well-established capsaicin pain model, these results open the possibility of a 
model involving direct manipulation of both immune and neural elements of pain. 
 
The clinical relevance of this endotoxin/TRPV1 interaction was demonstrated by 
Hutchinson et al. (2013). A low dose of systemic LPS potentiated capsaicin-induced 
allodynia, hyperalgesia and flare when administered to the forearm (Hutchinson et al., 
2013). Further, the potentiation occurred at 3.5 hrs post LPS administration and not at 
earlier time points, correlating with maximum serum IL-6 and suggesting an immune-
induced sensitisation event. This endotoxin-capsaicin model is important evidence that 
neuroimmune interactions are relevant in clinical pain and offer the exciting potential of a 
unified clinical and preclinical model in which to study neuroimmune interaction. 
 
It is not possible for further cellular and mechanistic investigation of the clinical 
endotoxin-capsaicin model, leaving a myriad of unanswered mechanistic questions. For 
example, it is not known if LPS is acting centrally by effecting glial activity, or on 
peripheral afferent fibres by direct activation or peripheral immune activity. LPS is an 
agonist of innate immune receptor toll-like receptor 4 (TLR4); with the potential to 
activate both peripheral nociceptors and glia in the CNS (Borges et al., 2012; Buchanan et 
al., 2010; Lin et al., 2015; Wadachi et al., 2006). Questions also surround the nature of a 
TLR4/TRPV1 relationship, if this potentiation is resulting from direct interaction, or 
indirect via TLR4 induced transcription outcomes as the serum IL-6 correlation suggests. 
Translating the clinical endotoxin-capsaicin model into a preclinical model will allow 
further elucidation of molecular and cellular mechanisms. 
 
“Back-translation” of clinical results into preclinical animal models has been successfully 
demonstrated for numerous pain therapeutic agents including; non-steroidal anti-
inflammatories (NSAIDs), opioids and those approved for chronic neuropathic pain 
(anticonvulsants, antidepressants and anaesthetics) (Berge, 2011; Whiteside et al., 2008). 
However, pharmacological comparison of responses in humans and animal models reveal 
differences in sensitivity to these compounds, hypothesised as differences in tissue 
penetration, metabolism or binding characteristics (Whiteside et al., 2008). This gives hope 
of potential back translation of the endotoxin-capsaicin model. However, particular care 





This study aims to ‘back-translate’ the clinical endotoxin-capsaicin model into a preclinical 
model, and to study the potentiation mechanism at a molecular and cellular level. We 
hypothesise that in BALB/c mice we can recreate the LPS potentiated capsaicin-induced 
hypersensitivity. In order to achieve this, we will look to replicate as many aspects of the 
clinical model as possible, including sex, relative doses, relative timings and behavioural 
outcomes in a mouse intraplantar capsaicin model. If successful, this raises the exciting 
possibility of a unified clinical and preclinical model of neuroimmune potentiated pain. A 
novel situation, with the potential to reveal key similarities and differences between the 
models we use to screen therapeutic options, and the clinical system we aim to treat. 
 
 
5.3 Methods  
 
5.3.1 Animals 
Male adult BALB/c mice (6-12 weeks) (n = 6 - 10 per group) obtained from Laboratory 
Animal Services of the University of Adelaide (Adelaide, SA) were used in these 
experiments. Despite no previous usage in capsaicin-induced preclinical pain models, 
BALB/c mice were used due the characteristics of their immune response. Given the LPS 
challenge that accompanies capsaicin in this model, it was decided the Th2 dominant 
BALB/c strain would provide a more balanced immune response compared to the Th1 
dominant, commonly used C57/Bl6 strain (Watanabe et al., 2004). All mice were group-
housed in the Medical School Animal Facility of the University of Adelaide. Mice were 
allowed free access to food and water in a temperature-controlled environment (23 ± 3°C) 
maintained on a 12:12 h light/dark cycle (lights on at 0700). Animals were left to 
acclimatise to the facility for at least one week before handling began. One week of 
handling and acclimatisation to the experimental set-up was carried out prior to use. All 
experiments reported in this study were approved by the University of Adelaide Animal 
Ethics Committee (Ethics approval number M-227-13B) and complied with the Australian 
code for the care and use of animals for scientific purposes. 
 
5.3.2 Materials 
Capsaicin and (2-Hydroxypropyl)-β-cyclodextrin were purchased from Sigma-Aldrich 
(Castle Hill, NSW). (+)-Naltrexone was kindly provided by Dr Kenner Rice (Chemical 
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Biological Research Branch, National Institute on Drug Abuse and National Institute on 
Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD). Sterile 
saline (0.9%) was purchased from Baxter Australia (Old Toongabbie, NSW, Australia). 
Von Frey filaments were purchased from North Coast Medical Inc. (Gilroy, California). 
 
(2-Hydroxypropyl)-β-cyclodextrin was diluted in 0.9% sterile saline to make a 38% 
solution. A stock capsaicin solution of 5 mg/mL was created using 38% (2-
Hydroxypropyl)-β-cyclodextrin, protected from light, and stored at 4°C for a maximum of 
1 month. On the morning of use, this was further diluted in (2-Hydroxypropyl)-β-
cyclodextrin to the experimental concentration. (+)-Naltrexone was made up to the desired 
concentration in 0.9% sterile saline the week of experiment, and kept at 4°C. 
 
5.3.3 Intraplantar drug (i.pl.) administration 
Intraplantar administration was chosen for this model as the most commonly utilised 
technique in capsaicin literature which allows assessment of secondary mechanical 
hypersensitivity, while resembling the targeted peripheral administration of the clinical 
model (intradermal). All capsaicin and β-cyclodextrin administrations were conducted 
using the following technique. All injections were performed with a primed 25 μL 
Hamilton micro-syringe and 30G needle. To prime the micro-syringe, the plunger was 
removed, and 0.9% saline was injected into the barrel of the syringe until no air remained 
inside, the plunger was then reinserted. A 30G needle was attached to a 1 mL syringe 
containing 0.9% saline and saline was dispensed, filling the needle tip. The 30G needle tip 
was then carefully removed, filled with 0.9% saline and attached to the full micro-syringe; 
leaving no air inside either the micro-syringe or needle tip. The plunger was then pushed 
all the way down, and pulled up to the 5 μL mark, creating a small air bubble. The desired 
volume of solution could then be withdrawn and dispensed. Animals were gently 
restrained in a thin towel and 5 μL of the solution was injected at the distal end of the 






Figure 5.1: Intraplantar (i.pl.) drug administration. (X) represents the site of needle 




5.3.4 Behavioural testing 
A von Frey test modified from the Nicotra et al. (2014) method was performed on all 
animals. Immediately following all i.pl. drug administrations, animals were placed on a 
wire mesh shelf that allowed access to the plantar surface of the hindpaw and covered with 
an opaque cup. Von Frey filaments were touched to the proximal end of the plantar surface 
of the hindpaw to allow assessment of secondary hypersensitivity, as elicited in the clinical 
model (Fig. 1). Force was then applied until the filament bent and held for two seconds 
before being slowly removed for one second and reapplied. Animals were tested at 7, 45 
and 90 min following i.pl. capsaicin administration, timings which would allow resolution 
of hypersensitivity based on review of preclinical capsaicin literature. All animals received 







between application of a different filament strength. Baseline testing was conducted 24 h 
prior to i.pl. capsaicin administration for all experiments. 
 
5.3.5 Systemic endotoxin-capsaicin model  
BALB/c mice were administered LPS (1 μg or 1 mg/kg) or the equivalent volume of saline 
by intraperitoneal (i.p.) injection. Capsaicin (0.8 μg/5 μL i.pl.) was administered 4 h 
following LPS. Animals were tested with filaments 1.65 (0.008 g), 2.44 (0.04 g) and 3.22 
(0.16 g). Capsaicin dose for this and all subsequent experiments was based on data from 
pilot studies guided by review of literature utilising capsaicin to produce mechanical 
hypersensitivity. 
 
5.3.6 Local administration endotoxin-capsaicin model  
BALB/c mice were administered LPS (100 ng/5 μL i.pl.) (Calil et al., 2014) or equivalent 
volume saline. Capsaicin (0.8 μg/5 μL i.pl.) was administered 15 min or 4 h following 
LPS. Animals were tested with filaments 1.65 (0.008 g), 2.44 (0.04 g), 3.22 (0.16 g) and 
3.84 (0.6g).  
 
For experiments involving a primed LPS response, the first dose of LPS (100 ng/5 μL i.pl.) 
or saline was administered 7 days prior to the second dose, all other doses and 
administration timings remained the same. (+)-Naltrexone (60 mg/kg i.pl.) was 
administered 30 min prior to the first dose of LPS (Lewis et al., 2012).  
 
5.3.7 Analysis 
Data was analysed using GraphPad Prism v7.0a (GraphPad software, Inc. San Diego, CA). 
Two-way ANOVA with repeated measures and Tukey’s multiple comparison test was used 
to compare treatment effect over time from all behavioural experiments. Sidak’s multiple 
comparisons test was used to compare treatment groups at individual time points. P-values 










5.4.1 The human endotoxin-capsaicin model does not directly translate to BALB/c mice 
Systemic LPS did not affect capsaicin-induced hypersensitivity in BALB/c mice. 
Capsaicin-induced hypersensitivity was observed across both LPS and saline groups as 
shown by increased von Frey responses (Fig. 5.2), however not consistently across all von 
Frey filaments tested. Post hoc analysis revealed that among LPS treated animals all 
filaments produced a significantly higher number of responses at 7 min post capsaicin 
compared to baseline (Fig. 5.2A. p < 0.0001, Fig. 5.2B. p < 0.01, Fig. 5.2C. p < 0.05). In 
the vehicle groups the 0.008 and 0.16g filaments produced a significant increase in the 
number of responses at 7 min compared to baseline (Fig. 5.2A. p < 0.001, Fig. 5.2C. p < 
0.05), while there was no difference observed for the 0.04g filament. In all groups, 
hypersensitivity was resolved by 45 min, with no significant differences seen at 45 and 90 
min post capsaicin when compared to baseline. Two-way ANOVA comparing the change 
in responses from baseline between LPS and vehicle groups revealed an effect of time 
following capsaicin administration for all three von Frey forces tested (Fig. 5.2A. F(3,30) = 
19.82, p < 0.0001, Fig. 5.2B. F(3,30) = 8.09, p < 0.001, Fig. 5.2C. F(3,30) = 7.27, p < 0.001), 
however no effect of treatment (Fig. 5.2A. F(1,10) = 0.78, p = 0.40, Fig. 5.2B. F(1,10) = 0.07, 
p = 0.80, Fig. 5.2C. F(1,10) = 0.018, p = 0.68) and no interaction (Fig. 5.2A. F(3,30) = 0.28, p 
= 0.84, Fig. 5.2B. F(3,30) = 0.75, p = 0.53, Fig. 5.2C. F(3,30) = 0.19, p = 0.90) (Fig. 5.2). Post 
hoc analysis revealed no significant difference between LPS and saline groups at any time 
point. These results are representative of multiple experiments using multiple LPS doses (1 
μg, 1 mg/kg), capsaicin doses (1.6, 1.0, 0.8 μg/ 5 μL) and different time points (3, 4 h) 









Figure 5.2: Systemic LPS does not potentiate capsaicin-induced hypersensitivity. Mice 
were administered LPS (1 mg/kg; i.p.) or saline 4 h prior to capsaicin (0.8 μg/5 μL; i.pl). 
Testing included 10 applications of von Frey filaments (0.008 (A), 0.04 (B), 0.16g (C)) and 
was performed at 7, 45 and 90 min following capsaicin administration. n = 6 for all groups, 























5.4.2 Local LPS administration does not consistently produce potentiated capsaicin-
induced hypersensitivity at multiple time points 
Applying LPS directly to the capsaicin injection site resulted in a large amount of variation 
in von Frey responses. Analysis revealed increased responses to the 0.6g filament in the 
LPS group for both 15 min and 4 h treatment groups (Fig. 5.3). However, the time at which 
potentiated hypersensitivity occurred was not consistent. A 15 min gap between LPS and 
capsaicin injection was chosen based on in vitro endotoxin-capsaicin studies (Diogenes et 
al., 2011). Two-way ANOVA revealed an effect of time for all filaments tested (Fig. 5.3A. 
F(3,30) = 7.79, p < 0.001, Fig. 5.3B. F(3,30) = 4.3, p < 0.05, Fig. 5.3C. F(3,30) = 7.41, p < 
0.001) but not treatment (Fig. 5.3A. F(1,10) = 0.95, p = 0.35, Fig. 5.3B. F(1,10) = 0.42, p = 
0.53, Fig. 5.3C. F(1,10) = 4.50, p = 0.06) or interaction (Fig. 5.3A. F(3,30) = 0.74, p = 0.54, 
Fig. 5.3B. F(3,30) = 0.14, p = 0.93, Fig. 5.3C. F(3,30) = 2.59, p = 0.07) on von Frey responses 
when there was 15 min between LPS and capsaicin injections. Interestingly, post hoc 
analysis revealed that von Frey scores did not significantly deviate from baseline at 7 min 
post capsaicin (Fig. 5.3A-C), while at 45 min the LPS group had significantly higher von 
Frey responses to the 0.6g filament than the saline control (p < 0.05) which did not deviate 
from baseline (Fig. 5.3C). As with the systemic LPS administrations we considered 4 h 
between LPS and capsaicin; which corresponds to the timing of potentiation observed in 
the Human endotoxin-capsaicin model (Hutchinson et al., 2013). Two-way ANOVA 
revealed an effect of time for all filaments tested (Fig. 5.3D. F(3,30) = 22.63, p < 0.0001, 
Fig. 5.3E. F(3,30) = 22.73, p < 0.0001, Fig. 5.3F. F(3,30) = 7.41, p < 0.001) and an effect of 
treatment for the 0.16g filament (Fig. 5.3E. F(1,10) = 6.337, p = 0.03). No treatment effect 
was observed for the two other filaments tested (Fig. 5.3.D. F(1,10) = 1.61, p = 0.23, Fig. 
5.3F. F(1,10) = 1.96, p = 0.19) and no interaction was observed for any filament (Fig. 5.3D. 
F(3,30) = 0.84, p = 0.48, Fig.5.3E. F(3,30) = 1.20, p = 0.33, Fig. 5.3F. F(3,30) = 2.90, p = 0.05). 
Unlike for the 15 min time-point, capsaicin-induced hypersensitivity was observed for all 
filaments; with post hoc analysis revealing that von Frey responses significantly increased 
at 7 min compared to baseline for both saline (p < 0.0001 (Fig. 5.3D, F); p < 0.001 (Fig. 
5.3E)) and capsaicin (p < 0.0001 (Fig. 5.3D-F)) groups. Post hoc analysis also revealed 
that for the 0.6g filament there was a significantly increased response in the LPS group at 
90 min following capsaicin (p < 0.05) (Fig. 5.3F). A lower dose of LPS was also tested (50 
ng/5 μL), interestingly again a treatment effect was observed (F(1,9) = 6.10, p = 0.04) for 
the 0.16g filament, although this time in the 15min LPS group, no other group differences 






Figure 5.3. Local LPS (100 ng) administration does not consistently produce 
potentiated capsaicin hypersensitivity. BALB/c mice were administered LPS (100 ng / 5 
μL; i.pl) 15 min or 4 h prior to capsaicin (0.8 μg/5 μL; i.pl.). Von Frey testing was carried 
out at 7, 45 and 90 min following capsaicin administration. Three von Fey filaments were 
used, 0.04 (A, D), 0.16g (B, E) and 0.6g (C, F). n = 6 for all groups. Error bars represent 














5.4.3 A primed LPS response produces extended capsaicin-induced hypersensitivity, an 
effect reversed by (+)-naltrexone 
In the next study, 2 doses of LPS (i.pl./i.pl.) separated by 7 days were administered prior to 
capsaicin; using the same von Frey stimulations as in the previous experiment. (+)-
Naltrexone was used as a TLR4 antagonist and administered prior to the first LPS dose. 
Two-way ANOVA revealed a main effect of time (Fig. 5.4A. F(3,93) = 102.8, p < 0.0001, 
Fig. 5.4B. F(3,93) = 119.4 , p < 0.0001, Fig. 5.4C. F(3,93) = 129.9, p < 0.0001) across all three 
filaments. However, a treatment effect was only observed across the 0.04 (Fig. 5.4A. F(2,31) 
= 7.5, p = 0.002) and 0.6g (Fig. 5.4C. F(2,31) = 7.0, p = 0.003) filaments, with no treatment 
effect observed for the 0.016g (Fig. 5.4B. F(2,31) = 6.3, p = 0.05) filament. An interaction 
effect was observed for all three filaments (Fig. 5.4A. F(6,93) = 3.1, p = 0.008, Fig. 5.4B. 
F(6,93) = 3.5, p = 0.003, Fig. 5.4C. F(6,93) = 3.4, p = 0.004). Post hoc analysis revealed that 
LPS alone had no effect on von Frey scores (Fig. 5.4). For all filaments, extended 
hypersensitivity was observed; the LPS-capsaicin group had significantly increased von 
Frey responses when compared to the saline control at both 45 (p < 0.01) and 90 (p < 
0.001) min. Despite significant differences between these groups, it should be noted that 
there appears to be two populations of responders. Between 6 and 8 out of 14 (depending 
on filament) animals tested produced a response that didn’t significantly differ from the 
saline group, while the remaining animals showed potentiation and extended 
hypersensitivity (Fig. 5.4D-F). In fact, if the LPS primed group was split into two based on 
level of response, high (90 min score outside 2 standard deviations of vehicle control) and 
low, it is possible to view significant differences between the two (Fig. 5.4D-F). At 45 min 
a significant difference was observed at the 0.04g filament (P < 0.01) and at the 0.6g 
filament (p < 0.05). At 90 min all three filaments showed a significant difference between 
high and low groups (p < 0.01). The high responding group was significantly higher than 
vehicle for all filaments at 45 and 90 min (p < 0.01) and at the 7 min time point for the 
0.04g filament (p < 0.05) (Fig. 5.4D-F). The group receiving (+)-naltrexone did not differ 
from the saline group at any point. Significant differences between (+)-naltrexone-LPS and 
LPS only groups were only observed at the 90min time point for 0.04g (p < 0.05) and 0.6g 






Figure 5.4. Two LPS doses prolongs capsaicin-induced hypersensitivity, an effect 
reversed by (+)-naltrexone. BALB/c mice were administered two doses of LPS (100 ng / 
5 μL; i.pl.) 7 days apart. 4 h after the final dose animals received capsaicin (0.8 μg/5 μL: 
i.pl). Von Frey testing was carried out at 7, 45 and 90 min following capsaicin 
administration. Three von Frey filaments were used, 0.04 (A, D), 0.16g (B, E) and 0.6g (C, 
F). D, E and F represent the 2 x LPS + capsaicin group split into high and low responders 
compared with the 2 x veh + capsaicin control group. n = 6 for (+)-naltrexone group, n = 
14 for all other groups receiving capsaicin, n = 8 for LPS-vehicle group. For graphs (D, E, 
F) which split 2 x LPS + capsaicin group, n = 7 (D), 6 (E) and 8 (F) for high responding 
group and 7 (D), 8 (E) and 6 (F) for the low responding group. Error bars represent SEM. * 
p < 0.05; ** p < 0.01, *** p < 0.001, p < 0.0001 2 x LPS + capsaicin and 2 x LPS + 
capsaicin (high responders) vs 2 x saline + capsaicin; # p < 0.05; ## p < 0.01 NTX + 2 x 
LPS + capsaicin vs 2 x LPS + capsaicin; & p < 0.05; && p < 0.01, &&& p < 0.001 for 2 x 








The aim of this study was to back-translate the clinical endotoxin-capsaicin model into 
BALB/c mice. Not only would this enable investigation of mechanisms underlying the 
clinical endotoxin-capsaicin results but create a unified clinical/preclinical model; a unique 
drug screening paradigm. Further to these, it may also shed light on the nature of the 
relationship between TLR4 and TRPV1. We failed to replicate the mechanical 
hypersensitivity observed in the clinical endotoxin-capsaicin model using both systemic 
and targeted peripheral LPS application. LPS priming did cause an observed potentiated 
hypersensitivity, which was reversed by TLR4 antagonist (+)-naltrexone. However, the 
variability of this response suggests further investigation is required. 
 
We produced a reproducible capsaicin-induced hypersensitivity in BALB/c mice using a 
best of 10 von Frey approach (Fig. 5.2), applying 0.8 µg of capsaicin per paw. To our 
knowledge this is the first time this model has been established in BALB/c mice. 
Hypersensitivity to von Frey stimuli is observed at 7 min and is resolved by 45 min; a 
timeframe which correlates well with clinical observations following intradermal capsaicin 
(Aykanat et al., 2012; Liu et al., 1998). Importantly the magnitude of hypersensitivity 
following 0.8 µg of capsaicin never exceeds 80% of the maximum response rate and drops 
rapidly, which allows room for potentiation of magnitude and duration to be observed.  
 
Systemic LPS was unable to potentiate capsaicin-induced hypersensitivity at 1 μg or 1 
mg/kg, across all filament strengths tested (Fig. 5.2, Sup Fig. 5.1). Multiple filaments were 
tested for numerous reasons, the most practical being minimising the chance of reaching an 
effect ceiling. Secondly, in the case potentiation occurs in only a particular subset of 
nociceptors. TRPV1 is found on both small and medium C and Ad primary afferents, 
which have been shown to be activated by different stimuli and stimulus force (Hsieh et 
al., 2015; Szallasi et al., 2007). In the event of potentiation, using multiple forces may have 
revealed if a particular neuronal subset was responsible for the change. Finally, the lowest 
fibre we used elicited less than one response from 10 at baseline, considered completely 
innocuous (data not shown). The highest filament we used elicited an average of 2 
responses from 10 and was considered noxious (data not shown). This gave the study the 
possibility of distinguishing if the observed hypersensitivity may be a result of an allodynic 
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(innocuous filament) or hyperalgesia (noxious filament) mechanism in the event that 
potentiation occurred.  
 
Careful consideration was given to the timing of LPS as this was an important factor in 
clinically observed potentiation; peak plasma cytokine (IL-6) levels correlated with 
potentiated allodynia in that case (Hutchinson et al., 2013). Inflammatory mediators 
including TNFa, bradykinin, NGF, IL-1b, IL-6 are implicated in TRPV1 sensitisation and 
upregulation; suggesting pro-inflammatory conditions induced by TLR4 signalling may be 
responsible for the observed potentiation (Chuang et al., 2001; Fang et al., 2015; Hensellek 
et al., 2007; Zhang et al., 2005). Therefore, capsaicin potentiation was tested at observed 
peak cytokine following LPS administration in BALB/c mice (4 h) (Ostberg et al., 2000). 
Interestingly, recent evidence reports differences in cytokine response due to variation in 
LPS administration. With the exception of IL-10, cytokine levels were delayed and 
variable after i.p. administration compared to i.v.. Again, this suggests the use of an 
extended time period between endotoxin and capsaicin, compared to that observed in the 
clinical model (Somann et al., 2019). Timing is a factor that could be explored further, 
clinical studies which administered the same (0.4 ng/kg) and higher (0.8 & 2 ng/kg) LPS 
doses report peak pro-inflammatory cytokines (IL-6, TNFa, IL-8) at 2 h, earlier than 
reported by Hutchinson et al. during the clinical endotoxin-capsaicin study (Benson et al., 
2012; de Goeij et al., 2013; Hutchinson et al., 2013; Wegner et al., 2014). Therefore, any 
future studies might consider a longer timepoint of 5-7 h, past peak plasma cytokine 
resulting from i.p. administration. While i.v. administration should also be considered if 
the nature of a systemic immune response is altered by administration location.  
 
LPS potentiated capsaicin responses have also been observed in trigeminal nociceptors 
over much shorter time frames. LPS stimulation of rat trigeminal ganglion neurons for 15 
min causes a potentiation of capsaicin-induced increase in intracellular calcium and CGRP 
release, which is attenuated by TLR4 antagonist LPS-RS (Diogenes et al., 2011; Ferraz et 
al., 2011). We attempted to stimulate peripheral neurons directly based on this direct and 
fast acting potentiation. TLR4/TRPV1 co-localisation has been observed in peripheral 
tissues including dental pulp, TG and DRG of humans, rats and mice respectively (Ferraz 
et al., 2011; Min et al., 2014; Wadachi et al., 2006). Reports of direct activation of afferent 
nociceptors by LPS alone, further supports evidence that TLR4 may be directly involved in 
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nociceptive responses (Li et al., 2015; Meseguer et al., 2014). Administration of local LPS 
did not potentiate capsaicin-induced hypersensitivity at either the 15 min or 4 h time 
points. In contrast with earlier studies, we observed no sensitivity to LPS alone at 100 
ng/paw at the tested time points (15 – 105; 240 – 330 min) (data not shown) (Calil et al., 
2014). Interestingly the addition of an intraplantar injection 15 min prior to intraplantar 
capsaicin-administration eradicated capsaicin-induced hypersensitivity (Fig. 5.3A-C). 
Further investigation is warranted to understand which systems attenuate capsaicin 
hypersensitivity following injection stressor in the hind paw. 
 
Local priming of the LPS response produced a statistically different hypersensitivity in 
LPS primed and control groups. It has been observed that LPS priming has significant 
impact on pain sensitivity and immune cell activation when administered centrally (Cahill 
et al., 1998; Clark et al., 2010). Our model produced an all or nothing response, with 
animals either displaying an extended hypersensitivity to 90 min, or no change from 
vehicle control, resulting in a large amount of variability. An extra group of 8 animals was 
used after post hoc power analysis, which did lead to a statistically significant effect. 
However, this did not resolve the obvious variability. Rather than considering this an 
unreliable model, we suggest that differences in mechanisms between these two 
populations (high and low responders) would be of interest. Just as the mechanisms 
between a pain patient and a patient without pain if they had been given the same stimulus 
would be of interest – why did one develop the symptoms and the other did not? 
Interestingly the potentiation displayed a markedly different profile to the magnitude shift 
seen in the clinical model, with potentiated hypersensitivity not observed immediately 
following capsaicin administration. Taken together with the single peripheral application 
data above, it appears within BALB/c mice, for any given batch and serotype of LPS the 
response behavioural outcomes are highly variable. Genetic variability is a candidate for 
observed differences given evidence of significant variation in inbred strains including 
BALB/c’s (Pritchard et al., 2006). For greater relevance it would be useful to determine 
how local LPS administration, and priming, elicits molecular and cellular changes in 
central and peripheral tissues. If analysis of immune cell infiltration or reactivation and/or 
locally induced inflammatory mediators also display significant intrasubject variability it is 




Although capsaicin-induced hypersensitivity is overwhelmingly tested using rodent hind-
paw models, sensitisation by LPS in clinical models is region specific. In the clinical 
endotoxin-capsaicin model, allodynia and hyperalgesia were observed on the forearm, and 
not on the forehead, interesting considering preclinical endotoxin-capsaicin models have 
utilised trigeminal nociceptors (Hutchinson et al., 2013). Wegner et al. reported low-dose 
systemic LPS sensitisation in man, reporting lower back sensitisation while the calf and 
shoulder remain unaffected (Wegner et al., 2014). These results in particular introduce the 
possibility that some anatomical regions may involve different pain mechanisms, however 
anything from altered peripheral sub-populations to varied higher order CNS processing 
could account for such variances. Subcutaneous, intramuscular in intradermal capsaicin 
administration over the back or calf is perhaps an option in rodent models if further 
investigation was to occur, although new testing paradigms would need to be designed to 
assess mechanical sensitivity at these locations.  
 
Poor preclinical to clinical translation of novel therapeutic agents has rightly brought into 
question the usefulness of current preclinical models in pain research (Hill, 2000; Huggins 
et al., 2012; Landry et al., 2012). We attempted to bridge the clinical to preclinical gap by 
creating a unified pain model involving both immunological and immune elements of pain 
signalling. Unfortunately, this study was unable to replicate the behavioural results seen in 
the clinical endotoxin-capsaicin model. Therefore, we were unable to shed any further light 
on the mechanism that underlies LPS-induced capsaicin potentiation observed in the 
clinical setting. We did observe a potentially interesting paradigm whereby a primed LPS 


















Supplementary Figure 1. Systemic LPS does not potentiate capsaicin-induced 
allodynia. Mice were administered LPS (1 μg/kg or 1 mg/kg; I.P.) or vehicle (0.9% sterile 
saline) 3- (G-I) or 4- (A-F) h prior to capsaicin (1.0 μg or 1.6 μg/10 μL; i.pl). Testing 
included 5 applications of a 0.008 (A, D, G), 0.04 (B,E,H) or 0.16g (C,F,I) von Frey 
filament. Testing was performed at 7, 13, 23, 30, 45, 60, 75 and 90 min following 
capsaicin administration, the 7 and 23 min timepoint were skipped for the 0.04g filament. n 
= 6 for all LPS groups except in the group receiving 1 mg/kg LPS and 1.0 μg/10 μL 
capsaicin (A - C) where n = 12; for vehicle groups n = 18 (A-C), 8 (D-F) and 2 (H-I). * p < 
0.05 vehicle vs 1 mg/kg LPS; # p < 0.05, ## p < 0.01 1 mg/kg LPS vs 1 μg/kg LPS, error 





Supplementary Figure 2. Local administration of LPS (50 ng) does not potentiate 
capsaicin-induced allodynia. Mice were administered LPS (50 ng/5 μL; i.pl) or vehicle 
(0.9% sterile saline) 15 min (A-C) or 4 h (D-F) prior to capsaicin (0.4 μg/5 μL; i.pl). 
Testing included 10 applications of a 0.04 (A, D), 0.16 (B, E) or 0.6g (C,F) von Frey 
filament. Testing was performed at 7, 45 and 90 min following capsaicin administration. n 
















Chapter 5 revealed that intraplantar (i.pl.) administration of LPS 15 min prior to capsaicin 
completely attenuated capsaicin-induced mechanical hypersensitivity. This effect limits 
our ability to understand the in vivo relevance of short LPS stimulation on TRPV1 activity. 
We therefore aim to uncover mechanisms behind this response, as well as any potential 
effects on capsaicin responses following hindpaw administration. We hypothesised the role 
of endogenous opioids are key to this response, and we therefore investigate the role of 
opioid antagonists at various time points in relation to i.pl. administration of capsaicin. 
Further we look to examine if this peripheral stimulation elicits central changes. 
 
Chapter 6. Naltrexone non-stereoselectively reverses intraplantar injection-induced 
analgesia and extends capsaicin-induced mechanical hypersensitivity. 
 
6.1 Abstract 
Capsaicin-induced pain models are used to investigate nociceptive physiology and screen 
for novel analgesic agents. Capsaicin activates neuronal ion channel, transient receptor 
potential cation channel subfamily V member 1 (TRPV1) to produce localised burning 
pain and extended hypersensitivity resulting from peripheral and central sensitisation. A 
common method of inducing pain in preclinical models is an injection into the ventral 
hindpaw of rodents. Our aim is to understand the effects of intraplantar (i.pl.) 
administration on the nociceptive outcome of capsaicin-induced pain. We found that i.pl. 
administration of saline (5 µL) 15 min before capsaicin challenge attenuates mechanical 
hypersensitivity in BALB/c mice. This effect was blocked by classical and non-classical 
opioid antagonists (-)- and (+)-naltrexone, restoring capsaicin-induced mechanical 
hypersensitivity to 90 min (p < 0.05). Both (-)- and (+)-naltrexone had no effect on 
capsaicin-induced mechanical hypersensitivity when administered pre-capsaicin. 
Interestingly, when administered following induction of hypersensitivity they significantly 
potentiated and extended capsaicin-induced mechanical hypersensitivity up to 135 min (p 
< 0.0001). If hypersensitivity recovered, naltrexone had no effect, even if administered 
prior to 135 min post capsaicin. Immunohistochemical analysis of the spinal cord revealed 
that extended hypersensitivity was not a result of increased neural activity measured by c-
Fos activation at the spinal cord level. Therefore, i.pl. administration influences 
nociceptive outcomes of capsaicin administration by classical and non-classical opioid 
mechanisms. Behavioural effects of antagonising these mechanisms are dependent on 





Capsaicin is commonly utilised in pain research for its ability to produce observable, 
spontaneous behavioural responses and extended hypersensitivity (O'Neill et al., 2012). 
Capsaicin, the pungent ingredient of chilli peppers, is an agonist of transient receptor 
potential cation subfamily V, member 1 (TRPV1), a non-selective cation channel found on 
multiple tissue types including C and Ad-fibre primary afferent neurons (Brito et al., 2014; 
Caterina et al., 1997; Szallasi et al., 2007). In addition to capsaicin, TRPV1 channel 
opening is induced by endogenous ligands and environmental factors (e.g. temperature, 
pH) resulting in activation of nociceptors, primary afferent neurons involved in 
transmission of noxious stimuli (Brito et al., 2014; Sutherland, 2014). Controlled, direct 
activation of nociceptive circuits by capsaicin makes it ideal for models investigating pain 
physiology; it is also frequently used to assess novel analgesic efficacy (Fialho et al., 2017; 
Hutchinson et al., 2013; Kang et al., 2010; Ren et al., 1994). 
 
Preclinical pain models allow investigation of molecular and cellular mechanisms that are 
not possible in clinical models, while providing multi-system input that in vitro 
experiments lack. Use of capsaicin in preclinical animal models dates back multiple 
decades, utilising multiple animal species and routes of administration (Kinnman et al., 
1995; Kupers et al., 1997; Laird et al., 2000). In addition to producing spontaneous pain 
behaviours, a number of common behavioural tests can be performed to establish 
hypersensitivity to mechanical and thermal stimuli following capsaicin administration. 
Mechanical application of force to the hind paw offers the ability to assess sensitivity at a 
secondary site, away from the application of noxious stimulation (Kinnman et al., 1995; 
Tamaddonfard et al., 2017). This gives researchers using capsaicin the ability to 
discriminate between peripheral and central origins of pain sensitivity, known respectively 
as peripheral and central sensitisation (von Hehn et al., 2012). 
 
Peripheral and central sensitisation are separate mechanisms which produce unique 
outcomes, it is therefore important to distinguish between them to fully understand the 
effect of treatment in pain models. Both mechanisms result in exaggerated responses to 
noxious stimuli (hyperalgesia) and painful responses to innocuous stimuli (allodynia) (von 
Hehn et al., 2012). However, peripheral sensitisation involves changes to structure and 
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function of primary afferents; as such these symptoms are located at the site of 
damage/insult (von Hehn et al., 2012). Central sensitisation involves changes within the 
central nervous system (CNS), resulting in increased excitability and decreased inhibitory 
tone (Grace et al., 2014). The ‘over-excited’ environment within the CNS results in 
crosstalk between usually non-nociceptive sensory neurons and pain transmitting 
secondary afferents. As a result, innocuous stimuli can cause pain sensations (allodynia). 
Secondly, signals from primary afferents at sites away from the injury are amplified upon 
entering the ‘over-excited’ CNS; causing secondary hyperalgesia and allodynia (von Hehn 
et al., 2012). Importantly, capsaicin models are able to produce both primary and 
secondary hypersensitivities enabling researchers to analyse separate pain mechanisms. 
 
Our group utilised a clinical intradermal capsaicin pain model in an attempt to investigate a 
relationship between capsaicin-induced nociception and systemic endotoxin 
(lipopolysaccharide (LPS)) (Hutchinson et al., 2013). This model used multiple 
behavioural measures, including spontaneous pain, mechanical allodynia, punctate 
mechanical hyperalgesia and flare, in order to elucidate either a central or peripheral effect. 
Endotoxin potentiated capsaicin-induced hyperalgesia, allodynia and flare, suggesting both 
central and peripheral actions, which required further investigation (Hutchinson et al., 
2013). It is necessary to recreate the observed endotoxin potentiated capsaicin response in 
a preclinical model in order to ask detailed molecular and cellular questions within the 
CNS.  
 
In our preclinical capsaicin model, studies revealed an attenuation of capsaicin-induced 
hypersensitivity due to pre-treatment injection timing, highlighting the complexities 
present in even this basic pain model. Of particular concern are the effects of endogenous 
opioid responses following a subcutaneous application of capsaicin to the hindpaw, an 
effect known as stress-induced analgesia (SIA) (Butler et al., 2009). Common endogenous 
opioid classes include endorphins, enkephalins, dynorphins and endomorphins which can 
be released following stressful stimuli, acting at classical opioid receptors (Feng et al., 
2012; Labuz et al., 2016; Stein et al., 2003). Classical opioid receptors include µ-, k- and 
d-opioid receptors (MOR, KOR, DOR) (Ahlbeck, 2011; Feng et al., 2012). Upon 
activation, alteration of ion channel function attenuates production and release of 
neurotransmitters, subsequently reducing neuronal activity (Feng et al., 2012; Stein et al., 
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2003). Further, the relatively non-selective opioid antagonist naloxone blocks opioid 
mediated SIA in multiple rodent models, including electroacupuncture, intraperitoneal 
hypertonic saline administration and foot shock (Hemingway et al., 1987; Watkins et al., 
1982; Wright et al., 1985). There is evidence that endogenous opioid peptides also 
attenuate mechanical hypersensitivity in a mouse neuropathic pain model (Labuz et al., 
2016). The potential of an endogenous opioid response in our preclinical capsaicin pain 
model complicates the endotoxin-capsaicin effect we are aiming to replicate. Therefore, it 
is necessary to investigate the potential role of opioid receptor activation following 
intraplantar (i.pl.) capsaicin administration. 
 
Classical opioid responses are not the only means by which stress-induced analgesia 
occurs. Non-classical opioid effects refer to morphine-like analgesia which do not engage 
classical opioid receptors (McDonald et al., 2013). Glutamate, g-aminobutyric acid 
(GABA), endocannabinoids and monoamines are examples of endogenous non-classical 
opioid compounds, due to their role in descending inhibitory facilitation (Butler et al., 
2009). Synthetic, clinically approved compounds include Tapentadol, which inhibits 
norepinephrine re-uptake and MOR activation, however retains efficacy in MOR knockout 
models (Langford et al., 2016) (Kogel et al., 2011). Likewise, stereoisomers of classical 
opioid antagonists (+)-naltrexone and (+)-naloxone are able to attenuate neuropathic pain 
in rodents, despite lack of affinity to classical receptors (Hutchinson et al., 2008; Lewis et 
al., 2012; Valentino et al., 1983). Nociceptin/orphanin GQ (N/OFQ) receptor (NOP) is an 
identified non-classical opioid receptor. NOP is structurally homologous to classical opioid 
receptors but shows low affinity towards their agonists and is therefore recognised as a 
non-classical opioid receptor (Mollereau et al., 1994; Toll et al., 2016). 
 
This study aimed to investigate the effects of i.pl. administration on capsaicin-induced 
mechanical hypersensitivity. I.pl. administration of saline (5 µL) 15 min before capsaicin 
challenge attenuates mechanical hypersensitivity in BALB/c mice. Both (+)-and (-)-
naltrexone reversed the attenuated capsaicin response, while immunohistochemical 
examination showed no effect on c-Fos expression in the spinal cord. Both naltrexone 
stereoisomers were able to extend hypersensitivity, however only when administered post-
capsaicin. The results suggest a local endogenous non-classical opioid response alters 
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6.3. Methods  
 
6.3.1 Animals 
Male adult BALB/c mice (6-14 weeks) (n = 6-10 per group) obtained from Laboratory 
Animal Services of the University of Adelaide (Adelaide, SA) were used in these 
experiments. All mice were group-housed in the Medical School Animal Facility of the 
University of Adelaide. Mice were allowed free access to food and water in a temperature-
controlled environment (23 ± 3°C) maintained on a 12:12 h light/dark cycle (lights on at 
0700h). Animals were left to acclimatise to the facility for at least one week before 
handling began. One week of handling and acclimatisation to the experimental set-up was 
carried out prior to use. All experiments reported in this study were approved by the 
University of Adelaide Animal Ethics Committee (Ethics approval number M-227-13B) 




Capsaicin in 38% (2-hydroxy-propyl)-β-cyclodextrin was kindly donated by the PARC 
clinical research group of the University of Adelaide (Adelaide, SA). (-)-Naltrexone was 
kindly provided by Dr Andrew Somogyi (University of Adelaide, School of Medicine, 
Adelaide, SA). (+)-Naltrexone was kindly donated by Dr Kenner Rice (Chemical 
Biological Research Branch, National Institute on Drug Abuse and National Institute on 
Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD). (2-
Hydroxypropyl)-β-cyclodextrin was purchased from Sigma-Aldrich (Castle Hill, NSW). 
Sterile saline (0.9%) was purchased from Baxter Australia (Old Toongabbie, NSW, 
Australia). Von Frey filaments were purchased from North Coast Medical Inc. (Gilroy, 
California). PBS (10X) (137 mM sodium chloride, 2.7 mM potassium chloride, 1.5mM 
dihydrogen potassium orthophosphate, 8 mM disodium hydrogen orthophosphate 
(purchased from Chem Supply, South Australia, Australia)) was made and diluted in on-
site Milli-Q filtered H2O. Rabbit @ c-Fos antibody (K-25: sc-253) was purchased from 
Santa Cruz Biotechnology, Texas, USA. Donkey @ Rabbit secondary antibody and 3,3'-
 
 125 
Diaminobenzidine (DAB) substrate were purchased from Vector Laboratories (California, 
USA). PierceTM streptavidin peroxidase-conjugated antibodies were purchased from 
ThermoFisher Scientific (North Ryde, NSW). 
 
(2-Hydroxypropyl)-β-cyclodextrin was diluted in 0.9% sterile saline to make a 38% 
solution. A stock capsaicin solution of 5 mg/mL was created using 38% (2-
Hydroxypropyl)-β-cyclodextrin, protected from light and stored at 4°C for a maximum of 
1 month. On the morning of use, this was further diluted in (2-Hydroxypropyl)-β-
cyclodextrin to the experimental concentration. Both (-)- and (+)-naltrexone were made up 
to the desired concentration in 0.9% sterile saline the week of the experiment and kept at 
4°C. 
 
6.3.3 Intraplantar drug administration 
All capsaicin and β-cyclodextrin administrations were conducted using the following 
technique. All injections were performed with a primed 25 μL Hamilton micro-syringe and 
30G needle. To prime the micro-syringe, the plunger was removed, and 0.9% saline was 
injected into the barrel of the syringe until no air remained inside, the plunger was then 
reinserted. A 30G needle was attached to a 1 mL syringe containing 0.9% saline and saline 
was dispensed, filling the needle tip. The 30G needle tip was then carefully removed, filled 
with 0.9% saline and attached to the full micro-syringe; leaving no air inside either the 
micro-syringe or needle tip. The plunger was then pushed all the way down, and pulled up 
to the 5 μL mark, creating a small air bubble. The desired volume of solution could then be 
withdrawn and dispensed. Animals were gently restrained in a thin towel and 5 μL of the 
solution was injected at the distal end of the plantar surface, directly under the skin at the 





Figure 6.1: Intraplantar (i.pl.) drug administration. (X) represents the site of needle 




6.3.4 Behavioural testing 
A von Frey test modified from the Nicotra et al. (2012) method was performed on all 
animals. Immediately following i.pl. drug administration, animals were placed on a wire 
mesh shelf that allowed access to the plantar surface of the hindpaw and covered with an 
opaque cup. Von Frey filaments were touched to the proximal end of the plantar surface of 
the hindpaw to allow assessment of secondary hypersensitivity, as elicited in the clinical 
model (Fig. 6.1). Force was then applied until the filament bent and held for two seconds 
before being slowly removed for one second and reapplied. Animals were tested up to 180 
min following i.pl. drug administration. All animals received 10 applications of each von 







filament strength. Baseline testing was conducted 24 h prior to i.pl. capsaicin 
administration for all experiments.  
 
6.3.5 Naltrexone studies  
6.3.5.1 Intermediate saline  
BALB/c mice were administered (-)-naltrexone (6 mg/kg) or equivalent volume saline by 
intraperitoneal (i.p.) injection 15 min pre i.pl injection of saline. 15 min later animals were 
administered capsaicin (0.4 μg/5 μL; i.pl.) or the equivalent volume of β-cyclodextrin 
(Bazzo et al., 2013). Animals were tested with filaments 2.44 (0.04 g), 3.22 (0.16 g) and 
3.84 (0.6g) at 7, 45, 90 and 135 min following capsaicin administration. 
 
 
Figure 6.2: Intermediate saline effect. Time course of drug administration and 
behavioural testing investigating pre-capsaicin i.pl. injection stress effect.  
 
 
6.3.5.2 Naltrexone pre-capsaicin 
BALB/c mice were administered (-)- or (+)-naltrexone (6 mg/kg) or equivalent volume 
saline (i.p.) 30 min prior to capsaicin (0.4 μg/5 μL; i.pl.) or the equivalent volume of β-
cyclodextrin (Bazzo et al., 2013). Animals were tested with filaments 2.44 (0.04 g), 3.22 
(0.16 g) and 3.84 (0.6g) at 7, 45, 90 and 135 min following capsaicin administration. 
 
 
Figure 6.3: Pre-naltrexone effect on capsaicin-induced hypersensitivity. Time course 







6.3.5.3 Naltrexone post-capsaicin 
BALB/c mice were administered (-)- or (+)-naltrexone (6 mg/kg) 30 min post capsaicin 
(0.4 μg/5 μL; i.pl.) or (-)-naltrexone (6 mg/kg) 110 min post capsaicin (0.4 μg/5 μL; i.pl.) 
(Bazzo et al., 2013). Control animals were administered equivalent volume saline (i.pl.) at 
the same time points. Animals were tested with filaments 2.44 (0.04 g), 3.22 (0.16 g) and 
3.84 (0.6g) at 7, 45, 90 and 135 min following capsaicin administration. Animals 
administered (-)-naltrexone at 110 min, were also tested at 180 min following capsaicin.  
 
 
Figure 6.4: Post-naltrexone effect on capsaicin-induced hypersensitivity. Time course 
of drug administration and behavioural testing investigating post-capsaicin naltrexone.  
 
 
6.3.6 Tissue collection 
Animals were administered (-)-naltrexone (6 mg/kg) 30 min following capsaicin (0.4 μg/5 
μL; i.pl.). 2 h following capsaicin, animals were sacrificed by i.p. sodium pentobarbitone 
(300 ng/ kg), immediately followed by transcardial perfusion with 4% paraformaldehyde 
(PFA) and flushed with sterile PBS (pH 7.4). The spinal column and brain were dissected 
and post fixed in 4% PFA for 48 h. Tissue was then washed twice for 30 min in sterile PBS 
(pH 7.4); the lumbar spinal cord (SC) was dissected out. Tissue was then stored in 70% 
ethanol before overnight processing in a Sakura Tissue Tek VIP Junior Vacuum 
Infiltration Processor (Olympus, Notting Hill, Australia). Tissue was then embedded in 
paraffin using a Sakura Tissue Tek TEC 5 Embedding Centre (Olympus, Notting Hill, 
Australia). Tissue was cut into 10 µm slices using a Leica RM2125 RT microtome (Leica 
Microsystems, Mt Waverly, Australia) and mounted on Superfrost microscope slides. 
 
6.3.7 Immunohistochemistry 
Slides were placed in an oven at 37°C for 15 min, then into a Dako CoverStainer (Santa 
Clara, United States) for de-waxing. Slides were removed, washed in water and placed in 
methanol containing 3% H202 for 30 min. Slides were washed twice in PBS for 5 min. 
Heat-induced epitope antigen retrieval was performed in 10 mM sodium citrate (pH 6). 
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Slides in sodium citrate were brought to the boil and kept at 95°C for 10 min. Slides were 
allowed to cool to room temperature (RT) before two, 5 min washes in 1X PBS. Slides 
were dried and 3.3% normal horse serum (NHS) applied to each section for 30 min in a 
humidifying chamber at RT. NHS was removed and c-Fos antibody (1:3000) was added to 
each section. Slides were left in a humidifying chamber overnight at RT. Slides were 
washed twice in 1X PBS for 5 min and biotin conjugated Donkey @ Rabbit (1:250) diluted 
in 1X PBS was applied for 30 min at RT. Slides were washed twice for 5 min in 1X PBS 
and PierceTM streptavidin peroxidase-conjugated antibodies (ThermoFisher Scientific) 
(1:1000) were applied for 60 min at RT. Slides were then washed in 1X PBS twice for 5 
min before DAB was applied for 7 min. DAB was removed and slides washed in running 
water for 10 min before haematoxylin counterstaining and cover slipping in a Dako 
CoverStainer (Santa Clara, United States). Slides were allowed to dry overnight and 
imaged using a NanoZoomer (Hamamatsu C10730-12 2.0RS, Shimokanzo, Japan). 
Staining in dorsal horn lamina I - III was analysed for c-Fos positive cells and area stained 
using Image J (1.52t, Maryland, USA). 
 
6.3.8 Analysis 
Data was analysed using GraphPad Prism v7.0a (GraphPad software, Inc. San Diego, CA). 
Two-way ANOVA with repeated measures and Tukey’s multiple comparison test was used 
to compare treatment effect over time for all behavioural experiments with the following 
exception. Sidak’s multiple comparisons test was used to compare treatment groups at 
individual time points for (-)-naltrexone administered at 110 min post capsaicin and to 
compare individual time points to baseline for all experiments. One-way ANOVA with 
Tukey’s multiple comparison test was used to compare treatment effect in each of the 





6.4.1 I.pl. saline attenuates i.pl. capsaicin-induced mechanical hypersensitivity when 
administered 15 min prior, an effect reversed by (-)-naltrexone 
An i.pl. injection of capsaicin produces rapid hypersensitivity in BALB/c mice. This 
response was not observed when saline (i.pl.) is administered just 15 min before capsaicin 
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(Fig. 6.5). No values significantly differed from baseline at the lowest filament; a 
significant difference was observed for the 0.16g (p < 0.01) and 0.6g (p < 0.05) filaments 
at 7 min only (Fig. 6.5). The magnitude of these differences was much lower than observed 
in previous studies. (-)-Naltrexone (6 mg/kg) administered 30 min before capsaicin, 
reversed this effect. Two-way ANOVA revealed an effect of time (Fig. 6.5A. F(2.5,52) = 
36.72, p < 0.0001, Fig. 6.5B. F(2.6,55) = 50.81, p < 0.0001, Fig. 6.5C. F(3.3,70) = 66.96, p < 
0.0001) and treatment (Fig. 6.5A. F(2,21) = 15.31, p < 0.0001, Fig. 6.5B. F(2,21) = 19.98, p < 
0.0001, Fig. 6.5C. F(2,21) = 17.57, p < 0.0001), as well as an interaction effect (Fig. 6.5A. 
F(8,84) = 11.98, p < 0.0001, Fig. 6.5B. F(8,84) = 16.93, p < 0.0001, Fig. 6.5C. F(8,84) = 16.14, p 
< 0.0001), on von Frey responses for all filaments tested. Post hoc analysis revealed 
capsaicin-induced hypersensitivity was significantly greater in the (-)-naltrexone pre-
treated group versus the saline pre-treated for all filaments at 7 (p < 0.01) and 45 min (p < 
0.05) (Fig. 6.5). Interestingly for the heaviest filaments an extension in hypersensitivity 
was observed until 90 min (p < 0.05). Von Frey responses were also significantly different 
for the (-)-naltrexone-capsaicin group compared to the (-)-naltrexone-vehicle control at 7 
(p < 0.01) and 45 min (p < 0.05) for all filaments tested (Fig. 6.5). Like the saline-
capsaicin group, an effect was observed for the (-)-naltrexone-vehicle group compared to 
baseline at 7 min for the heaviest filament (p < 0.05). At all other points no significant 
difference from baseline were observed. Interestingly, (-)-naltrexone alone appeared to 












Figure 6.5. I.pl. saline 15 min pre-capsaicin attenuates mechanical hypersensitivity; 
an affect is reversed by (-)-naltrexone. Mice were administered 0.9% saline (i.pl.) 15 min 
prior to capsaicin (0.4 μg/5 μL; i.pl). (-)-Naltrexone (6 mg/kg; i.p.) or saline (0.9%; i.p.) 
were administered 15 min prior to saline (0.9 %; i.pl.), followed by either capsaicin (0.4 
μg/5 μL; i.pl) or vehicle (5 μL; i.pl). Testing included 10 applications of von Frey 
filaments (0.04 (A), 0.16 (B), 0.6g (C)) and was performed at 7, 45, 90 and 135 min 
following capsaicin administration. n = 12 for saline + capsaicin, n = 6 for all other groups. 
* p < 0.05, ** p < 0.01, **** p < 0.0001 (-)-naltrexone + saline + capsaicin vs saline + 
capsaicin; & p < 0.05, && p < 0.01, &&&& p < 0.0001 (-)-naltrexone + saline + capsaicin 

















6.4.2 Neither (+)- or (-)-naltrexone affect capsaicin-induced mechanical hypersensitivity 
when administered pre-capsaicin. 
To examine the effects of naltrexone on capsaicin-induced hypersensitivity the 
‘intermediate’ i.pl. saline injection was removed from the protocol; leaving a single i.p. 
administration of (+)- or (-)-naltrexone 30 min prior to i.pl. capsaicin. Two-way ANOVA 
revealed an effect of time (Fig. 6.6A. F(3,63) = 40.24, p < 0.0001, Fig. 6.6B. F(2.6,55) = 38.64, 
p < 0.0001, Fig. 6.6C. F(3.2,66) = 66.32, p < 0.0001) on von Frey reposes for all filaments 
tested. A treatment effect was also observed for the 0.04 and 0.16 g filaments (Fig. 6.6A. 
F(2,21) = 5.13, p = 0.0153, Fig. 6.6B. F(2,21) = 4.49, p = 0.0205) but not for the 0.6g filament 
(Fig. 6.6C. F(2,21) = 1.603, p = 0.2249). No interaction effect was observed for all filaments 
(Fig. 6.6A. F(8,84) = 1.395, p = 0.211, Fig. 6.6B. F(8,84) = 1.232, p = 0.2909, Fig. 6.6C. F(8,84) 
= 1.310, p = 0.2497). Post hoc analyses revealed there was no significant difference 
between the (-)-naltrexone group and saline control at any time point tested (Fig. 6.6). 
Interestingly when (+)-naltrexone was administered hypersensitivity was observed at 135 




Figure 6.6. Neither (-)- or (+)-naltrexone effect i.pl. capsaicin-induced 
hypersensitivity. (+)-Naltrexone, (-)-naltrexone (6 mg/kg; i.p.) or saline were 
administered 30 min prior to capsaicin (0.4 µg/ 5 µL; i.pl.). Von Frey testing was 
conducted 7, 45, 90 and 135 min post capsaicin administration. n = 10 for saline group, n = 
8 for (+)-naltrexone group, n = 6 for (-)-naltrexone group. & p <0.01 (+)-naltrexone vs (-)-






6.4.3 Both (+) and (-)-naltrexone administered post capsaicin extend hypersensitivity. 
Following the observed (+)-naltrexone effect (Fig. 6.6) and extended hypersensitivity 
observed at high (-)-naltrexone doses (Supp. Fig. 6.1); (+)- and (-)-naltrexone were 
administered 30 min post-capsaicin. We observed a significant effect of time (Fig. 6.7A. 
F(3.3,70) = 53.15, p < 0.0001, Fig. 6.7B. F(2.8,58) = 74.28, p < 0.0001, Fig. 6.7C. F(3.0,62) = 
149.8, p < 0.0001) and treatment ((Fig. 6.7A. F(2,21) = 6.988, p = 0.0047, Fig. 6.7B. F(2,21) = 
22.63, p < 0.0001, Fig. 6.7C. F(2,21) = 42.89, p < 0.0001) on von Frey responses for all 
filament strengths. An interactive effect was also observed for all filaments (Fig. 6.7A. 
F(8,84) = 3.17, p = 0.0034, Fig. 6.7B. F(8,84) = 4.99, p < 0.0001, Fig. 6.7C. F(8,84) = 13.43, p < 
0.0001). Of interest were the group differences at 45 min onwards (as naltrexone was 
introduced at 30 min). Post hoc analysis revealed that 15 min following naltrexone 
administration (+)-naltrexone produced significantly higher scores for the 0.04g (p < 0.05), 
0.16g (p < 0.0001) and 0.6g (p < 0.0001) filaments compared to saline control animals. In 
contrast, (-)-naltrexone was significantly different than the saline group at 45 min using 
only the heaviest filament (0.6g) (p < 0.0001). Both (+)- and (-)-naltrexone produced 
significantly higher von Frey scores at 90 and 135 min post capsaicin (Fig. 6.7). There was 
no significant difference between the (+)- and (-)- naltrexone groups at any time point (Fig. 
6.7). In the absence of capsaicin, (+) - and (-)-naltrexone had no effect on von Frey 













Figure 6.7. (+)- and (-)-naltrexone extended hypersensitivity when administered 30 
min following i.pl. capsaicin. (+)-Naltrexone, (-)-naltrexone (6 mg/kg; i.p.) or saline were 
administered 30 min (dotted line) following capsaicin (0.4 µg/ 5 µL; i.pl.). Von Frey 
testing was conducted 7, 45, 90 and 135 min post-capsaicin. n = 10 for saline group, n = 8 
for (+)-naltrexone group, n = 6 for (-)-naltrexone group. * p < 0.05, ** p < 0.01, *** p < 
0.001, **** p < 0.0001 (-)-naltrexone vs saline; # p < 0.05, ## p < 0.01, ### p < 0.001, 




















6.4.4 Administration of (-)-naltrexone at later time points does not restore mechanical 
hypersensitivity following capsaicin. 
Following the extended hypersensitivity observed above we asked whether addition of 
naltrexone at later time points would reverse a return to baseline. Using (-)-naltrexone we 
observed no difference compared to control when administered 110 min following 
capsaicin (Fig. 6.8). Two-way ANOVA revealed an effect of time (Fig. 6.8A. F(2.9,29) = 
19.18, p < 0.0001, Fig. 6.8B. F(2.8,28) = 21.68, p < 0.0001, Fig. 6.8C. F(2.9,29) = 31.51, p < 
0.0001), however, no treatment (Fig. 6.8A. F(1,10) = 0.62, p = 0.4508, Fig. 6.8B. F(1,10) = 
1.74, p = 0.2163, Fig. 6.8C. F(1,10) = 0.08, p = 0.7861) or interaction effect (Fig. 6.8A. 
F(5,50) = 0.14, p -= 0.98, Fig. 6.8B. F(5,50) = 0.91, p = 0.4862, Fig. 6.8C. F(5,50) = 1.89, p = 
0.1137), on von Frey responses for all filaments tested. Post hoc analysis revealed no 
difference between groups at any time point. For the lightest filament (0.04g) there was no 
time point significantly greater than baseline past (-)-naltrexone administration. For the 
0.16g filament, the (-)-naltrexone group only was significantly higher than baseline at 135 
min (p < 0.05), neither group was statistically different than baseline at 180 min. Similarly, 
(-)-naltrexone group only was significantly higher than baseline for the 0.6g filament at 
180 min (p < 0.01), neither group differed from baseline at 135 min (Fig. 6.8). Reflecting 
these results, we observe no effect when (-)-naltrexone is delivered at 155 min post 
capsaicin; no group differences and no change from baseline post (-)-naltrexone 
administration (Supp. Fig. 6.2).  
 
 
Figure 6.8. Administration of (-)-naltrexone 110 min following i.pl. capsaicin does not 
restore mechanical hypersensitivity. (-)-Naltrexone (6 mg/kg; i.p.) or saline were 
administered 110 min (dotted line) following capsaicin (0.4 µg/ 5 µL; i.pl.). Von Frey 
testing was conducted 7, 45, 90, 135 and 180 min post-capsaicin. n = 6 for all groups. 
Error bars represent SEM. 
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6.4.5 Spinal cord c-Fos is unaltered by application of (-)-naltrexone applied 30 min 
following capsaicin administration. 
Neuronal activation marker c-Fos was investigated 120 min post capsaicin and 90 min post 
(-)-naltrexone, a time point where we observed significantly higher sensitivity compared to 
controls (Fig. 6.7). No changes were observed, in either the contralateral or ipsilateral 
dorsal horn of the lumbar spinal cord (Fig. 6.9). One-way ANOVA revealed no effect of 
treatment on cell count or area stained for all ipsilateral and contralateral spinal cord 
sections (Supp. Tab. 6.1). Post hoc analysis revealed no differences between treatments at 



















Figure 6.9. Administration of (-)-naltrexone 30 min post capsaicin does not alter c-Fos 
expression in the lumbar spinal cord lamina 1-3. C-Fos staining in the lumbar spinal 
cord 90 min following (-)-naltrexone (6 mg / kg; i.p.) and 120 min following capsaicin (0.4 
µg/ 5 µL; i.pl.). Representative images at L3 (A, B, C), L4 (D, E, F) and L5 (G, H, I) of 
saline (A, D, G), capsaicin (B, E, H) and (-)-naltrexone-capsaicin (C, F, I) groups. Scale 
bar represents 250 µm. J and K represent the number of c-Fos positive cells in the 
ipsilateral and contralateral dorsal horn respectively. L and M represent the area stained by 
c-Fos antibody as a percentage of ipsilateral and contralateral dorsal horn lamina 1-3 




The aim of this study was to investigate the effect of i.pl. administration on capsaicin-
induced mechanical hypersensitivity. This would enable improved interpretation of i.pl. 
capsaicin behavioural data by gaining a more rounded multi-system understanding. We 
observed injection-induced attenuation of capsaicin hypersensitivity, which was reversed 
by both opioid receptor antagonist (-)-naltrexone and its opioid inactive stereoisomer (+)-
naltrexone. Further to this, we were able to extend capsaicin-induced hypersensitivity 
when naltrexone was administered during a period of behavioural sensitivity post-
capsaicin. Analysis of CNS c-Fos activation revealed no increase in c-Fos positive cells in 
the spinal cord dorsal horn that would account for the behavioural observations. These 
results suggest i.pl. drug administration recruits both endogenous opioid and non-classical 
opioid systems, and the consequences of these systems depends upon the current level of 
activity within the nociceptive pathway. 
 
We were able to demonstrate that an i.pl. injection stressor 15 min before capsaicin 
administration attenuated the magnitude of hypersensitivity in BALB/c mice. To the best 
of our knowledge, the effect of an i.pl. injection stressor on nociceptive hypersensitivity 
has not been reported. Injection-induced stress effects in rodent models are well 
documented. I.p. saline administration in rats increases blood and tissue (ventral 
hippocampus) corticosterone, and decreases blood nitric oxide (Freiman et al., 2016). 
These findings suggest a single injection was able to activate the hypothalamic-pituitary-
adrenal (HPA) axis which is involved in stress responses (Freiman et al., 2016). Further, 
corticosterone is elevated 30 min following intraperitoneal injection in male BALB/c mice, 
again suggesting involvement of the HPA axis (Drude et al., 2011). Rats and mice have 
also been used to show the effects of restraint handling during injection, with increased 
restraint resulting in increased blood cortisone; an area of concern for i.pl. administration 
which requires significant animal restraint (Meijer et al., 2006; Stuart et al., 2015). While 
there is no doubt that handling and injection cause stress responses in animal models, the 
mechanisms behind the analgesia reported here requires further investigation. 
 
Stress-induced analgesia (SIA) is a well-documented phenomena with multiple potential 
mechanistic drivers including opioid, endocannabinoid and monoaminergic systems acting 
at all levels of pain circuitry (Butler et al., 2009). Injection stressors are not used to study 
SIA, making comparisons to this work difficult. I.p. injection of hypertonic saline causes 
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reduced tail withdrawal latency to radiant heat in rats, however in this case it appears the 
effect is due to the hypertonic nature of saline rather than the injection itself (Wright et al., 
1985). Opioid antagonist naloxone did not reverse this effect but enhanced analgesia, again 
suggesting the mechanism is dissimilar to what we observe here (Wright et al., 1985). 
Electric foot shocks are a commonly used stressor in both clinical and preclinical pain 
models, and perhaps the most relevant method to the i.pl. effect we observe here. Both 
mouse and rat studies have used intrathecal naloxone to block the analgesic effects of foot 
shock (Chesher et al., 1977; Hemingway et al., 1987; Watkins et al., 1982). One study 
reported location-dependent opioid actions, with reversal of analgesia observed in forepaw, 
but not hindpaw (Watkins et al., 1982). This is in contrast to our study which found 
hindpaw analgesia was resolved by both classical and non-classical opioid antagonism. An 
interesting finding here is that naloxone could not reverse analgesia past onset; we did not 
administer naloxone between saline injection and capsaicin to test this in our model 
(Watkins et al., 1982). Such an experiment could be conducted in future to determine if our 
analgesia is similarly spinally mediated. Acupuncture-induced analgesia is another, less 
commonly utilised stressor with potentially similar impact to our model. In rabbits, 
naloxone reverses tail withdrawal analgesia induced by electroacupuncture (Zakusov et al., 
1981). While SIA is a possible cause of the observed analgesia further characterisation of 
opioid vs non-classical opioid mechanism and peripheral or central action needs to be 
determined. 
 
Both classical and non-classical opioid antagonists administered prior to the injection 
stressor, reversed analgesia in this study. Interestingly, not only was the analgesia reversed 
but hypersensitivity was observed at 90 min following stimulation with the highest 
filament. I.pl. capsaicin-induced hypersensitivity has never lasted 90 min in this, or any of 
our previous experiments utilising i.pl. capsaicin at higher doses. Evidence from the wider 
pain community for similar and higher capsaicin doses also shows resolution of 
hypersensitivity prior to 90 min using a von Frey test (Abdelhamid et al., 2013; Carey et 
al., 2016; Laird et al., 2001b). This suggests an effect of (+)- and (-)-naloxone in not only 
reversing attenuation but extending allodynia, an effect observed both with and without the 
intermediary i.pl. saline injection. 
 
To further investigate, we administered naltrexone at later time points to observe their 
effect on the duration of capsaicin-induced hypersensitivity. Naloxone administered 30 
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min post capsaicin caused extensions of hypersensitivity for the duration of the testing 
period (135 min), significantly longer than that observed due to pre-capsaicin naltrexone. 
These results mimic those observed in a mouse complete Freund’s adjuvant (CFA) pain 
model, which administered (-)-naltrexone post i.pl. administration (Corder et al., 2013). An 
inflammatory pain model, CFA produces mechanical hypersensitivity lasting 10 days, 
however (-)-naltrexone was infused throughout this entire resolution phase. Mechanical 
hypersensitivity remained elevated until the infusion was ended. The authors postulate a 
MOR mediated inhibition of pain is blocked by (-)-naltrexone (Corder et al., 2013). In 
contrast to our study however, the authors were able to reinstate mechanical and thermal 
hypersensitivity when (-)-naloxone was administered (i.p.) after initial resolution. They 
were also able to show that peripherally restricted naltrexone (naltrexone methobromide) 
had no effect, suggesting a central site of action (Corder et al., 2013). The authors propose 
enhanced pronociceptive synaptic strength via an N-methyl-D-aspartate (NMDA) 
mediated adenyl cyclase activation. While this is in contrast to our result which shows no 
reinstatement of hypersensitivity (Fig. 6.8), it agrees with multiple clinical and preclinical 
studies. In mice, surgical incision and remifentanil administration-induced mechanical 
hypersensitivity resolves by day 20. At day 21 mechanical hypersensitivity was reinstated 
by (-)-naloxone, but not (+)-naloxone or peripherally acting naloxone methiodide. Again, 
the authors identified the effect was centrally mediated, however through KOR, with 
involvement of NMDA receptors (NMDAR) (Campillo et al., 2011). Similarly, primary 
and secondary mechanical hypersensitivity was reinstated in a concentration dependent 
manner by (-)-naloxone in mice and humans following mild heat shock (Pereira et al., 
2015). NMDARs are also implicated in non-nociceptive stress-induced latent pain 
sensitisation in rats (Le Roy et al., 2011). Latent sensitisation is a theory which postulates 
central sensitisation outlasts signs of hyperalgesia which can be reversed by antagonism of 
central opioid actions (Pereira et al., 2015). While much evidence exists for this process, 
our results only partially corroborate an opioid-induced latent central sensitisation due to 
the nature of classical and non-classical opioid extension of hypersensitivity. 
 
While limited, there are studies which indicate a possible mechanism by which opioid 
action can increase intracellular calcium and neurotransmitter/neurotrophic factor release 
(Samways et al., 2006). Enkephalin, noradrenaline and adenosine are released from 
guinea-pig myenteric plexus, rat spinal cord and SH-SY5 cells respectively following 
opioid exposure (Cahill et al., 1993; McDonald et al., 1996; Xu et al., 1992). However, in 
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each case concomitant stimulation of a secondary receptor (muscarinic receptor, N-type 
voltage-operated calcium channels and Gi/Go-coupled neuropeptide Y receptors 
respectively) was required. Similarly, in mouse dorsal root ganglion neurons capsaicin-
induced calcium is able to induce a rapid increase (30 s - 10 min) of surface DOR. Upon 
activation, DOR’s are able to release internal calcium stores leading to sustained elevated 
calcium (Bao et al., 2003). We suggest this mechanism warrants further investigation 
based on the context of this behavioural data. The rapid increase in surface DOR following 
capsaicin perhaps accounts for the observed potentiated responses only in the period 
immediately following capsaicin administration. Further evidence of naloxone-induced 
potentiation of hypersensitivity can be found in freezing behaviour induced by electric 
shock in rats (Fanselow et al., 1979). The authors suggest by blocking endogenous 
analgesic action, the shocks become more of an aversive stimulus, resulting in amplified 
and extended shock-induced behaviours (Fanselow et al., 1979). While we do not observe 
amplified hypersensitivity, we do observe an extended response. Interestingly the authors 
also note that timing is crucial to this effect. Naltrexone must be present before the shock, 
with no effect observed if naltrexone is administered post shock, in contrast to what we see 
here (Fanselow et al., 1979). The possibility of opioid and non-opioid mediated increases 
in intracellular calcium after TRPV1 activation offer an interesting alternative explanation 
to what we observe and warrants further study. 
 
Despite the mechanisms, the central and/or peripheral origins of the naloxone effect need 
to be determined. Future studies should consider the use of peripheral or centrally 
restricted antagonists, such as those used in the studies discussed above. We used multiple 
filament strengths in this study in order to attempt to behaviourally distinguish mechanism. 
The lowest fibre we used elicited less than one response from 10 at baseline, considered 
completely innocuous (data not shown). The highest filament we used elicited an average 
of 2 responses from 10 and was considered noxious (data not shown). This gave the study 
the possibility of distinguishing between an allodynic (innocuous filament) and 
hyperalgesic (noxious filament) mechanism. Secondly, stimulating away from the site of 
injury (Fig. 6.1) narrowed focus on changes induced by central mechanisms. Including an 
array of behavioural tests in this protocol would have been beneficial. Firstly, to monitor 
spontaneous behaviours which are clinically relevant and secondly a wider range of 
elicited behaviours (Backonja et al., 2004). Mechanical sensitivities at the site of 
administration would have allowed for peripheral sensitisation effects but may require 
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administration at separate sites that allow easier access to the injection site than the 
footpads of a mouse. For example, cheek or calf administration which have been 
demonstrated previously (Akiyama et al., 2014; Shimada et al., 2008). Secondly, 
introducing thermal testing, which would provide useful comparisons to previous studies 
in which opioid antagonism has varying effects on mechanical and thermal stimuli (Labuz 
et al., 2016). 
 
We investigated neuronal activation (c-Fos) states in the dorsal horn of the spinal cord. 
Pilot studies were unable to identify differences between groups, suggesting that increased 
neuronal activation is not responsible for the observed behavioural differences. Multiple 
studies report increased c-Fos in superficial lamina at comparable doses between 30 min 
and 1.5 h post capsaicin (Hossaini et al., 2014; Hossaini et al., 2011; Zou et al., 2001). 
Despite the difference in timing, one would expect to see increased c-Fos in capsaicin 
treated animals. The induction of phosphorylated extracellular signal-regulated kinase 
(pERK) may also be worth considering as an alternative. Associated with noxious 
stimulation, pERK is produced rapidly in dorsal horn neurons correlating closely with 
induction of hypersensitivity compared to c-Fos, which is induced 30 - 60 min following 
stimulation (Gao et al., 2009). Further, pERK was used in the previously mentioned study 
by Corder et al. (2013). They use pERK to highlight the effect of naltrexone in reinstating 
mechanical hypersensitivity. Their protocol included anaesthetising mice and applying 
light mechanical stimulation of the hindpaw (cotton bud wiping) prior to sacrifice and 
histological processing (Corder et al., 2013). We did not mechanically stimulate the paw in 
our protocol, which should be considered in future immunohistochemical studies 
investigating the effect of naltrexone potentiation of mechanical hypersensitivity. 
 
Understanding the multisystem effects elicited by drug administration is important when 
interpreting data from subsequent behavioural testing. Here we show that i.pl. 
administration can affect capsaicin-induced hypersensitivity. Further to this we show that 
blocking both opioid and non-classical opioid pathways can reverse this effect and extend 
hypersensitivity following capsaicin depending on the timing of administration. The 
production of extended hypersensitivity appears to be dependent on the environment of the 
nociceptive pathway at the time of antagonism but is not due to increased neuronal activity 
at the level of the spinal cord. Despite the need for further elucidation of mechanism, these 
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Supplementary Figure 6.1: (-)-Naltrexone reverses i.pl. saline attenuated capsaicin-
induced mechanical hypersensitivity, which is extended at high doses. Mice were 
administered 0.9% saline (i.pl.) 15 min prior to capsaicin (0.8 μg/5 μL; i.pl). (-)-Naltrexone 
(0.6 mg/kg (A, B, C); 60 mg/kg (D,E, F); i.p.) or saline (0.9%; i.p.) was administered 15 
min prior to saline (0.9 %; i.pl.), followed by either capsaicin (0.8 μg/5 μL; i.pl) or vehicle 
(5 μL; i.pl). Testing included 10 applications of von Frey filaments (0.04 (A, D), 0.16 (B, 
E), 0.6g (C, F)) and was performed at 7, 45, 90 and 135 min following capsaicin 
administration. n = 12 for saline + capsaicin, n = 6 for all other groups. * p < 0.05, ** p < 
0.01, *** p < 0.001, **** p < 0.0001 (-)-naltrexone + saline + capsaicin vs saline + 
capsaicin; & p < 0.05, && p < 0.01, &&&& p < 0.0001 (-)-naltrexone + saline + capsaicin 
vs (-)-naltrexone + saline + vehicle; $ p < 0.05, $$ p < 0.01 (-)-naltrexone + saline + 





Supplementary Figure 6.2. (-)-Naltrexone does not restore capsaicin-induced 
mechanical hypersensitivity when administered 155 min following i.pl. capsaicin. (-)-
Naltrexone (6 mg/kg; i.p.) or saline were administered 155 min (dotted line) following 
capsaicin (0.8 µg/ 5 µL; i.pl.). Von Frey testing included 10 applications of von Frey 
filaments (0.04 (A), 0.16 (B), 0.6g (C)) at 7, 45, 90, 135 and 180 min post-capsaicin. n = 6 
for all groups. Error bars represent SEM. 
 
 
Supplementary Table 6.1. One-way ANOVA results reveal no effect of treatment on 
cell count or area stained by c-Fos antibody (n = 2) (Fig. 6.9). 
 Normalised Cell Count Area (%) 
L3 L4 L5 L3 L4 L5 
Ipsilateral 
F(2, 3) = 
0.2032 
P=0.8265 
F(2, 3) = 
0.3071 
P=0.7562 
F(2, 4) = 
0.4837 
P=0.6484 
F(2, 3) = 
0.1834 
P=0.8411 
F(2, 3) = 
0.1908 
P=0.8356 




F(2, 3) = 
0.3803 
P=0.7125 
F(2, 3) = 
2.729 
P=0.2113 
F(2, 3) = 
0.7842 
P=0.5321 
F(2, 3) = 
0.3253 
P=0.7449 
F(2, 3) = 
3.439 
P=0.1674 













Chapter 7. Discussion 
 
The first aim of this thesis was to investigate the specifics of a functionally relevant 
interaction between toll-like receptor 4 (TLR4) and transient receptor potential cation 
channel subfamily V member 1 (TRPV1). Secondly, we aimed to utilise this interaction 
and create a novel preclinical pain model which directly engages both the immune and 
neuronal elements of neuroimmune signalling. This would create a unified preclinical and 
clinical pain model and enable further molecular and cellular investigation of mechanisms 
underlying endotoxin potentiated capsaicin-induced allodynia, hyperalgesia and flare in 
humans. We were able to successfully demonstrate TLR4 altered TRPV1 function in a 
HEK293FT cell line co-expressing both TLR4 and TRPV1. In this system we observed 
endotoxin potentiated increases in calcium accumulation following capsaicin but no altered 
influx dynamic. Interestingly we also observed TLR4 antagonists resulted in increased 
intracellular calcium accumulation. We were unable to replicate potentiated capsaicin 
responses observed in the clinical endotoxin-capsaicin study in a preclinical mouse model. 
Although we do report a potentiated mechanical hypersensitivity following primed locally 
applied LPS in a population of BALB/c mice. Complicating our efforts in creating a 
preclinical model was an apparent endogenous analgesic response following intraplantar 
capsaicin administration. We were able to identify this was the result of classical and non-
classical opioid analgesic mechanisms, blocked by the addition of both (-)- and (+)-
naltrexone. Therefore, we confirm the existence of a TLR4/TRPV1 functional interaction, 
both dependent and independent of TLR4 signalling, with relevant in vivo consequences. 
 
We were able to confirm that the presence of TLR4 is sufficient to alter TRPV1 function in 
a co-expression system. This result agrees with multiple studies which show alteration of 
TRPV1 mediated current and calcium accumulation when co-expressed with TLR4 (Min et 
al., 2018; Min et al., 2014). Live cell analysis suggests a population of TLR4/TRPV1 co-
expressing cells exhibit a rapid response, but what would cause this in our system is yet to 
be identified. Due to the unreliability of TLR4 antibodies we were unable to identify the 
relative expression of TLR4 protein, which may have provided more insight into these 
responses (McCarthy et al., 2017). In future, using conjugated LPS may offer an 
alternative while in situ TLR4 protein identification remains elusive (Diogenes et al., 
2011). In the absence of any intentional added stimulus these results suggest either a 
physical interaction or some level of basal signalling. A physical interaction has been 
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proposed between TRPV1 and the TIR domain of TLR4, which when removed reverses 
potentiated TRPV1 mediated calcium responses (Min et al., 2018). To investigate basal 
signalling effects we applied multiple antagonists which inhibit various aspects of the 
TLR4 complex including the MD2/endotoxin interaction (1J, (+)-Naloxone, LPS-RS) and 
interaction of TLR4 with its intracellular TIR adaptor proteins (TAK-242) (Gaikwad et al., 
2015; Matsunaga et al., 2011; Selfridge et al., 2015). These antagonists had no effect on 
the calcium response curve of TLR4/TRPV1 co-expressed HEK293FT cells, and 
surprisingly led to increased calcium accumulation following capsaicin, contrasting 
previous work in primary DRG neurons which shows no effect of LPS-RS on intracellular 
calcium (Diogenes et al., 2011). Based on these results, it is unlikely basal signalling is the 
cause of our altered capsaicin-induced calcium responses, further implicating physical 
interaction. Future studies will need to establish a physical protein-protein interaction to 
confirm this hypothesis; resonance energy transfer techniques such as bioluminescence or 
fluorescence resonance energy transfer (BRET or FRET) offer interesting avenues for this 
live cell work given the unreliability of TLR4 antibodies (Dimri et al., 2016).  
 
Relating to our second aim, we hypothesised the potentiation of TRPV1 responses 
following activation of TLR4 by LPS in vitro. Activation with LPS did not alter TRPV1 
mediated calcium influx dynamics, although it did induce increased calcium accumulation 
at high doses (100, 1000 ng/mL) following 18 min but not 4 h LPS incubation. It should be 
noted that cells not exposed to capsaicin expressing both TLR4 and TRPV1 showed 
increased calcium accumulation following 18 min LPS stimulation at 100 and 1000 ng/mL 
which may account for the difference observed in capsaicin stimulated cells. This response 
to LPS is also seen in rat DRG neurons, where the effect is blocked by TLR4 antagonism, 
suggesting the influx is TLR4 mediated; although LPS has no effect on calcitonin gene-
related peptide (CGRP) release (Diogenes et al., 2011; Li et al., 2015). Likewise, we 
recorded increases in intracellular calcium accumulation in cells only expressing TLR4. 
Together, these results suggest that TLR4 mediated intracellular calcium increases do not 
influence neuropeptide release, but offer an alternative mechanism to rapid alteration in 
TRPV1 sensitivity. 
 
Studies in both primary and HEK293FT cells agree that short LPS stimulation (< 1 min to 
15 min) potentiates TRPV1 responses measured using alternate assays, including inward 
current and CGRP release (Diogenes et al., 2011; Li et al., 2015; Wu et al., 2019). 
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HEK293FT cells are used in overexpression studies due to their active signal transduction 
pathways; importantly they express the intracellular components important for the 
sensitisation of TRPV1, including AKAP79, PKC, PKA, PI3K and PLC (Atwood et al., 
2011; Gardner et al., 2006; Song et al., 2014). Apart from ligand-induced physical 
changes, these scaffolding proteins and kinases represent a plausible route of rapid, 
calcium-induced sensitisation. Our conditions were almost identical to the HEK293FT 
overexpression system used previously which reported LPS-induced potentiation of 
capsaicin-induced inward currents (Li et al., 2015). Future studies which explore 
mechanism would be wise to include patch clamp data to ascertain if the small, rapid LPS-
induced intracellular calcium changes translate to altered TRPV1 channel conductance. 
 
In order to achieve our second aim and back-translate the clinical endotoxin-capsaicin 
model, an exhaustive literature review of preclinical pro-nociceptive capsaicin models was 
undertaken. It is evident that there are areas in need of refinement in this space; in 
particular in relation to capsaicin dose, reporting nomenclature and the use and reporting of 
data from both sexes. One such improvement is recognising which doses are necessary to 
produce duration of hypersensitivity required for the behavioural assessment. Rarely do 
researchers test animals for more than 3 h post capsaicin application, yet doses can vary 
hundreds of micrograms within the same species and application site. This is particularly 
evident in intra-colonic mouse studies, where a dose of 50 µg is established, yet to 500 µg 
is still used despite testing at the same 20minute time point (Gonzalez-Cano et al., 2017; 
Hockley et al., 2017). Likewise, in rat intraplantar injection studies 10 µg is established, 
while recently doses above 1 µg were administered for testing at the same or shorter time 
points (Huang et al., 2016; Leblanc et al., 2014). This is not true of all applications; 1.6 µg 
is commonly used at the mouse hindpaw with no evidence that significantly higher doses 
are used. We incorporated this dose in our pilot studies, eventually choosing to use 0.8 µg 
as it produced similar outcomes. We further reduced this to 0.4 µg in the later animal 
studies, finding it as effective as the higher doses. We suggest many doses used in 
capsaicin literature can be significantly refined. Another area in need of refinement is the 
use of language around subject responses. Throughout this manuscript we use the term 
‘hypersensitivity’ in reference to reduced mechanical and thermal thresholds. It became 
clear in our literature search that terms allodynia and hyperalgesia - commonly used in 
clinical trials due to the ability of subjects to self-report pain – are used interchangeably. It 
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is recommended to reduce confusion that researchers agree on a consensus term to refer to 
reduced sensory thresholds in pain literature. Finally, only 10% of studies include female 
subjects, presumably due to the added variables introduced by oestrous. However, this 
removes a significant research interest and is an important step forward in future 
experimental design. In addition, poor reporting of sex-independent results should be 
reviewed in order to clarify persistent questions around sex-related difference in pain. In 
order to back-translate the clinical model, an attempt was made to replicate as close as 
practicable the clinical conditions, leading to the initial use of male mice. Further 
investigations into the potentiated responses following a primed LPS response should 
investigate the phenomenon in female mice. We were therefore able to use the literature 
review to refine or procedures and reporting, while future steps should aim investigate 
primed LPS-induced capsaicin potentiation in female mice. 
 
We were unable to replicate potentiated capsaicin-induced mechanical hypersensitivity in 
BALB/c mice. As stated above, we attempted to replicate conditions present in the clinical 
model including; sex, stimulus intensity, route of administration and behavioural outcome; 
however, adaptions were necessary for a rodent model. These included relative capsaicin 
and LPS doses as well as LPS timing. Systemic LPS timing was investigated at both 3 and 
4 h to firstly replicate the clinical study, and then at a later timepoint to reflect the 
comparatively delayed peak cytokine response in BALB/c mice (Ostberg et al., 2000). 
Capsaicin doses were optimised to generate a submaximal response to mechanical 
stimulation, allowing for detection of potentiation. LPS doses 1 µg/kg and 1 mg/kg reflect 
both low and moderate immune inducing stimulus in BALB/c mice, reflecting low levels 
of serum cytokine increase in the clinical model (Kadafi et al., 2019; Meneses et al., 2018; 
Ostberg et al., 2000). However, none of the variables tested produced potentiated 
mechanical hypersensitivity. 
 
We chose to utilise a common method of measuring mechanical hypersensitivity in mice 
following application of capsaicin to the hindpaw. The clinical model reports potentiated 
mechanical allodynia, hyperalgesia and flare. Therefore, we adopted a von Frey approach 
using a range of filaments to replicate both innocuous and noxious mechanical stimulation. 
This would allow assessment of both allodynia and hyperalgesia in a rodent model. 
Adopting a best of 10 von Frey approach limited the number of fibres we could test due to 
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the rapid onset and transient nature of capsaicin-induced mechanical hypersensitivity; 
however, this offered significantly decreased variability over a best of 5 approach. 
Determining a threshold using either the Chaplan or the modified SUDO up-down methods 
rather than a best of 10 approach may be advantageous in future work using manual von 
Frey filaments across a short time frame. While they won’t allow inferences regarding 
allodynic or hyperalgesic mechanism, they offer fewer applications per animal per time 
point (Bonin et al., 2014; Chaplan et al., 1994). Ideally, electronic von Frey would be used 
to further minimise filament applications. It should be noted that the clinical endotoxin-
capsaicin model observed a larger potentiation to mechanical allodynia compared to 
hyperalgesia (Hutchinson et al., 2013). Hyperalgesia was measured using von Frey 
filaments, a static mechanical stimulus; while capsaicin-induced allodynia was measured 
using a foam brush, representing dynamic mechanical stimulation (Hutchinson et al., 
2013). Dynamic and mechanical stimuli can be differentiated by use of analgesics which 
block only either static or dynamic stimulation and can be produced independently by 
different nerve injuries (Field et al., 1999). These results suggest that each stimulation type 
recruits different nociceptor subsets, raising the possibility that LPS potentiation may not 
occur in those activated by punctate mechanical stimulation. Dynamic stimulation has been 
reported in capsaicin literature with use of cotton bud wiping, an alternative to consider in 
future studies (Laird et al., 2004; Laird et al., 2001b). 
 
In addition, we needed to modify the anatomical region tested when compared to the 
clinical endotoxin-capsaicin model. The hindpaw is an overwhelmingly popular choice to 
assess capsaicin-induced pain, however multiple studies have shown TLR4-dependent pain 
hypersensitivity is anatomically variable (Hu et al., 2017; Wegner et al., 2014; Wegner et 
al., 2015). In the clinical endotoxin-capsaicin model, the forearm produced potentiated 
sensitivity, however this is not an ideal location for administration of mechanical 
stimulation in rodent models. Alternatives already present in the capsaicin literature 
include intradermal application at the calf, vibrissae pad and nape (Akiyama et al., 2014; 
Peirs et al., 2016; Shimada et al., 2008). Based on clinical data suggesting LPS-induced 
mechanical sensitivity presents in back muscles, the back offers another potential 
alternative for intradermal capsaicin administration in mice (Wegner et al., 2014). A 
disadvantage of our intraplantar model is the endogenous analgesia induced by injection 
and its subsequent effect on hindpaw sensitivity. This becomes particularly relevant if 




We identified that injection stress attenuated capsaicin responses in BALB/c mice within 
15 min. Both classical and non-classic opioid antagonists (-)- and (+)-naltrexone reversed 
this response when administered pre-capsaicin. When administered post-capsaicin 
however, (-)- and (+)-naltrexone potentiated and extended capsaicin-induced mechanical 
hypersensitivity. Therefore, the timing of this effect was critical to this potentiation, and 
suggests it is not a result of nociceptor potentiation, but an attenuation of an endogenous 
analgesic response. Potential mechanisms must be rapid given the short time period 
between injection and altered capsaicin response and includes stress-induced analgesia 
resulting from intraplantar application of capsaicin, a phenomenon observed in rodent 
hindpaw following electric shock and acupuncture (Wright et al., 1985; Zakusov et al., 
1981). However, more investigation is required to narrow down mechanism, importantly, 
identifying if the effects are peripherally or centrally mediated would enable a more 
targeted mechanistic investigation. 
 
Although we weren’t able to observe potentiated capsaicin-induced hypersensitivity 
following systemic LPS, potentiated responses were observed following locally applied 
LPS. Due to the effects of LPS on DRG neurons described above we attempted to cause 
potentiation by targeting peripheral neurons directly (Diogenes et al., 2011; Ferraz et al., 
2011; Li et al., 2015; Wadachi et al., 2006). This was only possible at later time points due 
to the previously discussed analgesic action of intraplantar drug administration. We were 
unable to produce significant potentiation of capsaicin-induced mechanical 
hypersensitivity following a single LPS dose, with exception of a single time point (90 
min) using the strongest filament tested (0.6 g). Based on evidence in mice that primed 
LPS responses produce thermal and mechanical hypersensitivities and single LPS doses 
can lead to long lasting (> 2 weeks) but slow inducing thermal hyperalgesia, we tested a 
primed LPS response with two identical doses separated by 7 days (Abu-Ghefreh et al., 
2010; Cahill et al., 1998). We found that primed responses produced potentiated capsaicin-
induced mechanical hypersensitivity; an effect completely attenuated by TLR4 antagonist 
(+)-naltrexone. This data displayed considerable variability, with apparent high and low 
responding populations within the primed LPS capsaicin group. Separating this group 
reveals responses to mechanical stimulation were significantly higher in 50, 42 and 58% of 
animals stimulated with 0.16, 0.04 and 0.6g filaments respectively; with the remaining 
animals not statistically different from vehicle treatment. This potentiation is comparable 
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to that reported in the clinical endotoxin-capsaicin study, with enhanced mechanical 
sensitivity over multiple time points. It should also be noted that primed LPS alone did not 
result in changes to mechanical hypersensitivity in this case. We propose that mechanistic 
differences between the two populations are of interest, shedding light on why only a 
portion of animals developed hypersensitivity may highlight important mechanisms. This 
is an important question in clinical pain, in which some people develop chronic, 
dysfunctional pain and others do not despite being exposed to the same stimuli, for 
example chemotherapy or surgery (Borsook et al., 2018). In this case both central and 
peripheral blockade of TLR4 would emphasise areas for more detailed investigation. 
Further regional analysis of cellular activation states, gene activation and inflammatory 
mediators may highlight potential biological factors responsible for biasing 
hypersensitivity over unaffected nociception.  
 
The evidence presented here reinforces that innate immune receptors and pathogen 
associate molecular pattern (PAMP) activity are important elements of immune driven 
nociceptive sensitisation. Typically, innate immune responses are associated with 
inflammatory pain; nociceptive sensitisation to promote repair of damaged tissue. 
However, we show TLR4 influences nociception in the absence of activation, and LPS 
alters nociceptive processing at doses which do not induce inflammatory hypersensitivity. 
This suggests an alternate role in pain signalling. One suggestion is the direct activation or 
sensitisation of nociceptors by PAMPs as a danger signal similar to the effect of noxious 
chemical, thermal and mechanical stimuli. Direct activation of nociceptors by pathogens 
has been reported, with Staphylococcus aureus inducing pain hypersensitivity correlated 
with bacterial load. Interestingly, nociceptor activation by Staphylococcus aureus is 
associated with local nociceptor-induced immune suppression (Chiu et al., 2013). LPS 
induces TLR4 and TRPA1 dependent calcium influx in mouse DRG and nodose ganglion 
neurons respectively (Diogenes et al., 2011; Meseguer et al., 2014). In addition to TLR4, 
TLR3, -5, -7 and -9 are expressed on small and medium diameter nociceptors (Liu et al., 
2012; Liu et al., 2010; Wadachi et al., 2006; Xu et al., 2015). Activation of TLR3 and 
TLR7 by their respective ligands results in inward currents in mouse DRG neurons (Liu et 
al., 2012; Liu et al., 2010). While activation of TLR3, -7 and -9 result in prostaglandin 
(PGE2) release and upregulation of pro-inflammatory cytokines in murine DRGs (Qi et al., 
2011). Activation of TLR5 by flagellin allows entry of membrane impermeable compound 
QX-314 in medium diameter DRG neurons, further evidence of direct pathogen 
 
 152 
recognition by nociceptors via innate immune receptors (Xu et al., 2015). Therefore, 
further to the role in generation and maintenance of chronic pain following illness or 
injury, we suggest TLRs allow pathogen detection, sensitisation of neuronal ion channels 
and subsequent recruitment of local immune responses. Contradictory reports on the nature 
of nociceptive driven immune responses suggest further research is required. It is likely 
responses are pathogen specific, with suppression of immune reposes by some a host 
avoidance strategy, in other cases enhanced pro-inflammatory responses may represent an 
immune priming event. 
 
We were unable to successfully back-translate the clinical endotoxin-capsaicin model, 
although there are a number of variables outlined above which can be investigated further. 
We were however able to show in a similar model involving targeted LPS application that 
LPS indeed induces in vivo changes in TRPV1 function; requiring further mechanistic 
investigation. There is clear evidence in the literature, supported here, that TLR4 enhances 
TRPV1 action in vitro, although the mechanisms underlying rapid receptor sensitisation 
need to be elucidated. Understanding if these rapid changes are relevant in vivo is also 
necessary, as evidence here and in the wider literature suggest TLR4 mediated potentiation 
of TRPV1 in vivo occurs over longer timeframes, consistent with inflammatory 
sensitisation events. Given the importance of both TLR4 and TRPV1 to pathological pain 
models, and the clinical endotoxin-capsaicin proof of concept, the implications of a 
functional physical receptor interaction offers an interesting, novel, and specific 
therapeutic target. Additionally, a unique unified clinical/preclinical model offers 
interesting possibilities for drug screening and investigation into the relevance of murine 
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